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VISUALIZING THE DYNAMICS OF IMMUNE SURVEILLANCE IN BRAIN TUMORS 
BY INTRAVITAL MULTIPHOTON MICROSCOPY 
By 
Felix I. Nwajei, MD 
Supervisory Professor: Tomasz Zal, Ph.D. 
Brain tumors (BTs) generally have a bad prognosis despite conventional treatment 
strategies. Immunotherapy is a relatively novel treatment approach that has shown 
benefit for durable treatment of melanoma, and is a promising candidate for different 
tumor types including BTs.  Immunotherapeutic strategies work by exploiting and/or 
enhancing natural anti-tumor immune response, a process that is critically dependent 
on adaptive immunity, T cell infiltration and surveillance of tumor.  However, little is 
known about the dynamics and regulation of T cell surveillance in BTs. Resident 
immune cells of the myeloid lineage known as microglia are ubiquitous in the brain 
parenchyma while tissue-resident myeloid dendritic cells (DCs) known to activate T 
cells are relatively rare in the brain compared to DCs in other organs. Accumulating 
evidence indicates that myeloid cells infiltrate and create an immune suppressive 
microenvironment in BTs, but the identity of these myeloid cells and their role in the 
adaptive immune surveillance of BTs by T cells is unclear. Based on the predominance 
of microglia in the brain tissue, studies focused on understanding how BT immune 
surveillance is regulated, have been skewed toward microglia. Many conclusions 
regarding microglia function have been deduced from in vitro experiments. 
Nonetheless, in vivo studies in parallel models such as EAE indicate that DCs are 
superior to microglia in antigen presentation to T cells in the brain and to date, there is 
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no direct in vivo evidence to suggest otherwise. In addition, DCs are well-established 
cellular regulators of T cell surveillance in extracranial tumors. Therefore, I 
hypothesized that DCs, rather than microglia, play a major role in regulating T cell 
surveillance in BTs. To address this hypothesis, I have developed experimental 
imaging systems for longitudinal intravital multiphoton microscopy of immune cell 
dynamics in BTs in living mice and used this approach to interrogate T cell behavior in 
orthotopic glioma and in experimental intracranial metastases in vivo. I found that the 
myeloid infiltration of BTs was dominated by CD11c+ DC cells rather than microglia. 
Quantitative in situ tissue cell image cytometry further revealed that myeloid-derived 
CCR2+ monocytes accumulated in the BT core, CD11c+ DCs at the tumor margin, and 
CX3CR1+ microglia outside the tumor. T cells formed clusters around CD11c+ DCs, 
but not the microglia. Within these clusters, T cells vigorously interacted directly with 
CD11c+ DCs. CD11c+ DCs retained T cells and controlled their motility patterns, 
indicating that CD11c+ DCs play a major role in regulating T cell retention and motility 
in BT. Corresponding to the preferential distribution of CD11c+ DCs at BT margins was 
expression of the neuronal chemokine Fractalkine (CX3CL1). Deficiency of the 
Fractalkine receptor CX3CR1 resulted in decreased CD11c+ DC recruitment. In 
addition, decreased CD11c+ DC recruitment was accompanied by decreased T cell 
recruitment, an increase in the spatial diffusion of the few BT-infiltrating T cells, and 
subsequent outgrowth of a fibrosarcoma BT, which spontaneously regresses in the 
brain of control wild type mice in a CD8 T cell dependent manner.   
In summary, by using novel intravital imaging systems for longitudinal 
visualization of BT immune surveillance across several types of cancer, I showed that 
the recruitment, migration and retention of tumor infiltrating T cells in the brain is 
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mediated by incoming CD11c+ DCs rather than by the brain-resident CX3CR1 
microglia, and identified the neuronal chemokine Fractalkine as a key molecule that 
promotes T cell surveillance in BTs by recruiting CD11c+ DCs.  
These findings suggest that the non-microglial tumor-associating CD11c+ myeloid 
cells and the fractalkine/CX3CR1 chemokine pathway control T cell surveillance in BT 
and represent attractive immunotherapeutic targets that could be modulated for guiding 
endogenous or adoptive transfer of T cells to BT sites and for therapeutic modulation to 
enhance immunity against BTs.  
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BACKGROUND 
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1.1. General Introduction 
Mammalian tissues are under constant surveillance by the immune system1,2. 
The primary function of the immune system is to protect organisms from environmental 
pathogens such as bacteria or viruses that could prove fatal if left unchecked. 
Generally, the immune system recognizes molecular aspects of pathogens and mounts 
a rapid response in a two-layered manner to resist host organ invasion and damage. In 
contrast, nonviral cancer is a more sinister pathological event as it involves intrinsic 
mutational changes in an organism’s own cells that may be barely detectable by the 
immune system during cancer initiation. These mutations trigger a cascade of events 
including cellular transformation, immortalization, unabated proliferation, and a 
diminished survival capacity of the host organism. Although cancer cell-intrinsic factors 
play key roles in tumor development and progression, and cancerous cells were once 
thought to be undetectable by the immune system3-24, it is now established that during 
a natural anti-tumor immune response, immune cells are capable of detecting specific 
peptide antigens in transformed cancer cells. In addition, immune cells play a major 
role in both tumor progression and eradication, and have more recently been shown to 
be attractive targets for cancer therapy24-34.  
Cancer has been aptly described as “wounds that do not heal35.” This notion is 
based on decades of research uncovering striking similarities between chronic wounds 
and cancer. Importantly, both disease conditions are usually characterized by rich 
immune cell infiltrates and abundant immune cell-derived molecular signals, and 
epidemiological and mechanistic studies have linked chronic inflammation to cancer 
progression, indicating a pro-tumorigenic effect of immune cell infiltrates36-42. However, 
the significance of the immune system as a key antagonist of cancer growth has been 
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recognized due to better understanding of the immune system through finely-tuned 
molecular mechanistic studies and immunotherapeutic applications43-45. More than a 
decade ago, in a landmark review, Hanahan and Weinberg condensed the multitude of 
research data elaborating the mechanistic underpinnings of the cellular and molecular 
aspects of cancer progression into a handful of principles known as the “Hallmarks of 
Cancer.” These hallmarks include self-sufficiency in growth signals, insensitivity to anti-
growth signals, evading apoptosis, limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis46. This extensive review excluded 
the role of the immune system because there was only weak mechanistic evidence 
available to support the hypothesis of tumor immune surveillance proposed by Burnet 
and Thomas in 1957. More recently, however, the inflammatory and immune evasive 
properties of cancer have been included as part of cancer hallmarks based on 
mounting evidence that the immune system can in fact detect and eliminate cancer 
cells, and paradoxically also aid in cancer progression24,47,48. While each of the initially 
prescribed hallmarks were viewed from a mostly cancer cell-intrinsic  angle, myriad 
studies have been extensively reviewed in the updated version of the “Hallmarks of 
Cancer,” emphasizing that tumor immune infiltrates and immune-derived molecules 
play either major or supporting roles in almost all of the initially described hallmarks of 
cancer47,49-55.  
A reinvigorated interest in the historically controversial field of cancer 
immunology is due to a better understanding of molecular immunology and the 
accepted role of immunotherapy in the care of the cancer patient. 56-60 Nonetheless, a 
significant proportion of patients receiving immunotherapy do not respond. Therefore, 
to increase the efficacy of immunotherapy, it is pertinent to answer key questions 
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pertaining to why some tumors elicit robust immune responses while others do not. For 
example, it was hypothesized that differences in tumor neoantigenic load could explain 
differences in response to immunotherapy in different tumor types, and advances are 
already being made in understanding the impact of tumor mutational load and as a 
consequence, neo-antigens in response to T cell immunotherapy61-64. It is also known 
that immune cell compositions in different tissues are distinct in steady state and in 
cancer progression65-67, and this may play a role in determining the extent to which an 
adaptive T cell immune response to cancer works to eradicate cancer cells. A 
deepening of our understanding on immune response to tumors in the context of the 
complex biological milieu in which they might exist is essential for a better grasp of 
immune surveillance in specific tumor types.  
The brain is one such complex environment that presents a challenge for proper 
understanding of an immune response to tumors because of its distinct anatomy and 
immunological makeup. I will address brain tumors (BTs), the immunological 
composition of the brain, its anatomical barriers (blood brain barrier and CNS 
lymphatic), and the concept of brain immune privilege in different sections below. In this 
thesis, I have sought to investigate the extent to which BTs are infiltrated by T cells, the 
dynamics of potentially-infiltrated T cells in BTs, and the mechanisms by which T cell 
surveillance in BT is regulated. A comprehensive understanding of the mechanisms 
guiding T cell immune surveillance in BTs may reveal strategies that may be important 
for the development of potent immunotherapy for BT treatment and may pave the way 
for an organ-specific approach to immunotherapy application in cancer.  
 
 
4 
 
1.2. A brief historical perspective on brain tumor immunology research:  
Brain tumors constitute one of the most deadly types of cancer. Relative to other 
tumor types, BTs are one of the less well-understood in the context of tumor 
immunology. On the basis of research conducted by Medawar more than half a century 
ago, the brain was claimed to be an immune privileged site68,69.  About the same time, 
the inability to identify classical lymphatic vessels in the brain, which were known to be 
present in other mammalian tissues and organs and critical for immune cell trafficking,  
lent credence to the notion of brain immune privilege. Subsequent studies conducted a 
few decades after Medawar’s findings revealed no role for the immune system in 
controlling BTs in athymic immune-deficient nude mice and further bolstered the idea of 
brain immune privilege70,71. These findings led to the erroneous conclusion that the 
brain is shielded from surveillance by adaptive immune cells such as T cells, and likely 
has impeded progress in understanding the mechanisms of T cell surveillance of BTs. 
However, the idea of an immune-privileged brain was first challenged in observational 
studies showing the presence of dural lymphatic-like vessels and subsequent findings 
in which fluorescent tracers injected directly into mouse brain parenchyma were 
identified within non-vascular pathways in the olfactory lobe region, which were 
traceable to the cervical lymph nodes72. In the absence of a conventional channel for 
drainage of brain interstitial fluid (ISF) to the cervical lymph nodes, non-vascular tracks 
were proposed to serve as substitutes for lymphatics. Since then, studies have 
documented the presence of brain-derived myelin antigen-specific T cells in the 
parenchyma, brain meninges, and cervical lymph nodes in mouse models of multiple 
sclerosis and brain infections73-79. The latter studies suggested a model in which 
antigens in the brain can be transported to the cervical lymph nodes for potential 
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activation of naïve T cells 72,80. In support of this model, recent studies confirmed and 
extended these previous observations by identifying and describing distinct networks of 
lymphatic channels that drain directly into the cervical lymph nodes, indicating that 
lymphatic drainage of the brain is similar to extracranial peripheral tissues. In addition, 
it suggested that the brain is not sequestered from immune cell surveillance. Based on 
this, there is more impetus in the field of neuroimmunology to investigate the dynamics 
of antigen presenting cells and T cells in various brain pathologies.  
Historically, BTs have been classified according to histological appearance and 
studied as separate entities, and treatments have been applied differently according to 
the histological diagnosis81. In the section below, I will be discussing BT types and 
examine how immune infiltrates in such tumors could serve as a predictive/prognostic 
tool in patient survival. 82-88.   
 
1.3. Brain Tumors 
Brain tumors are heterogeneous and are classified into two main types 
according to the organ of origin. Primary BTs arise from within the brain tissue and 
secondary BTs or brain metastases originate from extracranial organs.  
I will briefly elaborate on the complexity in BTs types and subtypes based on the World 
Health Organization (WHO) and The Cancer Genome Atlas (TCGA) classifications5,89. 
 
1.3.1. Primary brain tumors 
Primary BTs arise within distinct anatomical brain regions in the pediatric patient 
relative to the adult patient. BTs in pediatric patients frequently develop in the 
infratentorial (brainstem) region, while they are mostly supratentorial (cerebral 
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hemispheres) in adults. However, the cell-specific origin for such tumors is not well 
understood90-94. Because of similar marker expression with several precursor or 
differentiated cell types, primary BTs are thought to originate from poorly differentiated 
glial cells such as oligodendrocytes, astrocytes, neural progenitor cells, and ependymal 
cells. For instance, astrocytomas share glial fibrillary acid protein (GFAP) expression 
with astrocytes and oligodendrogliomas stain for myelin basic protein (MBP), an 
oligodendrocyte marker. Based on aggressive histological characteristics and rapid 
patient mortality, a deadly type commonly known as glioblastoma multiforme (GBM) 
has become well-recognized among the multitude of primary BTs types and is thought 
to arise from astrocytes as it characteristically has GFAP expression. Recent studies 
based on gene-expression from TCGA dataset has further classified GBMs according 
to molecular characteristics95. Differential gene-expression and somatic molecular 
characteristics delineate GBM into four recognized subtypes including pro-neural, 
classical, and mesenchymal, thus indicating distinct molecular subtypes within the 
GBM histological subtype with associated differences in the inflammatory 
responses95,96. In this new classification, it is now recognized that in both primary and 
recurrent GBM, the mesenchymal subtype has the highest immune signature, 
characteristically infiltrated by neutrophils, both pro-inflammatory “M1” and immune 
suppressive “M2” macrophages, but reduced presence of activated natural killer T 
(NKT) cells in comparison with other molecular subtypes96. The proneural subtype has 
decreased resting memory CD4 T cells and the classical subtype has increased 
dendritic cell signature96. Despite the differences in the composition of immune 
infiltrates, in recurrent GBM of all subtypes, there is increased infiltration by regulatory 
T cells. Patients with primary or recurrent GBM of the mesenchymal subtype have the 
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worst overall or progression-free survival while the proneural subtype has the best96.  In 
sum, differences in immune cell presence may be exploited for effective 
immunotherapy in different GBM molecular subtypes. However, as these studies were 
nonfunctional, mechanistic work is required for better understanding of immune 
surveillance in BTs and could provide new knowledge for developing novel immune 
therapeutic strategies to improve patient survival. 
 
1.3.2. Brain metastases 
In contrast to primary BTs, brain metastases originate from cancers of 
extracranial tissues97. The epithelial to mesenchymal transition (EMT) process enables 
conditions favorable for cancer cells to migrate and penetrate the tissue basement 
membrane and gain access into the circulation98,99. Subsequently, disseminated cancer 
cells undergo a cascade of events that end with successful engraftment and growth of 
cancer cells in peripheral organs including brain tissue27,100. Brain metastasis is an 
event that can potentially occur during the progression of any malignant primary cancer 
type100. In the United States alone, it is estimated that approximately 170,000 new 
patients will be diagnosed with brain metastases annually, a number 10 times higher 
than in primary BTs101. Primary cancer types such as lung cancer, breast cancer, and 
melanoma have a high propensity to metastasize to the brain102 (Table 1). In contrast, 
brain metastases derived from soft tissue fibrosarcoma, cervical, prostate, and liver 
cancers are relatively rare103-106. Patients who develop brain metastases have very 
poor prognosis with a median overall survival ranging from a few weeks to months100. 
Present treatment strategies such as surgical resection, radiation therapy, and 
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chemotherapy have shown only modest benefit in extending survival of patients with 
brain metastases107,108. 
In comparison with GBM, the link between the immune system and brain 
metastases is even less well-understood despite its high incidence. Although there is 
no comprehensive comparison of immune cell infiltrates between distinct brain 
metastases types, recent characterization of patient brain metastases aggregated 
regardless of tissue of origin demonstrated that T cells can infiltrate brain metastases 
generally109,110. Further, it was shown that the density of T cells infiltrating brain 
metastases foci ranged from sparse to very dense109. In addition, T cell localization was 
found to correlate with “peritumoral edema” as defined by the flare region in pre-
operative magnetic resonance imaging, and higher T cell infiltration into brain 
metastases correlated with better overall survival time of patients109. These 
observations and associations are potentially translatable as they could serve as 
prognostic or predictive tools for patient outcome; however, the extent to which T cells 
infiltrate brain metastases foci originating from distinct primary tumor types is unclear. 
In addition, how T cells localize and are organized in BT and what mechanisms 
regulate T cell localization in the tumor and their interaction with other cells in the BT 
microenvironment remain unknown. These are questions that I will be probing in 
chapters 3 and 4 of this thesis. In sum, a better understanding of T cell surveillance in 
brain metastases is urgently needed. The knowledge gained may provide new insights 
into the development of novel immunotherapeutic strategies for brain metastases. 
Overall, the brain tissue is a common denominator for growth of both primary BTs such 
as GBM and brain metastases. Therefore, knowledge of immune response gained from 
studying one cancer type may be relevant for the other and vice versa. 
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 Adapted by permission from Macmillan Publishers Ltd: [Nat Rev Cancer] (Nguyen DX 
et al., Metastasis: from dissemination to organ-specific colonization 2009. Apr; 
9(4):274-84. Copyright Clearance Center. 
 
 
1.4. Mechanisms of tumor immune surveillance in the brain 
1.4.1 An overview of the immune system and anti-tumor immune surveillance 
The immune system is divided into two arms—innate and adaptive (Figure 1). 
The innate arm of the immune system is naturally wired with evolutionary conserved 
receptors that can sense conserved structures on pathogens and sterile tissues such 
as pathogen associated molecular patterns (PAMPs) and danger associated molecular 
patterns (DAMPs), respectively111-114. Innate immunity functions as the first line of 
defense during an immune response and responds rapidly relative to the adaptive 
immune system; however, this response is generally non-specific. In contrast, the 
adaptive arm of the immune system takes several days to respond during an immune 
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response, but its actions are highly specific. The specificity of adaptive immune cells is 
determined by an incredible capacity to recombine their receptors to recognize different 
antigens in a major histocompatibility complex (MHC)-restricted manner. Upon 
resolution of a disease, the adaptive immune cells can evolve a memory phenotype. 
Due to their intrinsic cellular properties, antigen-specific memory adaptive immune cells 
are capable of initiating very strong and rapid adaptive recall responses in the event of 
a re-encounter of the same antigen1,115,116. Innate immune responses are executed by 
myeloid cells including macrophages, microglia, monocytes, dendritic cells; 
granulocytes such as neutrophils, eosinophils, basophils, and mast cells; γδ-TCR T 
cells; and natural killer (NK) cells. On the other hand, adaptive immune cells include 
αβ-TCR T cells and B cells. For the purpose of this thesis, I will be focusing on how 
innate myeloid cells including microglia, monocytes, macrophages, and dendritic cells, 
and the adaptive T cells interact in BTs.  
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 Figure 1. Classification of cells in innate and adaptive immunity. Cells that 
participate in innate and adaptive immunity are illustrated within the bright lavender 
(left) and pink (right) colored circles, respectively. Natural killer (NK) and γδ T cells 
have characteristics that overlap between innate and adaptive immunity and are 
represented within the overlapping segment between both circles. Adapted by 
permission from Macmillan Publishers Ltd: [Nat Rev Cancer] (Glenn Dranoff, Cytokines 
in cancer pathogenesis and cancer therapy 2004. Jan; 4(1):11-22. Copyright Clearance 
Center. 
  
 
Immune surveillance of a tumor is based on the fact that immune cells are highly 
dynamic and can detect and recognize tumor-specific antigens (TSA) and/or tumor-
associated antigens (TAA). Tumors are composed of highly mutated cells that may 
provide a plethora of antigenic materials that are potentially ingested by antigen 
presenting cells such as dendritic cells (DCs) and macrophages, and transported via 
tumor-draining lymphatics to secondary lymphoid tissues for presentation to naïve T 
cells (Figure 2). Following T cell recognition of TSA/TAA displayed by DCs, T cells 
become activated, egress from the lymph node, and potentially migrate to the target 
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organ invaded by cancer to perform effector functions including an attempt to eradicate 
the tumor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Illustration of the dynamics of antitumor immune surveillance.  
Dendritic cells (green) engulf antigens from the tumor; process it, and present 
processed antigens to naïve T cells in the tumor-draining lymph node. Effective antigen 
presentation involves 3 signals (1. Peptide-MHC complex; 2. costimulatory molecules; 
and 3. cytokines), which lead to T cell activation, differentiation and proliferation of 
effector T cell that then migrate to the tumor (tumor infiltrating lymphocytes; TIL) to 
perform effector functions. In the absence of costimulation, T cells become anergic. 
Several cellular [myeloid derived suppressor cells (MDSCs) and regulatory T cells 
(Tregs)] and molecular (PD-1/PD-L1) regulatory mechanisms are present in the tumor 
or the lymph node to maintain tight control of this process and may cause immune 
suppression through a variety of mechanisms leading to T cell exhaustion.    
 
 
Afferent lymphatic 
Efferent lymphatic 
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The idea of tumor immune surveillance was first hypothesized by Thomas and 
Burnet in 1957 based on observations made in organ transplantation and subsequent 
studies in tumor graft transplantation24,117. Essentially, it was discovered at that time 
that following transplantation in rabbits, a donor tissue such as skin was frequently met 
with vigorous rejection by the recipient’s immune system118,119. In tumor transplantation 
experiments, it was observed that tumor transplantation into a non-syngeneic host 
resulted in tumor rejection, indicating that the recipient’s immune system was capable 
of recognizing what was likely a tumor antigen. Therefore, it was postulated that the 
infrequency of cancer occurrence in humans could be explained by an immune 
surveillance mechanism that continuously prevents the outgrowth of cancerous 
cells117,120. However, this idea was controversial because there was no mechanistic 
insight into how the immune system could recognize and eliminate a tumor, which was 
believed to express self-antigens as it originates from aberrant host cells117,121,122. Also, 
spontaneously arising tumors were rarely rejected despite the induction of an immune 
response123. Subsequent experiments by Osias Stutman revealed no difference in the 
development of tumor in immune-deficient athymic nude mice in comparison with 
control immune-competent mice, suggesting that the immune system played no role in 
the control of tumor progression, and discredited the immunosurveillance concept71. 
Despite these early setbacks, the first tumor antigen was eventually identified in 
1991124, athymic nude mice are now known to be “leaky” and not absolutely immune-
compromised125-128, and robust concrete evidence has accumulated in support of tumor 
immune surveillance in both animal models and humans leading to renewed 
enthusiasm for the immune surveillance hypothesis24,129-132. With advancements in the 
field of molecular biology and the availability of new tools including knockout (KO) mice, 
14 
 
the immune surveillance hypothesis has been overwhelmingly supported by 
observations from studies conducted in the laboratory of Robert Schreiber and 
others24,133-140. For example, sarcomas that were induced by a chemical carcinogen in 
recombination activation gene (Rag)-KO mice, which unlike nude mice completely lack 
adaptive immune cells, showed significant outgrowth in comparison with wild type mice, 
indicating that tumor growth is controlled by the adaptive immune system. Similar 
results were obtained in interferon-gamma receptor (IFNyR)-KO mice, STAT1-KO 
(lacking the gene responsible for IFNy signaling), perforin-KO, αβ T cell KO (lacking the 
TCR β-chain), and γδ T cell KO (lacking the TCR δ-chain) mice, all indicating that 
components of the immune system are involved in controlling tumor growth24,133-140 . 
Although the immune system plays a tumor surveillance role, spontaneous tumors tend 
to progress lethally from presumably immune-resistant cancer cell clones. In a set of 
experiments to test the role of the immune system in the development of tumor 
resistance clones, transplantation of a carcinogen-induced tumor from a primary wild 
type host to a secondary wild type recipient resulted in lethally progressive tumor. In 
contrast, transplantation of a similar tumor from a primary immune-deficient Rag-KO 
host to a secondary wild type recipient showed significant decrease in tumor growth. 
Together, these results suggested that the intact immune system in the primary 
immune-competent wild type host provided selective pressure for development of less 
immunogenic and resistant tumor clones while the lack of immune selective pressure in 
the primary immune-deficient RagKO host was necessary for the retention of tumor 
immunogenicity. This phenomenon of tumor sculpting by the immune system was 
conceptualized as the process of cancer immunoediting. 132,141-143. Cancer 
immunoediting is a process that includes three phases including elimination, 
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equilibrium, and escape (Figure 3). In effect, this concept includes tumor 
immunosurveillance during which tumor eradication occurs (elimination phase), 
immunological sculpting of the tumor leading to selection for resistant cancer cell 
clones, which are potentially less immunogenic or have acquired mechanisms of 
immune evasion or suppression (equilibrium phase), and subsequent uninhibited tumor 
progression  (escape phase)24,130,144.  
Despite our present understanding of cancer immune surveillance and aspects 
of immunoediting, most of the data is borrowed from research conducted in extracranial 
organs. In the brain, however, the mechanisms regulating immune surveillance in 
tumors remain unclear partly due to the idea of brain immune privilege. This idea first 
came to light following an experiment by Medawar69. He observed that skin to skin 
transplantation in rabbits caused the recipient rabbit to mount strong immune response 
with subsequent rejection of the transplanted tissue. However, when the same tissue 
was transplanted into recipient rabbit brain, the tissue was not rejected. In contrast, 
when he first transplanted donor skin tissue into the skin of recipient rabbits and waited 
a few days before transplanting similar donor skin tissue into the brain of the same 
recipient rabbits, the transplanted tissue in the brain was rejected69. This suggested 
that the brain is immunologically quiescent or privileged in comparison with peripheral 
tissues. Since then, in support of an immune-privileged brain, countless studies have 
demonstrated unique features of the brain that could prevent the development of robust 
immune response within the brain tissue68,145-148.  
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Figure 3. The process of cancer immunoediting.  
Cancer immunoediting encompasses three processes. (a) Elimination corresponds to 
immunosurveillance (b) Equilibrium represents the process by which the immune 
system iteratively selects and/or promotes the generation of tumor cell variants with 
increasing capacities to survive immune attack. (c) Escape is the process wherein the 
immunologically sculpted tumor expands in an uncontrolled manner in 
immunocompetent host. In a and b, developing tumor cells (blue), tumor cell variants 
(red) and underlying stroma and nontransformed cells (gray) are shown; in c,  
additional tumor variants (orange) that have formed as a result of the equilibrium 
process are shown. Different lymphocyte populations are as marked. The small orange 
circles represent cytokines and the white flashes represent cytotoxic activity of 
lymphocytes against tumor cells. Reprinted by permission from Macmillan Publishers 
Ltd: [Nature Immunology] (Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer 
immunoediting: from immunosurveillance to tumor escape. 2002;3:991-8); Copyright 
(2002). Copyright Clearance Center. 
 
 
1.4.2. The Blood-Brain Barrier (BBB) in steady state and inflammation 
The BBB has been pivotal in the debate on brain immune privilege and is 
believed to play a critical role in regulating interactions between the brain and immune 
cells in extracranial peripheral tissues. The BBB serves to tightly regulate the influx of 
molecules or cells from the circulation into the brain tissue in normal homeostatic 
conditions146,149,150. Unlike fenestrated capillaries in the extracranial peripheral tissues, 
the BBB is made up of endothelial cells that are bound together by tight junctions. This 
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basic endothelial structure is further reinforced by pericytes, astrocytic foot processes, 
and smooth muscle cells151. BBB tight junctions and efflux pumps are mechanisms that 
prevent small molecules from penetrating the brain parenchyma152-155. Consequently, 
delivery of small molecules such as kinase inhibitors and targeted therapy to treat brain 
pathologies such as brain tumors has been shown to be inefficient154. In contrast, 
systemic immune cells such as memory T cells have been found to be present in the 
brain at steady state156-158; however, only very small numbers of these cells have been 
identified in comparison with extracranial peripheral tissues147,158159. Furthermore, 
transmigration of T cells via the BBB into the brain parenchyma frequently occurs in 
diseases such as multiple sclerosis and viral encephalitis in humans74,79,160,161, or 
experimental acute encephalomyelitis (EAE) in mice79,162,163.  
As an early model system to understand how immune cells breach the BBB and 
penetrate into the brain parenchyma, several mechanisms have been proposed as to 
how the initiation of EAE occurs. Activated or encephalitogenic T cells, but not resting T 
cells were found to be able to penetrate the BBB after intravenous injection in 
rats164,165. This event was found to be independent of antigen recognition or MHC 
compatibility, but dependent on the activation and the blast stage of the T cell, 
indicating that T cell activation alone was sufficient for T cells to breach the BBB166.  
Subsequent studies showed that this process is dependent on P-selectin to access the 
leptomeningeal vascular endothelium, and lymphocyte function-associated antigen 1 
(LFA-1) and α4-integrins to penetrate the BBB167. Additionally, based on the 
constitutive expression of CCL19 in CNS endothelia, a CCR7/CCL19-chemokine-
dependent mechanism has been proposed for CCR7-expressing T cells to cross the 
BBB via the leptomeninges162,164,168,169. In another study, entry of T helper-17 cells into 
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the CNS via the choroid plexus into the brain ventricles was found to be a 
CCR6/CCL20-dependent process, required for the initiation of EAE170. Cumulatively, 
these data indicate that encephalitogenic T cells can access multiple brain interface 
sites to penetrate the BBB and induce neuroinflammation.  Although the prior studies 
were based on a model in which autoreactive T cells are constantly circulating in the 
bloodstream and are able to directly penetrate the BBB, a recent study showed that 
circulating T cell blasts lack the capacity to penetrate the BBB and initiate EAE in a rat 
model unless they are first licensed in the lungs171. In fact, after local stimulation of 
resting myelin-reactive memory T cells in the lungs of rats, those cells proliferated 
profoundly, migrated to the CNS, and caused paralysis in the rats171.  This indicated 
that the lung is a site of reactivation for autoaggressive T cells prior to induction of EAE.  
More recently, another study detailed the events that occur after the BBB has 
been breached following induction of EAE163. Shortly after cerebral vessel disruption 
following EAE induction with subcutaneous injection of myelin oligodendrocyte 
glycoprotein (MOG) peptide, Incomplete Freund’s Adjuvant (IFA), and intraperitoneal 
injection of pertussis toxin, microglia become activated, and this was followed by 
infiltration of DCs and T cells163. This latter study suggested a model in which activated 
microglia are the primary initiators of autoaggressive T cell entry into the CNS. 
However, only the green fluorescent protein-tagged receptor CX3CR1, which is broadly 
expressed by microglia, macrophages, and some DCs, was used to identify 
microglia163. In addition, the mechanisms by which T cells accumulate and are retained 
at sites of EAE remain unknown. In sum, there appear to be different mechanisms 
involved in the initiation of EAE. Whether the various mechanisms involved in EAE 
initiation are interconnected or work separately is an important question that is still 
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being dissected. Importantly, whether similar mechanisms are operational in brain 
tumors is being investigated.   
In patient GBM tissues, studies conducted in the 1970s and 1980s revealed high 
numbers of infiltrated microglia and macrophages, but rare infiltrating T cells. In 
addition, GBM patients were found to be highly lymphopenic, bearing resemblance to 
patients with immune-deficient disorders172-175. On one hand, it was believed that GBM 
patients were generally lymphopenic and on the other, due to the prevailing idea of 
brain immune privilege, it was thought that antigen presenting cells such as DCs and 
adaptive immune T cells were likely restricted from being present within these tumors. 
Regulatory T cells have been found in high numbers in peripheral blood and tumor 
tissue in patients with GBM, and have been suggested as an immune suppressive 
mechanism in GBM patients176-179. Hence, it is unlikely that the BBB preferentially 
restricts effector T cells from migrating into GBM tumor tissue. Alternatively, it was 
thought that inefficient or lack of antigen presentation to naïve T cells could explain the 
limited number of effector T cells in GBM tissue180-189. This latter theory seemed 
plausible partly due to the fact that classical lymphatics in the CNS had not been 
identified at the time190-192. As it would turn out, there is now evidence to support the 
idea of inefficient or lack of antigen presentation in GBM, and CNS lymphatics have 
been identified62,63,82. Thus, by using appropriate models in which antigen presentation 
is operational, one could address several important questions pertaining to the 
dynamics of T cell migration into BT, potential local proliferation in the tumor, and 
interaction with antigen presenting cells in the tumor microenvironment. These are 
questions that I will probe in chapter 3 of this thesis.   
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1.4.3. The role of CNS Lymphatics in immune response to brain tumor   
Lymphatics are critical in the generation of an immune response during tumor 
progression. Conventional lymphatic vessels are made up of endothelial cells that are 
identified by the expression of Prox1, CD31, LYVE-1, podoplanin, VEGFR3, and 
CCL2182,193,194. Similar to peripheral tissue capillaries, lymphatics are generally 
permeable, allowing for ISF, macromolecules, and cellular entry195. Anatomically, there 
are two types of lymphatics, including afferent and efferent lymphatics; the afferent 
lymphatic channel transports lymph and cells from the tissue to the draining lymph 
node while cells exit the efferent lymphatic into the bloodstream to a potential target 
tissue (Figure 2). Functionally, lymphatic vessels are classified into initial and collecting 
vessels195-198. Importantly, the collecting vessels possess bi-leaflet valves to allow for 
unidirectional flow of lymph.  Antigen presentation generally involves the migration of 
antigen presenting cells such as DCs via the afferent lymphatic vessel to the tissue-
draining lymph node where antigen presentation to naïve T cells occurs. The efferent 
lymphatic vessel serves as a conduit for activated effector T cells exit the lymph node 
into the bloodstream and migrate to a target tissue.  
In the brain, the mechanism of antigen transport is still been unraveled. In the 
1960s, lymphatic vessels were described to be present at the base of the skull 199. 
Subsequently, dural lymphatics were described in rats200. It was in the 1980/ 1990s that 
Cserr H.F. et al. first showed using functional experiments that tracer dyes that were 
directly injected into the CSF or brain parenchyma could be traced from beneath the 
olfactory lobe to the nasal lymphatics and the cervical lymph nodes72,80 (Figure 4). 
Recently, mechanistic studies have confirmed earlier findings and demonstrated that 
brain parenchymal ISF drains into cerebral perivascular spaces, termed “glymphatics”, 
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and that both ISF and cerebrospinal fluid (CSF) eventually drain into a recently 
described perisinusoidal conventional lymphatic network in the mouse meninges82,194 
(Figure 5a &b). In addition, a direct connection between the meningeal lymphatics and 
the cervical lymph node has been demonstrated. In light of these findings, the routes of 
antigen-presentation in EAE that I elaborated on in the BBB section are being 
reexamined193,201,202.  
In BTs, prior studies showed that vaccination of BT-bearing mice and GBM 
patients in the flank region with dendritic cells loaded with tumor antigen can induce 
antigen presentation in the inguinal lymph node and result in BT eradication86,203,204. 
This supported the idea that antigen presentation is likely defective in GBM patients. It 
also suggests a model in which antigen-presentation in a distal secondary lymphoid 
tissue from the brain can elicit robust immune response to BT. In addition, in a recent 
study, Dunn G.P. et al., identified the presence of neoantigens in GBM mouse tumor 
models including GL26163. Interestingly, these mouse tumor models were found to 
contain very high mutational load of up to 26, 000 compared to less than 100 in GBM 
tissues22,63. Following direct inoculation of mice with cancer cells into the brain, antigen-
specific T cells for the same previously identified neoantigens were recovered with 
tetramers from both the tumor mass and the cervical lymph node. These findings 
suggest a model in which BT antigens are transported from the brain parenchyma to 
the cervical lymph node likely via the “glymphatic” and meningeal lymphatic routes 
described above. Whether BT antigen-presentation occurs at multiple sites other than 
the cervical lymph node or whether the extent of BT antigen presentation varies in 
different lymphoid tissues remains to be elucidated. In sum, the brain appears to be 
open to surveillance by immune cells such as T cells. This gives further support for the 
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questions I aim to answer pertaining to T cell surveillance in BTs. In the next few 
sections I will go into details into the key cells involved in tumor immune surveillance, 
the distinct immune cells found in the brain, and the roles they might play in BT 
surveillance.       
 
 
 
 
 
 
Figure 4. Prior view of CNS lymphatics. Schematic showing the drainage paths of 
lymphatics in a rat brain (Black arrows). Adapted by permission from John Wiley 
&Sons, Inc.: [Neuropathol Appl Neurobiol.] (Kida, S., CSF drains directly from the 
subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and 
immunological significance 1993 Dec; 19(6):480-8.). Copyright Clearance Center. 
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Figure 5. New view of CNS lymphatics.  
a. Schematic showing the drainage paths of lymphatics in a mouse brain (Green 
arrows). The blue and orange arrows show the flow of CSF and ISF, respectively. 
Adapted by permission from Elsevier: [Neuron] (Louveau A., Lymphatics in 
Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis 
and Alzheimer’s Disease? 2016 Sep 7;91(5):957-73.). Copyright Clearance Center.  
b. Schematic depiction of the glymphatic pathway. In this brain-wide pathway, CSF 
enters the brain along para-arterial routes, whereas ISF is cleared from the brain along 
paravenous routes. From here, solutes and fluid may be dispersed into the 
subarachnoid CSF, enter the bloodstream across the postcapillary vasculature, or 
follow the walls of the draining veins to reach the cervical lymphatics. “From [Iliff, 
Jeffrey J. et al. “A Paravascular Pathway Facilitates CSF Flow Through the Brain 
Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid Β.” Science 
translational medicine 4.147 (2012): 147ra111. PMC. Web. 11 Mar. 2017.]” Reprinted 
with permission from AAAS. Copyright Clearance Center. 
a 
b 
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 1.4.4 Myeloid cells 
Macrophages  
Macrophages are critical in regulating tissue homeostasis, and controlling tissue 
inflammation involving pathogens and cancer53,205.  Macrophages originate from the 
yolk sac during embryogenesis in mice and migrate into tissues to become tissue 
resident cells such as Kuppfer cells in the liver, microglia in the brain, Langerhan cell in 
the dermis, and alveolar macrophages in the lungs. During inflammatory conditions, 
macrophages presumably originate from circulating monocytes, which are derived from 
the bone marrow common macrophage dendritic precursor (MDP) cells206. However, 
the specific population of blood monocytes that differentiates into macrophages in 
tissue is yet to be identified. Within different tissues, the mechanisms by which 
macrophages are sustained vary. In general, macrophages are able to self-renew in 
tissue by local proliferation while a portion of tissue-resident macrophages are 
replenished from the circulation by blood monocytes207. Macrophages in mice and 
humans can be identified by a combination of surface markers including CD11b 
(mouse/human), F4/80 (mouse), CD68 (mouse/human), CSF1R (mouse/human), 
MAC2 (mouse/human), CD11c (mouse/human), Ly6G (mouse), Ly6C (mouse), IL-
4Ralpha (mouse/human), and CD163 (human)208. Importantly, there is no single 
marker that defines macrophages exclusively and typically a combination of high 
CD11b, F4/80, and low CD11c (enriched in DCs), Ly6G (enriched in granulocytes), and 
Ly6C (enriched in monocytes) are used to identify them. In addition, other surface 
markers such as CX3CR1 and Iba1 together with cellular morphology are utilized for 
identifying specialized tissue macrophages such as microglia and other CNS 
macrophages residing at brain interfaces209,210. 
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Microglia and CNS macrophages 
In the adult steady state brain, microglia make up the highest number of resident 
myeloid cells in the brain parenchyma 75,211,212 (Figure 6). Microglia play critical roles 
during neural development and in maintaining tissue homeostasis in the adult brain by 
pruning developing neurons and engulfing cellular debris, respectively211,213. In steady 
state, microglia soma are fixed, and they rely on highly motile cell processes that 
continuously extend and retract to survey the surrounding brain region for potential 
dead cells214. In a recent finding, TAM (named after receptor tyrosine kinases Tyro3, 
Axl, and Mer) receptor tyrosine kinases Mer and Axl, and corresponding ligands Gas6 
and protein S, which are known regulators of innate immune response, were found to 
control phagocytic functions of microglia at steady state215.  However, in the presence 
of inflammatory signals such as IL6, TNFalpha, and nitric oxide (NO), microglia become 
sensitized to neural-derived factors such as adenosine triphosphate (ATP), glutamate, 
and the chemokine fractalkine (CX3CL1)216-219. They then become activated, transform 
into an amoeboid form, and subsequently migrate to areas of perturbation to prevent 
further damage to the brain tissue or, in some cases, exacerbate the inflammation215.  
For a long time, microglia were thought to arise from bone marrow progenitor cells, 
which give rise to some tissue macrophages220-223. Fate mapping studies in mice, 
however, have revealed a colonization of the brain by microglia during only 
embryogenesis224 (Figure 7). Around embryonic day 9.5 (E9.5), yolk sac myeloid cells 
migrate to the brain to become the brain microglia. It was also believed that circulating 
monocytes could replenish microglia in an adult brain221. However, numerous studies 
have now shown that microglia in an adult brain are not replenished by peripheral 
myeloid cells, indicating that microglia self-renew and that resident microglia and       
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Figure 6. Organization of innate myeloid cells in the healthy brain. Microglia are 
present within the parenchyma of the brain in steady state. Other myeloid cells are 
named according to location occupied in the cranial compartment including choroid 
plexus macrophages (location: choroid plexus in the ventricles); perivascular 
macrophage (location: perivascular space); meningeal macrophage (location: 
meninges); and dendritic cells (location: meninges and perivascular space). Adapted by 
permission from Macmillan Publishers Ltd: [Nat Rev Neuroscience] (Marco Prinz and 
Josef Priller, Microglia and brain macrophages in the molecular age: from origin to 
neuropsychiatric disease 2014 May; 15(5):300-12. Copyright Clearance Center. 
 
infiltrating monocytes/macrophages derived from the circulation may play distinct roles 
in steady state and pathological conditions206. However, the radioresistant nature of 
microglia as well as the quick regenerative properties of monocytes/macrophages have 
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made it technically challenging in delineating the distinct roles played by each of these 
subsets in chronic diseases such as cancer225,226.   
Apart from microglia which are the resident intraparenchymal myeloid cells of 
the CNS, there are other resident macrophages that reside within specific niches at 
brain parenchyma interfaces including meningeal (mMF), perivascular (pMF), and 
choroid plexus macrophages (cpMF). Recent studies have provided a better 
understanding of the relationship between these cell types209. Despite the believe that 
other CNS macrophage subsets originate from the fetal liver and can be replenished by 
circulating bone marrow-derived monocytes, recent findings indicate that CNS 
macrophages and microglia are actually ontogenically related209 (Table 2). Apart from 
cpMFs which originate from both the yolk sac and fetal liver myeloid precursor cells and 
can be replenished by circulating Ly6C+ monocytes in a CCR2 dependent manner, 
mMFs and pMFs were demonstrated to originate from only the yolk sac and migrate 
into their distinct niches in the brain at similar times with microglia209. And both mMFs 
and pMFs are not replenished by circulating monocytes in similarity to microglia. At the 
transcriptional level, CNS macrophage subsets and microglia depend on the 
transcription factor PU.1, but not Myb, Batf3, and Nr4a1. In addition, they share surface 
expression of CX3CR1, CSF1R, and Iba1. Notwithstanding, all CNS macrophage 
subsets showed higher expression of Ptprc (CD45) at both the mRNA and protein level 
when compared with microglia, while perivascular macrophages were enriched for 
Mrc1 (CD206) and CD36 in addition to CD45209. Furthermore, CNS meningeal and 
perivascular macrophage development was shown to be independent of Flt3+ 
multipotent hematopoietic precursors in the BM, indicating that CNS macrophages are 
distinct from BM derived cells. 
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Table 2. Characteristics of resident myeloid cells in the brain parenchyma and at 
central nervous system interfaces 
 
 
In fact, it was demonstrated that previous observations of BM-derived cells infiltrating 
the brain interfaces in chimera experiments was due to irradiation-induced CNS tissue 
inflammation, which could damage the BBB and artificially attract BM cells to the 
brain221. Morphologically, microglia are ramified, meningeal macrophages are 
amoeboid, and perivascular macrophages are elongated in alignment with proximal 
blood vessels. Therefore, they can be distinguished by imaging studies. In addition, 
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intravital imaging has shown that microglia and CNS macrophages extend and retract 
cell protrusions differently209. However, whether CNS macrophage subsets play distinct 
roles from bone marrow-derived macrophages or microglia is not yet known. In sum, 
different myeloid cell subsets have to be taken into consideration when investigating 
the role of myeloid cells in BTs.  
 
 
Figure 7. Myeloid cell colonization of the brain from embryonic to adult life in 
mice. At embryonic day 9.5 (E9.5), Yolk-sac (YS)-derived macrophages gain access 
into the circulation, migrate, and localize in the embryonic brain to give rise to microglia. 
Other brain macrophages depicted in Figure 6 differentiate from YS and fetal liver-
derived monocytes, and the bone marrow becomes a major source of monocytes in 
adult steady state or inflamed brain.  Adapted from Frontiers open-access publisher: 
[Front Cell Neurosci.] (Ginhoux F, Origin and differentiation of microglia 2013 Apr 
17;7:45.)  
 
Role of Macrophages and Microglia in brain tumors 
In the context of cancer, macrophages constitute a widely researched population 
in the tumor microenvironment termed tumor-associated macrophages (TAMs)227-231. 
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Early investigations into immune response to BTs revealed that BTs are largely 
infiltrated by classical macrophages and the brain resident microglia205,232. Since then, 
there has been immense interest in understanding macrophage plasticity and its role in 
BT progression. Based on the availability of certain molecular factors such as IFN-
gamma, IL-1, and TNF-α, TAMs can be skewed to an “M1” anti-tumor or “classical” 
phenotype, while immune suppressive cytokines such as IL-4, TGF-beta, and IL10, 
tend to skew TAMs to an “M2” pro-tumor or “alternative” phenotype233,234. However, 
most of these studies are in vitro and may not rigidly translate in vivo as represented by 
a recent study that found that these macrophage phenotypes do not exist at polar ends 
of a spectrum but rather in continuum, with more resemblance of an unpolarized “M0” 
phenotype235. Depletion of presumably “M2” TAMs by various strategies including small 
molecule inhibitors such as colony stimulating factor 1 receptor (CSF1R) inhibitors in 
vivo has shown reversal in tumor growth, and this is presently an area of intense 
research as CSF1R inhibitors are currently being tested in clinical trials236-239.  
However, the origin of TAMs in brain tumor remains very controversial. 
Experiments in mice have shown that TAMs are mostly composed of infiltrating cells 
from peripheral tissues such as the bone marrow; however, a recent study claims that 
TAMs in BT are composed of mainly microglia and not circulating monocytes, and that 
microglia drive BTs progression240. In the latter study, head-shielded mice were 
irradiated, leading to eradication of only bone marrow hematopoietic cells and 
circulating cells in the periphery but not the cranial compartment. Microglia but not 
blood-derived macrophages or monocytes were found to be diffusely infiltrating the 
tumors. Conflicting with other investigators, the authors claimed that microglia have 
high expression of CD45 (a marker that has been shown to be strikingly low in 
31 
 
microglia and used as a separation marker for microglia and CD45hi-expressing 
macrophages)240 and suggested that the literature on microglia should be reevaluated. 
Furthermore, the authors failed to consider CNS macrophage subsets at brain 
interfaces, skull bone marrow myeloid cells, and brain dendritic cells that were not 
eliminated with irradiation 209,212,241. In fact, a more recent study showed that 
macrophages residing at CNS interfaces express high levels of CD45 at both the 
mRNA and protein levels, in contrast to microglia, and may play a crucial role in neuro-
oncologic diseases209. As such, the composition of myeloid cells in BTs is still unclear 
and deserves thorough scrutiny. In this thesis, I have generated a novel reporter mouse 
model and developed a new method of analysis in an attempt to better characterize 
myeloid cell subsets in BTs. 
For a long time, there has been uncertainty as to whether DCs could play a 
major role in antigen presentation in BTs since only very small numbers have been 
detected in BT tissue242. Due the predominance of microglia and macrophages, which 
have been estimated to make up about 30% of BT tissue, it has been suggested that 
these are the cells that play a major role in regulating immune surveillance in BT 
progression. In studying immune regulators in BTs, microglia and macrophages are 
commonly lumped together due to the difficulty in distinguishing between both cell 
types. Thus, it is unclear as to whether both cell types play distinct roles in immune 
response to BTs. Nevertheless, glioma-infiltrating microglia/macrophages show high 
expression of TLRs, but are inefficient at producing inflammatory cytokines such as 
TNF-α, IL-1, and IL-6. In addition, despite showing high expression of MHC-II, they lack 
expression of costimulatory molecules CD80 and CD86242,243. This would suggest that 
they are likely ineffective at presenting antigens to T cells. Interestingly, in vivo 
32 
 
stimulation of glioma-infiltrating microglia/macrophages in rats by intratumoral injection 
of CpG-containing oligonucleotides, which engage TLRs, in glioma-bearing rats 
resulted in increased glioma growth and a reduction in cytotoxic T cell tumor lysis 
capacity244. This indicates that attempts at stimulating glioma-infiltrated 
microglia/macrophages, at least with CpG-containing oligonucleotides, may be 
ineffective in activating adaptive T cells and could be deleterious. In BT-bearing mice, 
microglia have been shown to express Fas ligand, a molecule involved in cell-mediated 
apoptosis. Inhibition of Fas ligand activity resulted in increased infiltration of leukocytes 
into the tumor mass. Thus, glioma-infiltrating microglia/macrophages are thought to be 
polarized to an “M2” tumor-promoting phenotype, in which form they suppress effective 
immune surveillance of BT245.  Importantly, interventions aimed at skewing presumable 
“M2” macrophages to an “M1” proinflammatory or anti-tumor phenotype or depleting 
glioma-infiltrating microglia/macrophages have resulted in extended survival in tumor-
bearing mice235,236,246 247. However, it is still unknown whether depletion by CSF-1R 
inhibitors actually acts on distinct “M2” macrophages since “M1/M2” macrophages are 
now known to be closely related and bear semblance to an unpolarized “M0” 
phenotype at least in human glioma, which may extend in a similar manner in mice. 
Nonetheless, the results indicate that glioma-infiltrating microglia/macrophages have an 
immune suppressive role in BTs, but does not reflect on their capacity to directly control 
T cell surveillance in BTs.  In addition, depleting glioma-infiltrating 
microglia/macrophages is inefficient as tumors recur frequently237. 
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Monocytes 
Monocytes play key roles in tumor progression248. They are thought to differentiate and 
replenish macrophages or DCs in tissue249,250. Monocytes originate from a common 
macrophage dendritic cell precursor (MDP) in the bone marrow250 (Figure 8), and are 
classified into Ly6C+ classical monocytes (CM) and Ly6C- patrolling monocytes 
(PM)250.  
 
 
 
 
 
 
 
 
 
 
Figure 8. Monocyte derivatives in peripheral tissues in health and disease. 
Resident monocytes express high levels of CX3CR1 which, upon interaction with 
fractalkine, facilitates extravasation into tissues, where these cells give rise to 
specialized cell types. Inflammatory monocytes express lower levels of CX3CR1 but 
have high levels of other receptors like CCR2 that respond to inflammatory 
chemokines, resulting in migration of the cells to sites of inflammation, where they 
subsequently differentiate into dendritic cells (DCs) or macrophage/myeloid derived 
suppressor cells.  Monocytes with no expression of CX3CR1 give rise to interferon 
producing cells (IPC) also called plasmacytoid DCs (PDC). Adapted by permission from 
Macmillan Publishers Ltd: [Immunity] (Geissmann F. et al., Blood Monocytes Consist of 
Two Principal Subsets with Distinct Migratory Properties 2003 Jul;19(1):71-
82.) Copyright Clearance Center. 
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Several transcription factors including PU.1, JunB, C/EBP-a, C/EBP-b and IRF8 play 
key roles in the development of myeloid cells in general and especially in CM. In 
contrast, development of hematopoietic cells into PM has only been recently shown to 
be dependent on Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) 
expression251,252. Although it was previously believed that CMs differentiate into PM, it 
is now known that CM and PM utilize distinct and independent pathways during 
development and likely perform different functions252.  The CM subset is identified by 
the surface expression of Ly6C+ CCR2+ CX3CR1lo CD62L+. Functionally, CMs migrate 
to tissues invaded by infectious agents or into inflamed tissues, and can differentiate 
into antigen presenting DCs and potentially mediate acute pathogen clearance or 
differentiate into monocytic myeloid derived suppressor cells (MDSC), in which case 
they contribute to immune tolerance in chronic disease states253. Importantly, CMs 
have also been shown to robustly migrate and infiltrate tumors, where they contribute 
to an immune suppressive population of monocytic cells also referred to as Ly6C+ 
CD11b+ Gr1+ CCR2+ monocytic MDSC as opposed to the neutrophilic population of 
Ly6G+ CD11b+ Gr+ granulocytic MDSCs. Both populations promote tumor growth and 
there is active research in this area to gain better understanding about their 
regulation254,255. Despite the availability of more evidence skewed toward revealing CM 
as pro-tumorigenic cells, some studies have also demonstrated an anti-tumor role for 
CM in the control of cancer cell metastasis, reminiscent of its capacity to also serve as 
precursor for antigen presenting DCs in infection and indicative of a dual role during 
inflammation256-258.  
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Table 3. Classification and characteristics of monocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In contrast, patrolling monocytes, which are identified by the surface expression 
of Ly6C- CCR2lo CX3CR1+ CD62L-, were known for long a long time to only survey 
healthy vasculature for potential damage259,260; however, recent intravital imaging 
studies in a model of lung tumor revealed a new role for PMs in preventing the 
adhesion of circulating cancer cells to lung tissue vasculature. In situations where 
cancer cells succeeded in engrafting into the lung tissue, PMs were found to be 
capable of transmigrating through the pulmonary vascular endothelium and infiltrating 
the established tumor. In addition, signaling via the Fractalkine chemokine receptor 
CX3CR1 was found to be required by PM to inhibit lung tumor initiation261. However, 
the extent to which CMs and PMs infiltrate brain tumor and their organization in the 
tumor microenvironment is unknown. In this thesis, I have attempted to analyze the 
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extent to which CMs and PMs are prevalent in BT. Nevertheless, it will be crucial to 
distinguish the functions of these monocyte subsets in BT progression.  
 
Dendritic cells  
Dendritic cells (DCs) are professional antigen presenting cells (APCs) and serve 
as a major link between the innate and the adaptive arms of the immune system212,262-
265. DCs utilize a diverse repertoire of receptors expressed on the cell surface to scan 
and recognize PAMPs in microbial infections266-273 Consequently, they endocytose and 
process such infectious microbial agents into peptides that are eventually presented to 
naïve T cells in the lymph node via peptide-MHC complexes I and II (pMHC-I and 
pMHC-II)274-276. Precisely, the engulfed tumor materials are processed through complex 
intracellular machinery such as the proteasome into distinct peptide antigens, which are 
then loaded unto MHCs in the endoplasmic reticulum, and eventually routed through 
the golgi apparatus and displayed on the surface of DCs277. During this process, DCs 
migrate through afferent lymphatic channels to the tumor-draining lymph node 
paracortical regions, where they encounter naïve T cells.  
Importantly, unlike other APCs such as macrophages, after phagocytosis of 
antigens, the acidic milieu in DCs is tightly regulated by NOX2 to prevent destruction of 
potential peptide antigens necessary for T cell activation278. In addition, DCs have an 
extensive capacity to process and present/cross-present antigens from both 
intracellular and extracellular pathways via pMHC I and II278. Further, in contrast to 
other APCs, DCs express costimulatory ligands CD80 and CD86 that are necessary for 
T cell priming.  Regardless, a clear distinction between DCs and macrophages still 
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remains controversial as there is no specific marker that delineates these two 
described cell types.  
DCs are recognized by their expression of a combination of several surface 
markers, including CD45+ CD11chi MHC-II+ CD11b+. Although CD11b is widely 
shared by myeloid cells including DCs and macrophages, CD11c is highly expressed 
on all subsets of DCs in mice in contrast to a low expression on macrophages (which 
have high expression of F4/80), while CD11b is expressed by only a few subsets of 
DCs. Therefore, CD11c expression has become almost interchangeable with the 
presence of DCs; however, care must be taken in interpreting results using this marker. 
CD11c is an integrin also referred to as integrin gamma X (ITGAX) and its functional 
role is unknown. Fluorescent transgene encoded by the CD11c promoter has been 
used to create a reporter mouse that has helped dissect the myeloid lineage within in 
vitro studies and has played a major role in increasing our understanding and 
appreciation of dynamic interactions between DCs and T cells in in vivo imaging 
studies.  
Two subsets of DCs have been recognized based on differences in phenotype 
and function. They include CD8α+ and CD8α- DC subsets. CD8α+ DCs are found in 
the spleen of mice279 and are critical in the activation of CD8+ cytotoxic T cells (CTLs). 
In peripheral tissues, however, similar DCs do not classically express CD8α. Instead, 
they are recognized by the expression of CD103280. Importantly, CD8α+/CD103+ DCs 
are efficient at engulfing and processing apoptotic cell bodies at sites of infection or 
cancer, and subsequently cross-present the peptide product of apoptotic cells to CD8+ 
T cells within the same vicinity281,282. Thus, it is likely that efficient T cell surveillance of 
BT will involve interactions between DCs, such as CD8α+ DCs, and T cells in the tumor 
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microenvironment. CD8α+/CD103+ DCs rely on several transcription factors for 
development including Batf3, IRF8, and Zbtb46283.  In Batf3 knockout mice in which 
CD8α+ DCs are absent, there is poor control of infections such as Toxoplasma gondii, 
and enhanced growth of tumor in cancer models284-286. This would suggest a possible 
role for CD8α+ DCs in BT control.  The second subset of DCs identified as CD8α- DCs 
are delineated by other surface markers including CD11b+ and CD4+. Importantly, they 
are involved in the activation of CD4+ T cells. CD8α- DCs are required in Th2 T cell 
responses in allergic diseases279,287. Apart from these latter DC subsets, a small 
population of resident DCs has been found to reside in certain regions of the brain 
involved in neurogenesis212. Based on marker expression such as CD115, Gr-1, and 
Ly-6C, it is thought that they are mucosal and monocyte-derived288. In addition, they 
can be identified by expression of CD11c, but some populations express CD11b and 
CD103. Interestingly, brain DCs can proliferate under the influence of IFN-gamma, can 
upregulate MHC-II, and can stimulate naïve CD8 T cells241,289. However, they are 
known to be largely radioresistant, in similarity to microglia, and their role in BTs needs 
to be determined.  In sum, DCs are likely to play a major role in controlling T cell 
surveillance in BT. In the next section, I will discuss T cells and the mechanisms by 
which DCs prime T cells during an immune response. 
 
1.4.5 T cell biology, T cell priming, and role of T cell subsets in cancer 
T cells are the main effectors of the adaptive arm of the immune system involved 
in cell-mediated immunity1. For T cells to function effectively, they must recognize 
antigens presented as peptides on MHCs via the T cell receptor (TCR). The TCR is a 
heterodimeric protein in the T cell membrane that consists of an alpha and a beta chain 
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(αβ-T cells); however, in a different type of T cells, the TCR is made up of a gamma 
and a delta chain (γδ T cells). Within the scope of this thesis, I will be focusing strictly 
on the role of αβ-T cells in BT surveillance. Developmentally, T cell precursors, which 
originate from the bone marrow, migrate to the thymus where they rearrange alpha and 
beta TCR chains and undergo positive and negative selection in the thymic cortical and 
medullary regions, respectively. During this selection process, T cells that bind strongly 
to self-antigens are clonally deleted290. T cells that are not deleted undergo clonal 
diversion to become regulatory T cells (Tregs), which play crucial roles in both 
autoimmunity and cancer progression. Following completion of T cell selection, mature 
CD4 and CD8 T cells exit the thymus into the systemic circulation and eventually 
localize and reside in secondary lymphoid organs such as lymph nodes (SLOs) and 
spleen291.  Within SLOs such as lymph nodes, T cells continuously scan for cognate 
antigens in the para-cortical region. However, for efficient antigen presentation, pMHC-
DCs rely on chemokine receptors like CCR7 to migrate to paracortical T cell areas in 
the draining lymph node over a CCL19/CCL21 chemokine gradient78,292,293. 
Correspondingly, naïve T cells also utilize CCR7 in addition to DC-CK1 (a DC-
expressed chemokine, which preferentially attracts naïve T cells294) to scan for pMHC-
bearing DCs.  Upon making contact with pMHC-bearing DCs, a three-signal model of T 
cell activation ensues295-298.  
The first step in T cell activation involves the engagement of T cells with the 
pMHC on DCs via the TCR. The avidity and affinity of the TCR for cognate pMHC 
determines the strength of the signaling cascade downstream of the TCR299,300. This 
TCR signaling can be monitored by use of transgenic mouse models such as nuclear 
factor of activated T cells (NFAT) or NR4A1-GFP reporter mice301-303, in which the 
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green fluorescent protein (GFP) transgene is expressed under the orphan nuclear 
receptor NR4A1/Nurr77 promoter. By using a reporter mouse such as NR4A1-GFP 
transgenic mouse, early T cell activation involving only the ligation of the TCR can be 
detected in the form of GFP accumulation in the T cell nucleus. The mechanism behind 
this involves TCR ligation to pMHC complex, which leads to translocation of the NR4A1 
transcription factor from the cytoplasm to the nucleus where it binds to DNA cassettes 
to promote further downstream signaling.  
Following TCR ligation, cell-cell contact between the T cell and pMHC-
expressing DCs initiate the second signal299,304; this is mediated by binding of 
constitutively-expressed CD28 on T cells to costimulatory molecules on pMHC-DC 
including CD80 (B7-H1) and CD86 (B7-H2). Efficient binding of CD28 to CD80/86, is a 
necessary step in T cell activation without which T cells become anergic305.  This step 
also helps to amplify the TCR signal strength. In some situations, very high TCR signal 
strengths that could be deleterious to the host are potentially possible and could cause 
T cells to function in an auto-reactive manner. To prevent this from occurring, 
peripheral tolerance regulatory mechanisms involving the upregulation of co-inhibitory 
molecules such as CTLA-4  on the surface of T cells, which has a high affinity for 
B7/H1 and B7/H2,  competitively bind to and work to out-compete CD28 for the same 
cognate receptors,  preventing cell cycle progression306. Furthermore, the programmed 
death receptor receptor (PD-1), which is upregulated by chronically activated or 
exhausted T cells and binds to its cognate ligands (PDL1 and PDL2) on tolerogenic 
DCs, inhibits T cell activation by recruiting SHP1/2 to the TCR. SHP1/2 
dephosphorylate early downstream signaling events307-311. Cancers appropriate the 
upregulation of these natural homeostatic mechanisms of immunity to prevent 
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immunological clearance. In addition to the immune checkpoints, cellular (Tregs and 
MDSCs) and other molecular factors including T cell Fas/Fas-ligand interaction, 
transforming growth factor-beta (TGF-b), IL-10, and indoleamine 2,3-dioxygenase 1 
(IDO1), and immune suppressive cytokines contribute to peripheral tolerance 
mechanisms in physiologic or pathologic states312,313. These factors are known to be 
involved in inhibiting T cell activation. This would imply that in situations such as viral 
diseases and cancer, the inhibition of T cells by upregulation of these factors could 
subdue effector functions of T cells including interferon-gamma (IFN-γ), perforins, and 
granzymes139. In fact, a number of studies have revealed the utility of blocking these 
inhibitory signals in the tumor microenvironment in preclinical models of a diverse type 
of cancers including BTs314. The results from those studies showed that inhibition of 
such inhibitory signals slows the rate of tumor progression and is associated with 
increased presence of cytotoxic effector T cells314-319.     
The third signal includes a variety of stimulating cytokines including type 1 
interferon (IFN-I) and IL-12. Mechanistically, IFN-I and IL-12 enhance T cell response 
to basal IL-2 by prolonging the surface expression of IL-2 high-affinity receptor, CD25, 
thereby activating downstream phosphoinositol-3-kinase (PI3K) pathway and cell cycle 
progression genes via FoxM1320. As such, the third signal maintains long-term T cell 
proliferation.  
 
CD4 effector T cells 
A subset of CD4 T helper cells enhance the activation of CD8 cytotoxic T cells 
and also perform effector functions such as tumor killing. The Th1 subset of CD4 
effector T cells is induced by IL-12 and IFN-γ and is identified by the expression of the 
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Tbet transcription factor and production of cytokines including IFN-γ, IL-2, and TNF-
ɑ321. This subset is involved in cell-mediated immunity and inflammatory conditions, 
elimination of intracellular pathogens, and autoimmunity. Importantly, during T cell 
activation, inhibition of the co-inhibitory molecules such as CTLA-4 resulted in a Th1-
mediated control of tumor322.  
The Th2 subset is induced by a cytokine milieu in which IL-4 and IL-2 
predominate323,324. Such T cells are identified by the expression of GATA-3 
transcription factor and the production of IL-4, IL-5, IL-6, IL-10, and IL-13. This subset 
is primarily involved in the production of antibodies by B cells, in elimination of 
extracellular pathogens, and in allergic diseases such as asthma.  
In chronic diseases, a different subset known as Th17 is induced by TGF-beta and IL-
6, and identified by the expression of RORγt and production of IL-17, IL-21, and IL-22. 
Th17 cells play a role in the exacerbation of autoimmune conditions such as Crohn’s 
disease and in the elimination of extracellular pathogens and fungal infections325. 
Although their function remains controversial, elimination of Th17 cells resulted in 
decreased tumor-bearing mouse survival326,327.      
 
CD4 Regulatory T cells (Tregs) 
CD4 regulatory T cells are a subpopulation of T cells that are usually 
characterized by FoxP3 expression. In steady state, Tregs maintain immune tolerance 
to self-antigens.  Within inflammatory diseases, Tregs suppress T cell activation328-332. 
Tregs are similar to other T cells in that they originate from the same lymphoid 
precursor that populates the thymus. However, Tregs only acquire a distinct signature 
during the later stages of T cell development in the medullary region of the thymus by 
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binding to intermediate levels of self-antigen presented by autoimmune regulator 
(AIRE+)-expressing medullary thymic epithelial cells333,334. In addition, before exiting 
the thymus, they begin expressing high levels of the forkhead box P3 transcription 
factor (FoxP3)335, a hallmark feature of functional regulatory T cells (Tregs). Deficiency 
of Tregs in mice and humans leads to the rapidly fatal autoimmune condition known as 
immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX)336,337, 
demonstrating the key role of Treg cells in the maintenance of immune tolerance. The 
thymus-derived Tregs are termed natural Tregs and are best defined by the expression 
of CD4+, CD25+, and FoxP3+338. In addition, an inducible form of Tregs, which can be 
identified with a similar set of markers, are potentially generated from effector T cells in 
disease microenvironment such as cancer due to abundant immune suppressive and 
differentiation cytokines such as TGF-beta339,340. Importantly, Tregs are highly enriched 
in tumors and play an immune suppressive role by producing cytokines such as IL-10 
and TGF-b305,334,341-343. Previous work showed that Tregs accumulate preferentially in 
high-grade human gliomas, such as GBMs, altered effector function of non-Treg T cell 
fraction in vitro, but there was no impact of Treg presence on patient survival179,344,345. 
However, following similar observations in glioma-bearing mice, depletion of Tregs with 
anti-CD25 antibody resulted in prolonged mouse survival indicating that Tregs play an 
immune suppressive role in the glioma microenvironment178,179,318,319,346. 
Mechanistically, the CCL2/CCR4 chemokine axis has been implicated in the 
recruitment of Tregs in human glioma and strategies have been tested to modulate this 
pathway347. In addition, small molecule inhibitors acting on pathways utilized by Tregs 
such as the signal transduction and activation of transcription 3 (STAT3) pathway have 
been shown to deplete Tregs and are about to be tested in clinical trials348,349. 
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Furthermore, checkpoint blockade therapies including CTLA4, which have been shown 
to alter the CD4 T cell compartment and prolong survival in glioma-bearing mice, are 
already in clinical trials315. Thus, there is great interest in understanding immune 
suppressive mechanisms that might be utilized by Tregs to subvert immune-eradication 
of cancer and potentially resist these promising treatment strategies. However, it is 
unknown how Tregs are regulated by DCs in brain tumor. This thesis will address how 
Treg dynamics might be regulated in the BT microenvironment.   
 
CD8 T cells 
CD8 T cells are crucial in the elimination of viral infectious agents and in 
controlling cancerous growths341,350-355. Depletion of CD8 T cells with monoclonal 
antibodies is known to result in increased tumor growth and decreased mouse 
survival356,357. CD8 T cell engagement with cancer cells in vitro results in the 
polarization of cytolytic granules including perforins and granzymes toward the contact 
area if effector function is maintained358. Perforins are released and contribute to cell 
killing, in part, by creating pores in the target cell membrane thereby enabling the 
penetration of granzymes and subsequent target cell lysis359,360. Because CD8 T cells 
are effective in eliminating cancer during cancer immunotherapy, CD8 T cell proportion 
in tumor has been applied clinically, to some extent, as a surrogate for response to 
treatment361-367. Following the clearance of cancer cells or pathogens, CD8 T cells 
contract and form a memory pool that can be rapidly recalled upon secondary 
challenge by the same cancer or pathogen.  
Memory CD8 T cells are also an attractive target in immunotherapy especially in 
formulating anti-tumor vaccines because of its potential to prevent tumor occurrence or 
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recurrence after successful treatment. An active area of tumor immunology research is 
trying to understand how endogenous or exogenous transferred CD8 T cells can be 
retained in tumor to promote tumor cell killing. Some survival molecules that are being 
investigated include cytokines such as IL-2, IL-7, IL-15, and IL-21368,369, because they 
are critical in both naïve T cell function and in maintaining memory CD8 T cell pool. In 
the brain, CD8 T cells have been shown to form a tissue-resident memory pool after 
the elimination of a model virus pathogen in mice370. This memory pool correlated with 
the presence of a subset of CD11c+ DCs371, indicating that memory T cells may require 
CD11c+ DCs after resolution of an infection, at least in the brain. In general, however, 
how T cells interact with DCs and may be retained in BTs is unknown. I will be 
investigating the retention and interaction dynamics of T cells in this thesis. 
 
1.4.6. Dynamics of DCs and T cells in anti-tumor immune surveillance  
Anti-tumor immune surveillance is a very dynamic process. For this to occur 
during a natural anti-tumor immune response there must be cell-to-cell interaction 
between myeloid cells and T cells, and between T cells and the tumor372-375. Classical 
immunological techniques such as flow cytometry, immunohistochemistry, and animal 
cell transfers or chimera experiments have been used to establish a basis for immune 
cell infiltration and interactions in tissue; however, they have limited primary utility, but a 
significant complementary role in dissecting, understanding, and defining distinct real 
time cell dynamics and interactions within the immune circuit. Recent advances in 
intravital confocal and two photon microscopy have played a major role in the 
investigation of cell interactions in various organs and tissues including the eye, skin, 
lung, liver, intestine, brain, and lymph nodes376. While this technical application has 
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advanced our understanding of immune cell interactions especially in the lymph 
node295,377-379, it has only been recently deployed to study immune surveillance of 
tumors in peripheral organs including the lungs, skin, brain, mammary fat pad, and 
abdomen374,380.  
Through intravital multiphoton microscopy and complementary in vitro live cell 
studies of mostly infectious diseases373,379,381-383, it has been established that naïve T 
cells in the lymph node are highly motile. Naïve T cells display high average velocities 
of between 10-15μm/min, show non-directed random motility, and high instantaneous 
speeds of up to 25μm/min. However, upon making contact with antigen-loaded DCs, T 
cells show reduced velocity and instantaneous speed and persist in long-lived 
contacts384.  Thus, the exceptionally high speeds displayed by T cells in the lymph 
node have been explained as a mechanism to enhance the scanning efficiency of 
naïve T cells for peptide-loaded DCs. 
Super-resolved in vitro microscopy studies of peptide-loaded DCs and T cells 
have enhanced our understanding of immune synapse formation between cytotoxic T 
cells (CTLs) and DCs385-393. This highly dynamic process involves a feedback 
mechanism between CTL actin cytoskeleton polarization and TCR signaling. The 
mechanism entails the polarization of CTL actin cytoskeleton toward the immune 
synapse, upregulation of adhesive molecules such ICAM-1 and LFA-1, ligation of the 
TCR to the pMHC-DCs, and subsequent TCR downstream signaling that eventually 
results in the activation of the CTLs. Calcium imaging studies and model antigens such 
as ovalbumin have also enhanced the appreciation of the level of strength of T cell 
activation during such interactions394-396. In addition to the TCR ligation, the expression 
of co-stimulatory ligands such as CD28 and its interaction with its cognate B7-H1/B7-
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H2 receptors on DCs has been detailed296,306,397. As these processes are critical for T 
cell function, it will be important to study these processes in the BT microenvironment, 
as there may be differences in how T cells interact with DCs in vivo.  
In the tumor, the dynamics of immune cells in general are less well-
understood398,399. Nevertheless, in time-lapse movies, antigen-experienced T cells 
engage cancer cells and potentially a myriad other immune and stromal cells. Although 
it was predicted that an activated T cell could make sequential one to one contacts to 
kill cancer cells as had been observed in vitro, it has become apparent that this is a 
more complicated process in vivo400. For example, intravital imaging has shown that it 
takes approximately 6 hours for one cytotoxic T cell to kill one cancer cell372. This 
indicates that cancer killing, in vivo, is a very slow process, and supports the idea that 
large numbers of cytotoxic T cells are required to make any meaningful impact in tumor 
progression. However, possibly due to antigen recognition, T cells display a variety of 
migration patterns in vivo such as maintaining prolonged interactions, less prolonged 
interactions (“kiss and run”), or no interaction401. Therefore, it is likely that given a 
certain number of cytotoxic T cells in the tumor, only a proportion of those T cells may 
be involved in active killing of cancer cells. Despite these potential limitations, valuable 
knowledge has been obtained by direct visualization of T cell surveillance in tumor. For 
example, in a a model of subcutaneous tumor, OVA-expressing EG7 thymoma cells 
were implanted in mice and subsequently infused with exogenous TCR transgenic OT-
I-CTLs.Tumor-antigen specific CTLs infiltrated the tumor and show high expression of 
CD69 and IFN-y, indicating T cell activation. They exhibited reduced velocity, their 
migratory pattern became more confined, and they showed increased arrest in the 
tumor relative to non-OT-I-expressing CTLs372,402,403. Recent studies in mammary fat 
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pad of mice also utilizing the model OVA-antigen have shown that exogenously 
transferred OT-I-CTLs can persist in prolonged contact with DCs at the margin of the 
tumor, where they undergo reactivation375. These findings indicate that T cells must 
recognize cancer antigens in order to engage in prolonged interactions in the tumor 
microenvironment, potentially with cells such as DCs, macrophages, and/or tumor. It 
must be recognized that despite the ease of using model antigens in mouse studies to 
simplify our understanding of anti-tumor immune response, parallel studies in human 
tissues require analysis of highly polymorphic MHCs expressing a vast array of tumor 
associated-antigens, and variably recombined TCRs may have different reactivity to T 
cell epitopes404. A more recent study utilizing intravital imaging within a subcutaneous 
tumor suggested that during tumor progression, DCs “trap” CTLs; however, little is 
known about the role of DCs in the regulation of T cell surveillance in tumor. 
Specifically, much less is known within BT. Therefore, I will be devoting chapter 3 of 
this thesis to comprehensively address some questions pertaining to the role of DCs in 
BT immune surveillance and their interaction with T cells. 
 
1.4.7. Role of chemokines in immune cell recruitment and surveillance in brain 
tumors 
For immune cells to establish cell to cell contact, they must first migrate to the 
tissue of interest. Immune cells are highly dynamic and can migrate over long and short 
distances405,406. Myeloid cells such as DCs are generally generated from monocytes 
that migrate from the bone marrow and seed tissues while adaptive T cells egress from 
lymph nodes to tissue after undergoing priming. Chemokines are cytokines involved in 
the chemoattraction of cells in normal homeostatic conditions and at sites of 
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inflammation407. Several chemokines have been identified and they are grouped into 
four subfamilies including C-, CC-, CXC-, and CX3C- based on the number and 
spacing of cysteines.  
During inflammation, chemokines may be expressed at tissue endothelial 
surfaces in a bound form or released as a soluble form into serum. Importantly, 
immune cells migrate over chemokine gradients and utilize adhesion molecules such 
as integrins to bind to endothelial-bound chemokines in order to transmigrate into 
tissues via the vasculature408,409. Interestingly, DCs have been shown to exhibit 
differential migration patterns depending on the form of chemokine available. For 
example, surface-immobilized CCL21 was found to induce random migration of DCs, 
whereas a soluble CCL21 induced a directional motility pattern408. Although the 
repertoire of chemokines necessary for myeloid and T cell migration is vast, the 
specifics of how immune cells migrate and organize themselves in BT remains unclear 
and the regulation of this process is largely unknown.  
In the brain, several factors have been implicated in immune cell recruitment 
during inflammation including chemokines, neurotransmitters, molecules of the 
complement pathway, and ATP216. In BTs, glioma cells have been shown to produce a 
host of chemoattractants, which have been implicated in the recruitment of TAMs.  
including CSF-1, monocyte chemoattractant protein-3 (MCP-3), monocyte 
chemoattractant protein-1 (MCP-1/CCL2), hepatocyte growth factor and scatter factor 
(HGF/SF), fractalkine (CX3CL1), glial cell-derived neurotrophic factor (GDNF), CXCL12 
(SDF-1), and granulocyte macrophage-colony stimulating factor (GM-CSF). This 
indicates that there are a multitude of chemoattractants that can mediate immune cell 
recruitment in BTs. However, many of these studies have been conducted in vitro using 
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microglia cell lines, and in vivo studies on the importance of some chemoattractants 
such as MCP-1 have been challenged216. Out of all these, fractalkine is a particularly 
compelling candidate since it is highly expressed at steady state in brain tissue in 
comparison with other organs and has been termed the “neuronal chemokine.” Yet, its 
role in BT immune surveillance is unknown.    
Fractalkine is constitutively expressed in a membrane-bound form by neurons in 
a healthy brain and can be subsequently cleaved into a soluble form by 
metalloproteinases (MMPs) such as ADAM10 and 17 following tissue damage210. In the 
membrane-bound form, fractalkine exists as a 373 amino acid with an extracellular 
domain and mucin-like stalk, a transmembrane domain, and a cytoplasmic tail410. 
Following MMP cleavage, however, the soluble form acts as a chemokine that has an 
extracellular domain and the mucin-like stalk. Thus, fractalkine can serve both adhesive 
and chemotactic functions depending on the state of the tissue411,412.  
Fractalkine acts on and signals via its only known receptor, CX3CR1413,414. 
CX3CR1 is a G-protein coupled receptor413. CX3CR1 has been studied extensively 
with respect to microglia and macrophages in the context of cellular adhesion, 
apoptosis, and migration (Figure 9) but CX3CR1 is also expressed on the surface 
membrane of monocytes, and some DCs as such CX3CR1 may mediate DC and 
monocyte  migration and function in both physiological and pathological 
conditions210,409-411,414,415. In steady state, CX3CR1 is ubiquitously expressed by 
microglia in the brain parenchyma.  
The expression of both fractalkine and CX3CR1 has been intensively studied in 
neurogenesis, neurodegenerative diseases such as Alzheimer’s, and in brain 
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tumors213,416. The disruption of CX3CR1 has been shown to affect neural pruning, 
suggesting that microglia is critical in brain development211,213. In addition, CX3CR1 
deficiency may or may not have a role in mediating microglia function duringplaque 
removal and neuronal damage in models of Alzheimers417,418. Recently, CX3CR1 
deficiency was found to be associated with Ly6C+ classical monocytes infiltration in 
BTs and reduced survival in BT-bearing mice; however, DCs and T cells were not 
studied419. In addition, this process was determined to be orchestrated by IL-1 since 
fractalkine showed very low expression in mouse or human GBM cells/tumor mass, 
where the monocytes/macrophages were localized.419. However, it seems unlikely that 
fractalkine that is constitutively and highly expressed in healthy neuronal cells and a 
major chemokine would be dormant during an inflammatory process involving tumor-
induced tissue stress/damage and immune cell recruitment237. In the brain, it is 
possible that aggressively progressing tumors damage neurons and induce of the 
release of soluble fractalkine, which is an ideal candidate to regulate the dynamics of 
anti-tumor immune surveillance. 
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Figure 9. Role of Fractalkine/CX3CR1 chemokine pathway.  
The roles of Fractalkine are illustrated in the figure. It shows membrane bound and 
soluble Fractalkine (cleaved by metalloproteinases) participating in cellular adhesion 
and survival anti-apoptosis/migration, respectively.  
 
 
1.5. Specific aims 
Based on the information in this chapter, my central hypothesis is that brain 
antitumor immune surveillance by T cells is regulated by extracranial myeloid cells, 
such as BM-derived DCs through the neuronal chemokine fractalkine. I will present 
results from the investigation of this hypothesis in two specific aims: 
1. Determine the role of antigen presenting cells in the recruitment and  
dynamics of T cells in brain tumor microenvironment by employing real time 
imaging techniques 
53 
 
2. Determine the role of fractalkine/CX3CR1 signaling pathway in the dynamics 
of immune response to brain tumors by utilizing genetic knockout mouse 
models and intravital microscopy. 
The work in this thesis is aimed at determining the identity and composition of 
myeloid cells infiltrating BT and understanding the fundamental cellular mechanisms 
regulating anti-tumor T cell immune surveillance.  In addition, I have examined a 
molecular mechanism involving how a local chemokine produced in the brain tissue 
governs immune response to BTs. The results obtained from the experiments 
conducted in this thesis will increase our understanding of BT immune surveillance and 
will be relevant in developing strategies to enhance conventional immunotherapy.  
 
1.6. Overall approach and rationale 
The studies conducted in this thesis will help in constructing a brain tumor 
landscape of immune cellular localization, migration, and interaction. For this to be 
accomplished, appropriate tumor models will be used. Genetically engineered mouse 
models of spontaneously developing tumors (GEMMs) are the gold standard for 
studying tumor progression in preclinical settings. However, these models are driven by 
mostly oncogenic mutations and lack the endogenous passenger mutational load that 
may be relevant for proper antigenic immune cell recognition and function. Similarly, 
cancer cells derived from human BTs contain genetic mutations that may be closest to 
those detected in human patients with cancer; however, they have to be grown within 
immune deficient mice to prevent rejection. Thus immune response to such tumors 
cannot be adequately studied. In contrast, experimental tumor models derived from cell 
cultures of carcinogen-induced cancer types from different tissues including the brain, 
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lungs, skin, and soft tissues can potentially develop in immune-competent syngeneic 
animals when re-implanted. Importantly, it has been shown that tumors derived from 
such cancer cell types possess high mutational loads63 and are strongly 
immunogenic117,139, suggesting that there is likely to be endogenous immune reactivity 
when implanted in vivo in immune competent mice and as such help in the 
understanding of T cell surveillance in tumor. Therefore, to investigate the dynamics 
and regulation of endogenous immune cells in BTs, I have employed longitudinal 
intravital multiphoton microscopy of immune cells in experimental BT models including 
GL261 glioma, Lewis lung carcinoma (LLC), B16 melanoma, and MCA fibrosarcoma 
brain metastases. The rationale for employing intravital two-photon microscopy is to 
provide high spatiotemporal 3-dimensional resolution time-lapse images to better 
understand T cell surveillance in BTs in a dynamic fashion.  
 
Two-photon microscopy: 
Two-photon microscopy is a powerful imaging technique in biological research. 
In contrast to a confocal microscope that generates single high-energy photons from 
ultraviolet lasers to excite molecules in a volume of tissue, a 2-photon microscope 
works by simultaneously directing two separate low-energy photons of long 
wavelengths generated by ultra-fast femto-pulsed infrared lasers at a molecule. In 
confocal microscopy, excitation works linearly, while it is non-linear in 2-photon 
microscopy, meaning that, theoretically, image resolution is better with confocal 
microscopy; however, practical adjustments can be made in 2-photon microscopy to 
produce confocal-like resolution images.  
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Figure 10. Illustration of tissue excitation and emission in confocal and 2-photon 
microscopy. The green region represents the volume of tissue excited by photons. 
The green sphere at the intersection of the inverted cones represents the volume of 
tissue at the focal plane of interest.  The region within the inverted cones represents 
the volume of tissue above and below the focal region of interest.  
 
It is worth noting that low-energy photons are significantly less absorbed by 
molecules such as fluorophores than high-energy photons. Based on this principle, 
several advantages of using a 2-photon microscope become apparent. First, in contrast 
to confocal microscopy in which high-energy photons excite molecules above and 
below the focal plane in a volume of tissue illuminated (Figure 10), the low-energy 
photons of a 2-photon microscope only excite molecules in a focal plane, where the 
probability of two separate photons converging on a single molecule is highest. Further, 
because a large volume of tissue is excited during confocal microscopy, there is a lot of 
light scattering that occurs from out-of-focus planes leading to a blurred image. Hence 
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a pinhole is required to prevent the collection of out-of-focus scattered light. In contrast, 
since a 2-photon microscope restricts excitation of a molecule to a single plane, 
scattering from out-of-focus planes is greatly diminished and a pinhole is therefore not 
required. This enables deeper penetration of more low-energy photons into the brain 
tissue, resulting in better signal-to-noise. Interestingly, a very good example of a tissue 
that is highly light-scattering is the brain. In addition, exposure of large volumes of 
tissue to excitation in confocal imaging can potentially lead to 
photobleaching/photodamage and possible loss in tissue viability, while 
photobleaching/photodamage are limited to the focal plane of interest in 2-photon 
imaging and as such better preserves tissue viability. Especially relevant to brain 
imaging, low-energy photons in 2-photon microscopy can penetrate deeper into 
biological tissues to depths of up to 600um to 1mm420-425, while confocal imaging is 
usually limited to the surface of tissues to a depth of about 100um from the surface. 
Apart from the advantages above, 2-photon imaging also has the capacity to produce 
signals from unlabeled tissue samples such as collagen and muscle based on second-
harmonic generation (SHG). In this thesis, SHG will be used during imaging to visualize 
skull and meninges without any labeling, which will enable differentiation from the 
underlying brain cortex.   
Despite the advantages of 2-photon microscopes, the image resolution is usually 
lower than with confocal imaging. This is immediately understandable because a 
microscope’s scale resolution is inversely proportional to the wavelength of light 
used420. As such, 2-photon imaging requires expensive objectives with high numerical 
apertures. In addition, thermal damage arises during imaging of pigmented specimen 
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and could be potentially problematic during imaging of pigmented tumors such as 
melanoma.     
The use of intravital two photon microscopy here is innovative because it has not 
been used previously to the extent of its application in the studies conducted in this 
thesis. In addition, it will reveal information such as real time in vivo single cell-cell 
interactions in a multidimensional manner that cannot be accessed otherwise.  
 
Tumor models 
The tumor types that will be utilized include fluorescent-labelled syngeneic 
GL261 glioma, Lewis Lung Carcinoma (LLC), MCA-fibrosarcoma, and B16-F10 
melanoma. I have selected these cancer types because they recapitulate the most 
prevalent and deadly of patient primary BT and brain metastases to a certain extent, at 
least in an experimental setting. Importantly, as described earlier, each of these models 
is syngeneic to the immune competent hosts in which they will be studied, and thus can 
implanted to be studied in an orthotopic or heterotopic manner. To visualize tumor 
growth by intravital imaging, the cancer cells have been made fluorescent. As it is likely 
that fluorescent cancer cells may have higher immunogenicity due to the fluorescent 
proteins, appropriate controls have been used for proper interpretation of the data. 
 
Experimental strategies  
To visualize immune cell interaction with tumor, a broad range of multi-color 
reporter mice have been used to visualize distinct groups of immune cell populations 
including microglia, monocytes, DCs, T cells, and Tregs. For further visualization of T 
cell subsets and important molecules involved in T cell interaction, cells have been 
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stained by tissue immunofluorescence. To increase the robustness of the investigations 
in this thesis, genetic knockout mice, cell-specific in vivo depletion experiments such as 
in cell-specific diphtheria-toxin receptor mice, and bone marrow transfer studies have 
been conducted. In addition, to ascertain relevance to human patients with brain 
tumors, selected studies have been conducted on human tumors. It is hoped that the 
studies completed here will reveal relevant mechanisms underpinning anti-tumor T cell 
surveillance in the brain and provide new insight into how to optimize immunotherapies 
for brain tumor patients.   
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CHAPTER 2:  
MATERIALS AND METHOD 
Cell lines  
MCA-205 fibrosarcoma cell line was obtained from Dr. Xiao-Feng Qin (The 
University of Texas MD Anderson Cancer Center (UTMDACC)) B16-F10 was obtained 
from Dr. Willem Overwijk (UTMDACC), LLC was obtained from Dr. Limo Chen 
(UTMDACC), and GL261 was purchased from American Type Culture Collection 
(ATCC). Cell lines were confirmed to be mycoplasma free. Cancer cells were 
maintained in RPMI culture medium containing 5% fetal bovine serum (FBS), 1% 
Penicillin/Streptomycin (P/S), 1% beta-mercaptoethanol or in DMEM/high glucose 
media containing 10% FBS and 1% P/S. Cells in culture were stored in incubators at 
370C and 5% CO2. To render the cells fluorescent for intravital microscopy, MCA-205 
fibrosarcoma, B16-F10 melanoma, Lewis-lung carcinoma (LLC), and GL261 glioma cell 
lines were transduced with VECTOR DESCRIPTION encoding the mCerulean 
fluorescent protein as previously described.426 
 
Animals 
Use of animals was approved by the institutional use and care committee 
(IACUC) under protocol number 00000878-RN01. All animals were on the C57Bl/6 
background and bred in-house or commercially purchased. C57Bl/6 wild type (WT), 
Rag1-/-, CX3CR1-GFP, and CCR2-RFP mice were purchased from the Jackson 
Laboratories (Bar Harbor, ME). Additional C57Bl/6 WT mice were purchased from the 
Radiation Oncology Department at UTMDACC. CD11c-EYFP mice were obtained from 
Dr. Michel Nussenzweig, The Rockefeller University, New York, NY; hCD2-DsRed mice 
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were from Dr. Dimitris Kioussis, The National Institute for Medical Research, Mill Hill, 
London, U.K.; and ROSAmT/mG mice were obtained from Dr. M. Konopleva, Dept. of 
Leukemia, UTMDACC. Various combinations of these strains were generated by 
interbreeding and genotyping. For experiments, mice of both sexes were used at ~1.5 
to 6 months old and euthanized by CO2 inhalation and cervical dislocation in line with 
the IACUC guidelines. 
 
Brain Tumor Models  
To generate tumors in mouse brain, cancer cells were prepared and injected 
either directly by intracranial injections or indirectly via the internal carotid artery. 
Cancer cells were harvested from 10 cm cell culture dishes at logarithmic growth phase 
by washing with 1x PBS and trypsinizing with 2ml of 0.05% trypsin for about 2 minutes 
and detaching the cells by gentle agitation of the dish, followed by trypsin neutralization 
with 8 ml media and cell concentration by centrifuging at 1,350rpm, 40C, for 10 
minutes, repeated for a second wash in HBSS. Cell concentration was measured with a 
hemocytometer and adjusted for injections as described later. Cells were kept on ice 
throughout the length of the injection procedure.  
 
Preparation of intravital thinned skull windows 
To create skull window for longitudinal imaging, the mouse was anesthetized 
with a loading dose of 10µl/g mouse of 10mg/mL ketamine and 1mg/mL xylazine 
cocktail intraperitoneally, followed by 50µl of same concentration every 15-20 minutes 
to maintain anesthesia until completion of surgery. Fur was depilated from the cranial 
vault, which extended to the nasal bridge anteriorly, the temporal skull regions laterally, 
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and the occipital region posteriorly. The skin was then decontaminated using swabs of 
betadine and 70% alcohol. The skin overlying the cranium was excised and the 
pericranium was gently detached from the underlying skull bone. Mouse was restrained 
with tapes on a surgical stage and warmed with a heating blanket for the entire length 
of the surgery. A 5-6 mm diameter parietal skull region to be thinned was marked using 
a pen 1-mm lateral to the sagittal suture and 1-mm posterior to the coronal suture. 
Vetbond glue was then applied on the dry skull except within the region marked with a 
pen. The marked skull region was thinned to about 10-20 μm in thickness using a high-
speed diamond drill with saline cooling. Specifically, the outer table or cortical bone and 
spongy medullary cavity of the mouse skull were surgically shaved off, leaving an intact 
inner table. Further shaving was done with cone-shaped drill bits to increase the optical 
quality of the inner table.  Thereafter, the thinned skull was reinforced with a 5mm-
diameter/1mm-thickness round cover glass that was lightly attached to the inner table 
to prevent indentation of the thinned skull into the cranial compartment. Further 
strengthening of the window preparation was done using dental cement.  
 
Internal carotid artery injection for metastasis models  
Brain tumors were induced by injection of cancer cells into the internal carotid 
artery (ICA). Specifically, the mice were anesthetized, the fur was depilated on the 
anterior region of the neck, and the exposed skin was decontaminated with betadine 
and 70% alcohol. After this, a 1 cm midline incision was made on the anterior aspect of 
the neck, followed by exposure of the common, external, and internal carotid arteries. 
The common carotid and external carotid arteries were ligated and 1 x 105 cancer cells 
in 0.1 ml volume of saline were infused via the patent part of the common carotid artery 
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into the internal carotid artery, which supplies the brain. Infusion of cancer cells was 
done slowly over 30 seconds to 1 minute. After this, the patent part of the common 
carotid artery was then ligated, and skin was closed using surgical staples. 
 
Orthotopic cancer injection for the GL261 glioma model 
For direct intracranial injection, the mice were anesthetized, the fur was 
depilated on the head, and the exposed skin was decontaminated with betadine and 
70% alcohol.  A 5-6 mm burr hole was placed in the parietal skull while preventing 
damage to the dura mater. 2 x 104 cancer cells were implanted using a glass pipette 
attached to a micromanipulator system (Sutter, Novato, CA). The glass pipette was 
stereotactically oriented at the center of the exposed brain region and inserted to a 
depth of 200-250 μm. Cancer cells were injected in 2 μl volume of phosphate-buffered 
saline (PBS) over a period of 2 to 5 minutes and the pipette was then withdrawn slowly 
over a period of 15 to 20 minutes. An air-brain interface was created by applying PBS 
or artificial CSF427,428 on the exposed brain. This was followed by closure of the brain 
by use of a glass coverslip that was adhered with Vetbond glue to the adjacent skull 
and further reinforced with dental cement. 
 
Tail vein injection 
For tail vein injection, cells were harvested with trypsin and washed twice in 
PBS. 105 cells were injected via the tail vein into mice.     
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In vivo depletion of CD8 T cells 
For CD8 T cell depletions, mice were injected with 100 mg/ml anti-CD8ɑ 
antibody (Clone #53-6.72, BioXcell, San Diego, CA) intraperitoneally, either one day 
before or on day 5 after injection of cancer cells and then every other day until the 
experiment was terminated at day 20 after cancer cell injection. Control animals were 
injected with PBS. Depletion was verified by flow cytometry analysis of CD8 T cell 
levels in mouse peripheral blood. 
 
Depletion of CD11c-YFP cells 
Mouse expressing both YFP and diphtheria toxin receptor (DTR) under the CD11c 
promoter was used for depletion of CD11c cells in longitudinal imaging studies. 
Specifically, CD11c cells were depleted by consecutive injections of100ng/day of 
diphtheria toxin (DT) on days 11 and 12 after a baseline time-lapse movie of CD11c-
YFP cells in the tumor had been acquired. Depletion of CD11c-YFP cells was 
confirmed by in vivo visualization of CD11c-YFP cells in the tumor on day 13.  
 
Bone marrow transfer studies 
CD11c-EYFP/hCD2-DsRed and CX3CR1GFP/GFP mice were used as donor and 
recipient, respectively. Bone marrow (BM) was harvested from CD11c-EYFP/hCD2-
DsRed mice, resuspended in RPMI media, and injected intravenously via the tail vein 
into unirradiated CX3CR1GFP/GFP mice (7 x 106 cells/mouse). BM infusion was done 
either one day before cancer cells were injected into mice via the ICA or five days after 
ICA cancer cell injection. Brains of recipient mice were harvested, and brain tumors 
were analyzed at day 20 after ICA cancer cell injection. 
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 Immunofluorescence  
Brain tissue was embedded in optimal cutting temperature (OCT) medium and 
stored at -800C immediately after mice were euthanized.  Embedded brain tissues were 
cryotome sectioned into 5-8 μm thin sections. Sectioned fresh brain tissues were 
stained with various antibodies, either alone or in combinations including, anti-mouse 
MHC-II biotin conjugated antibody (1:100; Clone M5/114.15.2; eBioscience) as a 
primary and APC streptavidin (1:500; Cat.#554067; BD Pharmingen) as secondary; 
and purified rabbit anti-mouse fractalkine (1:100; Cat.#TP233; Torrey Pines Biolabs 
Inc.) as the primary and Alexafluor-647 goat anti-rabbit (1:500; Cat.#A31633; Invitrogen 
Molecular Probes) as the secondary. Antibodies were used in a 1:100 dilution ratio in 
blocking buffer. Specifically, frozen tissues were first washed with PBS to get rid of the 
OCT. After this, the tissues were incubated with blocking buffer (SuperBlock blocking 
buffer; Thermo scientific; #37517) for 30 minutes. Subsequently, tissue samples were 
washed twice in PBS, and then incubated with antibodies overnight as described. 
Finally, the antibody was washed off of tissues by using PBS. For fresh tissue sections, 
the specimens were immediately incubated in blocking buffer for 30 minutes to 1 hr 
before proceeding through similar steps as with the frozen sections. Tissues were 
mounted with Prolong Gold (Invitrogen) and imaged using a Leica SP8 confocal laser 
scanning microscope (Leica Microsystems, Buffalo Grove, IL).  
  
In vivo dynamic microscopy 
Intravital microscopy was performed using a customized two-photon confocal 
SP5 laser scanning microscope (Leica Microsystems, Buffalo Grove, IL) with four 
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channel non-descanned detectors, including two hybrid (HyD) detectors, and two 
femtosecond lasers (Spectra-Physics). The system was operated in a fast resonant 
scanning mode with frame averaging or in a conventional galvo-scanning mode. Mice 
were anesthetized as earlier described. After confirming complete anesthesia, mice 
were head-immobilized with a custom-made stereotactic holder on a heated motorized 
microscope stage maintained at 370C throughout the entire imaging procedure. To 
highlight the vasculature, TRITC-dextran; 155kD (10mg/ml; Sigma Aldrich; #T1287-
50MG) was diluted at a concentration of 1:5 in PBS and 50μl injected via the tail vein or 
retro-orbital route. Time-lapse stacks of images were acquired using Nikon objectives 
(16X, NA = 0.8 or 25X, NA = 1.1), at a distance of 5 μm between Z-planes and a 20 to 
30 seconds inter-stack interval, for a period of 30 minutes to 2 hours. Interline 
sequential excitation at two femtosecond-pulsed wavelengths was used to enhance 
channel separation as follows: 840 nm excitation: CFP, GFP and TRITC emission; 990 
nm excitation: SHG, YFP and DsRed emission. Typical image format was 512 x 512 
pixels. Some sequences were acquired in 1024 x 1024 pixel format. For longitudinal 
studies, imaging was repeated on the same area using the vasculature as landmark at 
set time points after cancer cell implantation until about 30 days.  
 
Ex vivo imaging 
For ex vivo imaging, brain was harvested after mouse circulation fixation with 
4% paraformaldehyde under anesthesia. The brain was sectioned into 4-5 equal thick 
coronal sections (~2mm each) with a sharp blade, sections were overlaid with a PBS-
moistened cover glass and imaged through a 2X and 4X objectives (Olympus), or a 
16X NA = 0.8 objective (Nikon).  
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Image processing 
Prior to analysis, acquired images were subjected to processing using the Leica 
Application Suite version 1.7.0 build 1240 (Leica Microsystems).  Images were parsed 
through several stages. For example, if images were noisy, filtering was performed by 
applying a median filter width of 3. Next, crosstalk correction was performed on each 
channel to eliminate channel bleed-through. Subsequently, images were analyzed in 
xy-2-dimension maximum intensity projections created from all images, xyz-3-
dimension images, or xyzt-4-dimension time-lapse images.  
 
Image analysis: cell tracking 
For three-dimensional cell tracking and contextual analyses, Leica Image 
Format (lif) files were opened using Bitplane Imaris analysis software versions 7 to 
8.3.1 (Bitplane AG, Saint Paul, MN). Voxel dimensions were specified according to the 
objective used for image acquisition. If drift was present, it was corrected based on 
averaged landmark features such as cancer cell groups. T cell motility was analyzed by 
tracking individual T cells using the spot and surface tools of Imaris. For time-lapse 
images obtained from the open skull window experiments, cells at a depth of >100 μm 
below the cover glass were analyzed to avoid potential confounding surface tissue 
artifacts. Cells were tracked by initial automated spot detection followed by 
autoregressive spot tracking and manual tracking. Quantitative analyses were done on 
all tracks with a duration > 10 min. Contextual analyses, which involves determining the 
behavior of cells in context of other cells or anatomical structures, were based on 
surface detection followed by distance transformation.  
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Image analysis: static analyses 
Large area imaging by image stitching 
For gross analysis of the brain, multiple images were acquired and stitched. 
Each individual image was generated from a z-stack by projecting in 2-dimensions 
using maximum intensity projection in Leica processing software. Image stitching (tile 
alignment) was done in Photoshop CS6. Line intensity profiles were generated from 
images using the Line tool on Slidebook version 5/6 or ImageJ.   
Cells were counted using the spot function in Imaris. If direct counting of cells 
was not possible due to dense cellular clustering and insufficient image resolution in 
the image of the data set, then cell counts were obtained using a volumetric approach 
implemented in Imaris software429,430. Thus, volumes of either CD11c-EYFP or hCD2-
DsRed T cell objects were delineated in 3-dimensions by thresholding. Cell numbers 
were calculated by dividing each volume by the average calculated volume of a given 
cell type, which was calibrated in the same data set based on averaging individually 
measured volumes of multiple well-isolated single cells (10-20 cells). Overall cell 
densities were calculated by dividing the number of cells by the z-stack volume. 
Sphericity is the extent to which the shape of a cell closely approaches that of a 
mathematically perfect sphere. It is calculated by using the surface tool in Imaris to 
represent a cell, and the software models the cell’s shape and does calculations to 
determine the extent of sphericity, which ranges from 0 to 1. 
 
Cell-cell spatial correlation 
To analyze the degree of spatial correlation between cell types, each primary 
image was divided into nine equal sub-fields. In each sub-field, total areas of each cell 
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type were obtained by segmentation of images in respective channels. Resulting paired 
values (measured in pixels) were analyzed for correlation using GraphPad Prism 
Software. 
 
Contextual image analyses 
 
Proximity of T cells to DC or cancer cells.  
 
For calculating cellular densities inside and outside tumors, and at tumor 
margins, each of these regions was determined using the surface tool and distance 
transformation, followed by splitting the DC and T cell volumes (or spots) in each 
measured tumor region volume. Distances of T cell to CD11c-YFP DC was generated 
after converting T cells to spot objects by using the spot tool and CD11c-YFP cells to 
surface object by using the surface tool. Imaris Distance Transformation function was 
then used to create certain threshold distances outside CD11c-YFP cell surface 
objects. Finally T cell distance to CD11c-YFP cells was generated using the Filter and 
distance threshold functions. 
 
Analysis of myeloid cell subset numbers and densities within the tumor, at the margin, 
and within the extratumoral region or brain parenchyma. 
To identify all highlighted myeloid cells, CX3CR1+/GFP/CD11c-YFP/CCR2-RFP 
channels were all normalized and added together by using the Arithmetic processing 
function on Imaris to create a single “myeloid” channel. Each cell in the “myeloid” 
channel was then represented as a spot by using the spot tool. The Surface tool was 
then used to create tumor surface object, and the Distance Transformation tool/Filter 
and Distance threshold functions were used to generate distances from outside or 
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inside the edge of the tumor surface object and used to segregate spots (CX3CR1+/GFP 
/CD11c-YFP/CCR2-RFP) into different compartments (tumor outside, tumor margin, 
and tumor core) from the “myeloid” spot population. 
 
Human Samples 
Human GBM tissue and blood samples were obtained by Dr. A. Heimberger 
under approval from the Institutional Review Board of UTMDACC LAB03-0687. 
Informed consent was obtained from each participant. Patients’ tumors were graded 
pathologically as newly diagnosed glioblastoma (glioblastoma, n = 11) by a 
neuropathologist according to the World Health Organization (WHO) 
classification.  Peripheral blood was drawn from the patients intra-operatively or healthy 
donors (n=11). Control CD14+ cells [a general marker of monocytes and monocyte-
derived macrophages 431 (n = 4, age range of 26-35) from intractable epilepsy brain 
tissue was provided by Prof. Jack P. Antel (Montreal Neurological Institute). CD11b+ 
cells  from postmortem brain tissue (n = 4, age 67 and 78, gray and white matter, post 
mortem delay 7-9 h) were obtained from The Netherlands Brain Bank (NBB), 
Netherlands Institute for Neuroscience, Amsterdam (open access: www.brainbank.nl). 
All Material has been collected from donors who provided a written informed consent 
for a brain autopsy and the use of the material and clinical information for research 
purposes obtained by the NBB.  Human glioma or CNS tissue was digested with 
Liberase TM enzyme which contains highly purified collagenase I and II. This approach 
significantly improves cell isolation when compared with standard collagenase 
digestion.432 After enzymatic digestion, the myelin was removed by centrifugation using 
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a Percoll gradient which has previously been shown to result in the highest viability of 
CD11b+ cells.433 
 
Statistics 
GraphPad Prism version 6.00 (GraphPad Software), Microsoft Excel (Microsoft 
office package), and statistical software R v3.3.1 with packages nestedRanksTest v0.2 
and nlme v3.1-128 were used for statistical analyses. Student t-test was used to 
analyze normal-distributed data while the non-parametric Mann-Whitney test (two-
group comparison) was used to analyze non-normal distributed data. When 
appropriate, non-normal-distributed data were transformed by logarithm for the 
parametric analysis. For data including several mice in which T cells were followed 
longitudinally in the same mouse, the mixed effects regression model was applied to 
account for variability in T cell behavior and heterogeneity between mice. The mixed 
effects regression model434 was employed to examine the change of T cell velocity 
after CD11c-DC depletion. Each observation of velocity was first normalized using 
logarithmic transformation. T cell arrest coefficients were arranged in [0,1] with 
significantly inflated 0s and 1s, with 0 and 1 representing T cell values pre- and post- 
CD11c-DC depletion, respectively.  
For the mixed effects regression model: 
Suppose yij is the velocity of jth T cell from the ith mouse. APij takes value of either 0 or 1, where 
1 indicates that the jth T cell from the ith mouse is after depletion, 0 before depletion.  β i0 and 
β i1 are between-mouse random effects for intercept and slope. To examine the change of T cell 
velocity after depletion, we test whether H0: α1=0 against H0: α1!=0. 
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This can be mathematically represented as follows: 
log(yij) = α0 + β i0 + (α1 + β i1)*APij + εij 
β i0 ~ N(0, σ02) 
β i1 ~ N(0, σ12)  
ε i1 ~ N(0, σε2) 
 
Since we failed to transform arrest coefficient values to fit a Gaussian distribution, we 
applied non-parametric nested Mann-Whitney-Wilcoxon Test435 to make comparison 
before and after CD11c-DC depletion. 
Horizontal bars represent the means, and vertical bars represent +/- Standard 
Deviation (SD). P values of less than 0.05 were considered statistically significant 
(*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001). 
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CHAPTER 3: LONGITUDINAL INTRAVITAL VISUALIZATION OF ENDOGENOUS 
INNATE AND ADAPTIVE IMMUNE SURVEILLANCE IN BRAIN TUMORS 
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Part I: Development of an intravital imaging system to investigate immune 
response to brain tumors. 
Introduction 
 Multiple physiological mechanisms exist to protect the brain from immune-
mediated neuronal damage150. However, these same protective mechanisms make it 
challenging to tease apart physiological responses of brain immune cells in intravital BT 
imaging as traumatic brain preparations are involved. From the exterior; the 
pericranium, skull, dura, arachnoid and pia maters, and vascular barriers prevent the 
accessibility of the brain parenchyma to environmental pathogens, blood-borne 
infectious agents, molecules, and antibodies. Such barriers include the blood-brain 
barrier and the blood-CSF barrier68,145,146,148,149,152,155,436-439. In addition to these exterior 
deterrents, in the event that the brain vasculature is breached, there is rapid migration 
of microglia to the site of vascular damage, and is a process that is not clearly 
understood in the context of brain metastases initiation76,214. Recent studies have also 
shown in intravital movies how the brain vasculature is immediately repaired by 
macrophages, which are required to “glue” breached endothelial tips together440. All of 
these support a model in which the homeostatic state of brain resident immune cell 
populations changes rapidly upon direct mechanical manipulation of the brain.  
Multiphoton intravital imaging has provided unprecedented direct visualization of 
immune cell dynamics in various organs and tissues including the brain214,380. Despite 
the application of thinned and open skull imaging windows to answer fundamental 
questions214,428,441, studying the initial immune response to tumors in a physiological 
state is nearly impossible due to the surgical procedures involved. For example, 
mechanical trauma to the dura or arachnoid initiates a strong response by the resident 
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immune cells including the microglia and potentially the peripheral innate and adaptive 
immune cells214. Although it was previously thought that immune cells isolated from 
BTs in mice and humans were mostly microglia, recent understanding of broadly 
shared surface markers between microglia and peripheral immune monocytes and 
macrophages blurs the lines of distinction209. Thus, making conclusions about the 
contribution of immune cell populations to brain tumor immune surveillance during the 
various stages of tumor progression could be confounded by traumatic events during 
cancer cell implantation. Progress in intravital imaging has been made by the use of 
sliced brain organotypic cultures419; however, this isolates the brain from the systemic 
circulation and traumatizes the tissue as well. Recent methods now enable intravital 
imaging of tumors in intact brain tissue in living mice, but the studies still involve 
significant traumatic preparations and have been mostly limited to immune-deficient 
nude and subacute combined immune-deficient (SCID) mice441-449. Intravital imaging in 
immune competent mice has been conducted, but in some cases mice have been 
treated with immune suppressants such as dexamethasone, which prevents immune 
cell proliferation and effector functions441. To overcome these technical limitations in 
brain tumor imaging, which conventionally involves 1) brain trauma due to full-thickness 
skull bone removal and 2) cancer cell deposition by direct intracranial injection, I have 
developed a novel experimental model of intravital imaging of in vivo brain tumor 
immune surveillance. This system consists of a thinned skull window that is combined 
with internal carotid cancer cell injection. Thinned skull window preparations have been 
used in the past to study multiple physiological processes involving neurons, microglia, 
and the cerebral vasculature in pathological conditions such as Alzheimers and 
stroke417,450. Likewise, internal carotid injections have been conducted in previous 
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studies to answer a variety of questions related to the process of brain metastasis and 
stem cell biology100. Both techniques, when done separately, do not involve mechanical 
trauma to the brain parenchyma. Therefore, a combined system involving both 
techniques was developed for visualization of immune cells in brain metastases.This 
method was selected because it does not inflict mechanical injury to the brain tissue, 
when performed with appropriate expertise.  I present data that reveals this approach 
does not produce artefactual immunological activation and specifically, cancer cells 
engraft and grow from within the vasculature into the brain tissue beginning from single 
cancer cells closely recapitulating the clinical scenario. As a read-out of brain tissue 
injury, morphological response of microglia has been visualized in CX3CR1+/GFP mice 
as microglia are known to respond rapidly to regions of brain parenchyma or 
vasculature injury211,214. In addition, I have compared the behavior of microglia in 
response to cancer cells between models in which tumor is initiated by delivery via the 
internal carotid artery relative to cerebral injection. The experiments conducted here 
were focused on early tumor time points ending at day 7, which represents a phase in 
which acute mechanical trauma is potentially most detectable.    
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Results 
3.1a. Intravital imaging experimental setup 
To verify that skull thinning does not inflict mechanical trauma to the brain, 
CX3CR1+/GFP/hCD2-DsRed mice were used. In this mouse strain, GFP reporter gene 
has been knocked into the CX3CR1 locus encoding CX3CR1 protein expression and 
DsRed is expressed under the CD2 promoter; CX3CR1 is expressed by all microglia, 
and T cells can be visualized by the expression of Ds-Red. Importantly, the 
CX3CR1+/GFP reporter mouse strain faithfully reports very rapid reaction of microglia to 
injury within very brief time periods214. The CD2-DsRed mice have been used to show 
the influx of T cells into the brain parenchyma during stroke450.  
To first visualize microglia in the steady state brain, mice with thinned skull 
windows that were not injected with cancer cells were head-restrained with a custom-
designed mouse skull frame and stabilized on a heated custom-made motorized 
imaging stage. Imaging was performed transcranially via the glass window 5 to 10 
minutes after thinning of mouse skull, by using multiphoton microscopy settings as 
described in the methods section. Mouse body temperature and anesthesia was 
maintained throughout imaging, as described in the methods. A schema demonstrating 
this process is shown in Figure 11a. 
 Second harmonic generation (SHG) was applied during multiphoton imaging to 
differentiate the thinned bone and underlying meninges from the underlying brain 
cortex. This is possible because biological structures such as collagen, which constitute 
skull and meninges, exhibit inversion asymmetry and a structural arrangement that 
show a second order non-linear optical property451-453. This property can be harnessed 
during photonic molecular polarization to generate fluorescent signals from such 
77 
 
endogenous tissues without prior dye labeling and is known as SHG. Within the brain 
cortex, microglia were observed to be discretely distributed in both two-dimensional 
orientation and three-dimensional optical sections, with multiple dendrites extending 
from each cell soma (Figure 12a & movie 1). The soma and dendrites of some of the 
microglia appeared to be in direct contact with the cerebral vasculature. Time-lapse 
imaging revealed motile microglia dendrites around the relatively sessile soma, 
scanning the brain especially around vessels and presumably other adjacent brain 
structures such as neurons and astrocytes, as previously described214 (Figure 12b and 
movie 1). This observation was consistent with previous studies that have investigated 
the dynamics of microglia in healthy in vivo brain tissue214,215. Importantly, T cells were 
observed to travel within the lumina of microglia-associated blood vessels, but not 
extraluminally. This observation is similar to those made in sham controls in a previous 
study of T cell influx into the brains of mice with stroke450. Overall, these findings 
indicate that the proposed model does not cause changes in microglia dynamics and 
perturb the blood-brain barrier in mice.   
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Figure 11. Schematic diagram of skull window experimental systems for intravital 
imaging of brain metastases.  
a. A schematic of a new system combining thinned skull window and ICA injection. The 
model consists of thinning a 5-6mm diameter of a mouse skull leaving an eggshell 
osteotomy, followed by bonding of a cover glass to the edges of intact calvaria. Cancer 
Figure 11 
New: Thinned skull window + internal carotid artery inj. expt. setup 
Conventional method 1: Thinned skull window + intracranial inj. expt. setup 
Conventional method 2: Open skull window + intracranial inj. expt. setup c 
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cells are then injected to the brain via the ICA, and non-survival or longitudinal survival 
intravital imaging is performed. 
b. A schematic of a conventional system for intravital imaging system of brain tumor 
through a thinned mouse skull. A 5-6mm diameter of mouse skull is thinned as in (a), 
but cancer cells are implanted directly into the brain through the thinned skull at a depth 
of ~200-250μm by using an automated glass pipette, then the thinned skull window is 
secured with cover glass as in (a). Non-survival or longitudinal survival intravital 
imaging is performed.  
c. A schematic depicting open skull window imaging of brain tumor. Craniotomy is 
performed to completely excise a 5-6mm diameter piece of mouse skull unlike in (b) 
where an eggshell osteotomy is left. In similarity to (b), cancer cells are injected directly 
into the brain at a depth of ~200-250μm below the dura mater by using an automated 
glass pipette. Artificial CSF or PBS is applied to the exposed brain, and a round glass 
coverslip is used to protect the brain tissue from dehydration and reinforced with 
Vetbond glue and dental cement on the edges. Intravital imaging can be done through 
the window to obtain time-lapse images longitudinally, and tumor size can be followed 
by acquiring tumor mosaics. 
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Figure 12 
a. 
b. 
hMW-TRITC-dextran CX3CR1+/GFP hCD2-DsRed 
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Figure 12. Intravital imaging of healthy mouse brain.  
a. Representative image from z-stack imaging of healthy mouse brain showing 
meninges (white) in the xz/yz axes, distribution of microglia (CX3CR1+/GFP; green) 
within the brain cortex, and brain vasculature (cyan) in a three-dimensional xyz space. 
High molecular weight TRITC dextran dye was injected intravenously via the tail vein to 
visualize the vasculature. Imaging depth is up to 200µm (Movie 1).   
b. Representative still image from intravital time-lapse imaging of healthy mouse brain 
showing motility of microglia (CX3CR1+/GFP; green) and T cells (hCD2-DsRed), and 
brain vasculature (hMW-TRITC-Dextran; White). Inset represents zoomed-in region 
showing close-up structure (white lines; thick line represent microglia soma, dotted 
lines represents the dendrites) and motility of microglia dendrites (Movie 1) 
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3.2a. Internal carotid artery injection is a more physiologically relevant method than 
intracranial injection for studying the immune response to brain tumors from a single 
cancer cell level 
Direct implantation of cancer cells in mouse brain confounds the understanding 
of microglia dynamics in response to brain tumor initiation.  To test the extent of 
microglia reactivity to BTs beginning at a single cell level and without local mechanical 
trauma, the new model was used in syngeneic CX3CR1+/GFP mice on the C57BL6 
background (Figure 11a). In these reporter mice, microglia can be visualized in a 
healthy brain based on morphological characteristics (Figure 12a) while CX3CR1+/GFP 
monocytes from extracranial tissues are absent in the healthy brain. CX3CR1+/GFP 
monocytes are present in the brain only after trauma, in which case their morphology is 
ameboidal (Figure 13a & movie 2).  
In the new model,  within two days after mice wereinfused with cancer cells 
derived from methylcholanthrene (MCA)-induced fibrosarcomas by internal carotid 
artery injection, single cancer cells were found to be lodgedwithin cerebral 
microvasculature and the microglia mostly retained their typical ramified morphology as 
in Figure 12a & b. Seven days after ICA-inj., I could still visualize features of resting 
microglia including relatively immobile microglia soma as well as arrays of highly 
dynamic dendritic extensions. In contrast, in the conventional model (Figure 11b), mice 
receiving cancer cells directly into the brain showed CX3CR1+/GFP cell accumulation 
around the site of the injection and lost the typical microglia morphology, and the BBB 
appeared to have been breached as indicated by dye leakage from vessels in the brain 
parenchyma (Figure 13a & movie 2). At day 7 after cancer cell injection by intracranial 
(ICr) injection in the conventional model, I could not identify any distinct morphological 
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features of CX3CR1+/GFP cells resembling that of resting microglia, and analysis of 
CX3CR1+/GFP cell sphericity became technically challenging as the cells appeared to 
have clustered into “bee hive” formations. Quantitatively, the density of CX3CR1+/GFP 
cells in the imaging field of view increased after direct ICr-inj. while there was no 
observable change after indirect ICA-inj. of cancer cells to mice brain in comparison 
with healthy brain (Figure 13c). In addition, CX3CR1+/GFP cells in ICr-injected mice 
increased in sphericity as opposed to cells in ICA-injected mice and in steady-state, 
indicative of the potential activation status of microglia and/or infiltrating 
monocytes/macrophages following ICr injection. (Figure 13d). Importantly, it is 
impossible to distinguish activated microglia from infiltrating monocytes/macrophages 
in an inflamed brain as they both appear amoeboid in shape.  Together, these results 
suggest that ICA injection of cancer cells coupled with transcranial intravital imaging via 
thinned skull window provides a better physiological platform than direct ICr injection 
for studying the initial events of immune response to BTs.    
 
3.3a. CX3CR1+/GFP cells become motile after ICr (conventional model) but not ICA-
induced (new model) cancer cell injection. 
To determine the motility pattern of CX3CR1+/GFP cells in both systems, I tracked 
individual CX3CR1+/GFP cells two days after cancer cell injection (Figure 14a). In mice 
that were injected with cancer cells via ICr-inj., multiple elongated time color-coded 
tracks of varying lengths were found to be present around the site of cancer cell 
injection suggesting CX3CR1+/GFP cell motility. In contrast, after ICA-induced cancer cell 
injection or in the healthy brain, only dots of single colors were observed indicating that 
no CX3CR1+/GFP cell displacement had occurred (Figure 14a). Further, CX3CR1+/GFP 
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cells in the conventional model had significantly increased average velocity in 
comparison with the relatively immotile cells in the new model or steady-state microglia 
(Figure 14b). We were unable, however, to quantify the motility of distinct 
CX3CR1+/GFP cells seven days after ICr-inj. due to the extensive infiltration, cluster 
formation of the CX3CR1+/GFP cells around the injection site, and extremely blurred 
morphological features of individual cells (Figure 14b). Again, this indicates that the 
new model is a better system than the conventional model at least in terms of 
maintenance of CX3CR1+/GFP cell motility behavior as in the healthy steady state brain. 
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Figure 13 
hMW-TRITC-dextran Microglia/CX3CR1+/GFP hCD2-DsRed 
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Figure 13. Intravital imaging of brain tumor within the New Vs Conventional 
murine model systems.  
a. Representative still image from intravital time-lapse imaging of MCA brain tumor-
bearing mouse in the conventional model showing MCA cancer cells/tumor (blue), 
microglia/monocytes (CX3CR1+/GFP; green), and brain vasculature (hMW-TRITC-
dextran; cyan), 2 and 7 days after cancer cell injection by intracranial injection via a 
thinned skull window. The day 7 panel shows abnormally tortuous vasculature, and 
“bee hives” of CX3CR1+/GFP cells. Scale bar represents 100μm.   
b. Representative still image from intravital time-lapse imaging of MCA brain tumor-
bearing mouse in the new model showing MCA cancer cell/tumor (blue), microglia 
(CX3CR1+/GFP), and brain vasculature (hMW-TRITC-dextran; cyan),  2 and 7 days after 
cancer cell injection by the ICA injection method. The top panel shows MCA cancer cell 
trapped in brain vasculature, and microglia (based on morphology), 2 days after ICA 
cancer cell injection The right panel shows MCA cancer cell(s), brain vasculature, and 
microglia (based on morphology), 7 days after ICA cancer cell injection. Scale bar 
represents 100μm.   
c. Density of CX3CR1+/GFP cells in healthy brain and in MCA brain tumor-bearing mice 
2 days after ICr- or ICA-induced MCA tumor (n = 3 from 2 separate experiments; each 
dot represents the density of all cells in a field of view in a mouse brain; data analysis 
was done by unpaired t test; *P < 0.05). 
d. Sphericity of CX3CR1+/GFP cells in healthy brain and in MCA brain tumor-bearing 
mice 2 days after ICr- or ICA-induced tumor (Representative of 3 animals from 2 
separate experiments). 
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Figure 14. Window-located CX3CR1+/GFP cells become highly motile after IC 
injection, but not after ICA injection.  
a. Representative still images from Imaris cell tracking of CX3CR1+/GFP cells in mice 
brain in intravital time-lapse movies. The left and middle panels show green spots, 
which represent the positions of microglia over the duration of 9 min and 45 min, 
respectively. The right panel shows the positions of CX3CR1+/GFP cells (green spots) 
and their migratory tracks (time-scale color-coded lines) over 40min. Scale bar 
represents 40μm.  
Figure 14 
b 
Spot rendering of microglia/CX3CR1+/GFP cells 
Healthy brain ICA D2 ICr D2 
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b. Mean velocity of CX3CR1+/GFP cells in the imaging field of view within the skull 
window region in healthy brain and MCA tumor-bearing mouse brain after ICA- and ICr-
induction of BT (n = 2  from 2 separate experiments; the average velocity of individual 
CX3CR1+/GFP cells acquired over 20min to >1 hr of time-lapse movies were 
accumulated for comparison by using the non-linear mixed effects regression model; 
****P < 0.0001).   
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Discussion 
In this study, I successfully developed an experimental setup to study the 
immune response to BTs in near-physiological brain tissue in living mice and showed 
that ICA injection combined with thinned skull window imaging is better than the ICr 
injection approach with regards to non-specific immune cell motility. While the 
combination of open skull windows and ICr injection is conceptually superior to the 
thinned skull window technique because it enables direct penetration of photons into 
the brain tissue and ultimately enhances better imaging and visualization of cells 
located in deep remote brain regions, it is a more traumatic alternative.  In general, a 
unique advantage of the conventional thinned skull approach is that it aids relatively 
easy manipulation and cancer cell implantation454. In addition, it enables better 
predictability of tumor growth location, which potentially increases the extent of 
experimental reproducibility in terms of imaging different animals at similar time points, 
in longitudinal experiments. However, it carries an attendant risk of causing brain 
parenchymal damage before cancer cells engraft in the tissue and is associated with 
artifacts of early immune cell activation and response, with the disruption of the BBB. 
The study by Zhang L. et al. supports the conclusion above, in that following ICr 
injection, mouse brain develops gliosis due to injection injury as revealed by increased 
GFAP staining at the injection site454. By combining thinned skull window and ICA-inj., I 
have solved these problems; however, I cannot exclude effects that the procedure may 
have on aspects of microglia physiology that were not investigated such as molecular 
signaling pathways. In addition, because the cancer cells that are lodged in the brain 
after ICA injection are better at reproducing brain metastasis from extracranial tumors 
but may not truly recapitulate the early phase of tumor development in primary BTs, a 
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better physiological system for studying primary BTs would be one in which thinned 
skull windows are combined with spontaneously developing BT in GEMM models in 
which resident immune cells such as microglia can be visualized. Nevertheless, 
experiments conducted in part II of this chapter reveal the power of the ICA-inj./thinned 
skull imaging method in understanding the distribution of both resident and infiltrating 
myeloid cells in late stage BTs when ICA-induced tumors have engrafted extensively 
into the brain parenchyma.  
The novel system established here preserves intact brain vascular structures 
and perfusion. In contrast to the direct injection approach which traumatizes blood 
vessels and causes leakage of injected dyes into the brain tissue, vessels appeared 
normal in the system developed here suggesting an intact BBB442. However, we did not 
explore potential molecular changes such as signaling pathways in the cells composing 
the BBB145. Previous studies have shown that microglia respond rapidly to secure even 
very tiny breaches in the vasculature214. Since I did not observe such protective or 
crowding behavior of microglia around the vasculature at early time points, I suspect 
that cancer cells engraft into brain tissue by a mechanism that may not damage the 
vasculature and maybe undetectable by microglia.  
Microglia can potentially transform from a dendritic morphology to an amoeboid 
form, one that is strikingly similar to blood-derived monocyte and macrophages455. This 
makes it difficult to interpret studies using the conventional approach, as the traumatic 
nature of cancer cell deposition causes an increase in the sphericity of the 
CX3CR1+/GFP cells around the site of injection. In addition, the cells accumulate in 
clusters, making it difficult to assess the morphology of adjacent cells that may retain a 
dendritic morphology within the clusters. Increased motility of CX3CR1+/GFP cells 
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obscures the early physiologic response and behavior of microglia to cancer cells214. 
Therefore, this novel approach may provide better clarity in studying immune cell 
response to cancer cells in the brain at the single cell level.  
Since BTs in humans are thought to begin from single mutated cells or 
disseminated malignant cancer cells from secondary tumors, this approach now opens 
an avenue to study the different aspects of immune response to tumor initiation 
including the contribution of innate cells such as neutrophils, patrolling monocytes, 
dendritic cells, classical monocytes, and NK cells, and the subsequent onset of 
adaptive T cell immune response. Although microglia are brain resident and are quick 
to respond to pathologies such as brain parenchyma injury, there are other innate 
immune cells from the periphery such as neutrophils that are capable of initiating rapid 
response to a variety of disease conditions including trauma and even cancer cells261. 
However, the impact of the new system developed here on the early phase 
homeostasis of other innate cells such as neutrophils was not investigated as previous 
studies that utilized an approach similar to the conventional thinned skull method 
described here did not observe any recruitment of neutrophils to traumatized site in 
brain tissue after direct injection; however, changes in microglia were not investigated 
in those studies456.  
This new approach developed is not without limitations. With ICA-induced 
cancer cell injection, there is markedly reduced power of predicting the location of 
cancer cell entrapment and hence increased variability in timing longitudinal intravital 
imaging of tumor growth within the brain in different mice. This is especially 
pronounced given the small imaging window dimensions in mouse skull and the limits 
posed by anatomical skull suture lines in extending such windows. In addition, since 
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the intact skull can add to light scattering caused by brain tissue, the extent to which 
imaging of immune response in deep brain regions can be accomplished is reduced. 
Our approach may also be limited in use due to the requirements of specialized 
expertise with manipulating microvessels such as the common or internal carotid artery 
during cancer cell injection in mice and the longer duration it takes to complete the 
same procedure in several mice as opposed to conventional intracranial injection 
approaches. Nevertheless, both ICA and ICr injection systems may be combined to 
answer some questions by taking the strengths and limitations of each approach into 
consideration. In the future, additional ways of improving these model systems would 
include developing lasers or optical adaptors capable of deeper photon penetration 
through brain tissue and creation of GEMM BT reporter models.  
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Part II: Identification of a cellular mechanism for the regulation of T cell 
surveillance in brain tumors 
Introduction 
Immune surveillance is a critical aspect of tumor progression. Effective immune 
surveillance depends on a tightly regulated migration of immune cells between 
peripheral organs and secondary lymphoid tissues68,457. However, little is known about 
the dynamic behavior and interactions of immune cells in tissues invaded by cancer. In 
the brain, the dynamics and regulation of immune response in tumors has been 
masked for a long time by the idea of brain immune privilege, and has detracted from a 
comprehensive understanding of immune response in BTs and development of 
immunotherapy68,69. Further, our present understanding of anti-tumor immune response 
through in vivo intravital imaging experiments and analysis has been largely derived 
from studies utilizing model tumor antigens, such as ovalbumin, and exogenously 
transferred cognate antigen-specific clonal T cell populations. Despite the immense 
knowledge on immune cellular dynamics and interactions gained from model antigen 
experiments, tumors in humans have great diversity in antigens and the associated 
potential T cell response is most likely polyclonal. As such, the true biology in human 
patient tumor may not be recapitulated in such experiments.372,375,402. Moreover, in the 
brain, intravital visualization and analysis of anti-tumor T cell response is lacking442.  
Previous studies have attempted to understand brain tumor immune response 
by using brain slices419, thereby isolating the brain from the systemic circulation and 
extra-cranial immune response; other attempts at BT in vivo imaging studies have been 
limited technically by experimental systems and the range of reporter mouse models 
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available for concrete immune response readout444,446. Here, I have applied an array of 
longitudinal intravital imaging systems and reporter mice to visualize endogenous 
innate and adaptive immune surveillance in brain tumors. Specifically, I employed 
thinned skull window in mice in combination with ICA injection to visualize the innate 
and adaptive immune cell response to metastatic tumor types such as MCA and LLC. 
In addition, I used the open skull approach to image immune cell response to ICr-inj. 
orthotopic GL261 because of the inefficiency of this cancer cell type to engraft into the 
brain tissue after ICA injection. Also, this approach aided imaging of GL261 cancer 
cells and associated immune cells in deeper brain regions beyond the extent achieved 
by the thinned skull/ICA injection approach. The CD11c-YFP mouse strain has been 
developed and established for use in dissecting the dynamics of myeloid cells 
especially DCs, which have high expression of CD11c. In this study, I used the CD11c-
YFP mouse strain to visualize a population of innate myeloid cells that I will refer to as 
DCs based on their morphology; however, other myeloid cells such as macrophages 
can express the YFP fluorophore encoded by the CD11c promoter as elaborated on in 
chapter 1. In addition, I have used other myeloid cell reporter mouse strains including 
fractalkine and CCL2 chemokine receptors, CX3CR1 and CCR2, encoding GFP and 
RFP fluorophores, respectively, to better characterize the myeloid cell repertoire in BT. 
hCD2-DsRed mice were used to visualize T cells, which express DsRed that is 
encoded by the CD2 promoter. Finally, I have bred the mouse strains above to obtain 
double or triple reporter mouse strains to dissect the interactions between the innate 
and adaptive immune cells in BTs by intravital imaging.     
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Results 
3.1b. Longitudinal intravital imaging reveals differential immune response patterns in 
different brain tumor types.  
It is well established that for a natural immune response to be generated there must be 
an effective coordination between myeloid antigen presenting cells (APCs) and T cells 
in the lymph node379,397,458,459. At sites of inflammation, T cells are known to undergo a 
cyclical process of reactivation between contacting tumor and tumor-associated 
APCs301. Therefore, to directly visualize the endogenous immune surveillance in 
various brain tumor types in a longitudinal manner, I employed appropriate 
experimental intravital imaging systems (Fig. 11). These systems enabled me to 
capture longitudinal evolution of endogenous anti-tumor immune response (Figure 15). 
As shown in Figure 16 & movie 3, orthotopic GL261 glioma was visualized from about 
10 minutes after cancer cell implantation up to a 28-day terminal time point. GL261 
tumor progressed lethally, and although CD11c-YFP cells and T cells were robustly 
recruited temporally, the pace was slower than tumor growth. GL261 tumor-associated 
T cells steadily increased in migration velocity in the tumor microenvironment from 
8μm/min up to a peak of 13μm/min) between day 7 and 13, but decreased to ~9um/min 
at day 28.  
           Lewis lung carcinoma (LLC) brain metastasis, which was generated by ICA, 
progressed lethally over a 19-day period (Fig. 17 & movie 4). In this model, CD11c-
YFP cells and T cells were recruited robustly up to day 11, but sharply reduced 
afterwards. LLC-associated T cells showed relatively high average velocity at day 5 of 
~8μm/min at day 5, and decreased to ~6μm/min at day 11 after cancer injection. The 
decrease in T cell velocity continued steadily until day 19 (~4μm/min).  
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Figure 15: Schematic and confocal images representing a mouse brain with 
anatomical location of late stage brain tumor, and longitudinal appearance of 
tumor and immune cells via imaging window.  
The continuous blue line schematic above the image panels represents the anatomical 
boundaries of a mouse brain, defining the brain into specific regions and is 
Figure 15 
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superimposed on a representative confocal image of ex vivo whole brain with mosaic of 
GL261 tumor (blue), CD11c-YFP cells (white) and T cells (red). The red continuous 
circle indicates the region of the brain tissue directly underneath a virtual open skull 
window and protected by glass cover slip through which longitudinal intravital imaging 
was performed.  
The panels below the schema are arranged in a clockwise fashion and show 
representative mosaics of tumor (blue), CD11c-YFP cells (green) and T cells (hCD2-
DsRed) acquired longitudinally by 2-photon microscopy via imaging skull window. 
Some regions of mouse skull (white/gray) can be visualized by SHG at late stage time 
points when the brain tumor size is near or beyond the edges of the skull window. 
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          Lastly, in contrast to GL261 and LLC, MCA fibro-sarcoma cancer cells engrafted 
and progressed until day 7 (Fig. 18 & movie 5). Interestingly, the recruitment of 
CD11c-YFP cells and T cells continued in the tumor region, surpassed tumor coverage 
in the imaging field of view, and only began declining after observable tumor regression 
between days 10 and 12. MCA-associated T cells did not show any significant change 
in average velocity throughout the imaging time points (~9μm/min). These data suggest 
that robust anti-tumor immune response is mounted in the brain contrary to the notion 
of brain immune privilege, that the recruitment of CD11c-YFP cells and T cells correlate 
in a time-dependent manner, and that the average velocity of T cells exhibited during 
migration vary in different brain tumor types spanning from relatively high migratory 
activity throughout the length of observation in MCA and GL261 tumors to very low 
activity in late stage LLC tumors. 
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Figure 16. Longitudinal intravital imaging of immune response in GL261 brain 
tumor.  
Representative still intravital images from time-lapse imaging of DCs (CD11c-YFP; 
white) and T cells (hCD2-DsRed) in GL261 brain tumor (blue) from 10 min to 28 days 
Figure 16 
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after intracranial implantation. The graphs below the image panels show the temporal 
dynamics of GL261 tumor growth and infiltration of CD11c-YFP cells and T cells in the 
field of view and the mean velocity of T cells over the time period of imaging (n = 1 
mouse; represents longitudinal imaging sessions conducted in 5-6 different 
experiments; *P < 0.05, ****P < 0.0001; mean velocity was analyzed by using the non-
linear mixed effects regression model). Scale bar represents 50µm. 
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Figure 17. Longitudinal intravital imaging of immune response in LLC brain 
tumor.  
Representative still intravital images from time-lapse imaging of DC (CD11c-YFP; 
white) and T cells (hCD2-DsRed) in LLC brain tumor (blue) from 5 days to 19 days after 
LLC cancer cell injection via the ICA using the thinned skull window approach. The 
Figure 17 
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graphs below the image panels show the temporal dynamics of LLC tumor growth and 
infiltration of DC cells and T cells in the field of view and the mean velocity of T cells 
over the time period of imaging. (n = 1 mouse; represents longitudinal imaging 
sessions conducted in 3-4 different experiments ns = not significant; ***P < 0.001, ****P 
< 0.0001; mean velocity was analyzed by using the non-linear mixed effects regression 
model). Scale bar represents 50µm. 
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Figure 18. Longitudinal intravital imaging of immune response in MCA brain 
tumor.  
Representative still intravital images from time-lapse imaging of CD11c-YFP (white) 
and T cells (hCD2-DsRed) in MCA brain tumor from 7 days to 12 days after LLC cancer 
cell injection via the ICA using the thinned skull window approach. MCA tumor 
regresses at day 10 and is not evident at day 12. The graphs below the image panels 
Figure 18 
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show the temporal dynamics of MCA tumor growth and infiltration of CD11c-YFP cells 
and T cells in the field of view and the mean velocity of T cells over the time period of 
imaging. (n = 1 mouse; represents longitudinal imaging sessions conducted in 5 mice 
in 3 different experiments; ns = not significant; mean velocity was analyzed by using 
the non-linear mixed effects regression model). Scale bar represents 50µm. 
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3.2b. CD11c-YFP cells preferentially associate with tumor and T cells relative to 
microglia  
I reasoned that since CD11c-YFP cells and T cells correlate temporally during 
recruitment and population of brain tumor types longitudinally, they may also correlate 
in space, in spatially organized niches within the brain tumor microenvironment. 
Remarkably, across different brain tumors including GL261, LLC, MCA, and B16-F10, I 
observed that tumors that were infiltrated by T cells were those that contained high 
densities of CD11c-YFP cells, which unlike the CD11c-negative microglia, are relatively 
rare in normal brain (Fig. 19 and 20). T cell densities strikingly correlated with CD11c-
YFP densities spatially in tumor at both the microscopic (single brain regions acquired 
by high-magnification objective) and macroscopic scales (whole brain) (Fig. 19c and 
Fig. 21). In macroscopic tumors, both T cells and CD11c+ DCs were found in high 
densities around tumor margins (Fig. 21). However, very few CD11c-YFP and T cells 
was observed in B16-F10 brain tumor with only a weak correlation between both cell 
types (Fig. 19a & b) This was not surprising, as this tumor type is historically known to 
be poorly immunogenic.  
It is conventionally believed that microglia are the predominant immune cell 
population in brain tumors and potentially regulate anti-tumor immune 
response191,246,460,461. Based on this, I evaluated the correlation of the area density of 
microglia to the area of the image field of view occupied by MCA brain metastatic 
tumors, and found only a weak correlation between the density of microglia, MCA 
tumor, or MCA tumor-infiltrating T cells. In contrast, the density of CD11c-YFP cells 
was strongly correlated with the area occupied by MCA tumor (Fig. 19a & c). This 
106 
 
suggested a critical role for CD11c-YFP cells in the regulation of T cell immune 
response in brain tumors.  
Based on such striking spatial correlation between CD11c-YFP cells and T cells, 
I next assessed the interaction pattern between these two cell populations by using 
intravital two-photon microscopy. In the spontaneously regressive MCA tumor, T cells 
migrated preferentially closer to CD11c-YFP cells and adjacent blood vessels than with 
the tumor itself (Fig. 22). Similarly, in the progressive GL261 tumor, T cells also 
migrated in swarms around CD11c-YFP cells (Fig. 23a & movie 6). Analysis of T cell 
motility tracks revealed that the T cells centered around CD11c-YFP cells over a 
distance of 8-12µm, which is close to the range obtained in a previous study involving 
in vivo intravital imaging studies of lymph node DC/T cell interactions462. However, T 
cells maintained a high local migration speed around CD11c-YFP cells over time 
despite their proximity, and this contrasts to previous observations in the lymph node 
where T cells proximal to DCs showed reduced speed295,379 (Fig. 23b). This would 
indicate presumably very transient contacts between the T cells and CD11c-YFP cells 
in GL261 brain tumor despite the clustered pattern of T cell swarms that could be easily 
presumed for prolonged interaction with CD11c-YFP cells. Further, in GL261, although 
T cells appeared confined, the confinement was relatively weak with a confinement 
radius of ~73um that became apparent only during long observations. In contrast to 
GL261, T cells in MCA brain tumor were more tightly confined around CD11c-YFP cells 
with a confinement radius of 33um (Fig. 23c). Together, CD11c-YFP cells and T cells 
correlate in brain tumor niches and T cells are organized and motile around CD11c-
YFP cells. 
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Figure 19 
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Figure 19: CD11c-YFP cells preferentially associated with tumor and T cells 
relative to microglia.  
a. Top: Representative confocal images showing localization of endogenous CD11c-
YFP cells (white) and T cells (hCD2-DsRed) in different types of brain tumor including 
GL261 glioma, LLC, and B16-F10 melanoma (blue) captured between days 13 and 19. 
Tumor types were generated by direct intracranial injection (GL261) and ICA injection 
(LLC and B16-F10). Bottom: Confocal images show localization of endogenous 
CX3CR1 cells (identified as mostly microglia based on distribution and morphology as 
described in chapter 3), CD11c-YFP cells, and T cells in MCA brain tumor induced by 
ICA injection. Scale bar represents 50 µm.   
b. The first three graphs show the correlation between T cells and CD11c-YFP cells in 
various tumor types (n = 2-4 mice/tumor type; 9 areas of tumor-associated immune 
cells were analyzed from an average of 2 tumor nodules per mouse; each dot 
represents a single area analyzed).  
c. Graphs show the correlation of CX3CR1-GFP microglia and CD11c-YFP cells to 
MCA tumor, and the correlation of T cells to CD11c-YFP cells and CX3CR1-GFP 
microglia cells (n = 4 mice; 9 areas of tumor-associated immune cells were analyzed 
from an average of 2 tumor nodules per mouse; each dot represents a single area 
analyzed).  
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Figure 20. Confocal image of healthy mouse brain 
Representative still image from a healthy mouse brain showing brain vasculature 
(TRITC-Dextran; red), microglia (green), and CD11c-YFP DCs (white). 
 
Figure 20 
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Figure 21. Distribution of CD11c+ DCs and T cells correlate in brain tumor at a 
macroscopic level.  
Representative image of the axial (left) and coronal (right) planes GL261 brain tumor 
(blue) with associated CD11c-YFP DCs (white) and T cells (hCD2-DsRed), 
respectively. The cartoon in the middle depicts a mouse brain and the approximate 
location of the GL261 brain tumor. The dotted line demonstrates the margin of the brain 
and the straight line cuts through the midsection of the tumor. The corresponding line 
profile graph to the straight line shows the distribution of CD11c-YFP DCs and T cells 
in relation to GL261 brain tumor. (Represents experiments conducted in 5 different 
mice) 
 
Figure 21 
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Figure 22: T cells preferentially associate with CD11c-YFP cells and the brain 
vasculature Graph shows an example of the frequency of T cells migrating at a given 
distance relative to vasculature, MCA tumor, and CD11c-YFP cells in intravital time-
lapse imaging in a day 7 MCA tumor. Individual tumor-infiltrating T cells were tracked, 
and the frequency of the distance between the mean positions of T cell tracks to 
vasculature, MCA tumor, and CD11c-YFP cells were plotted in the same graph. The 
left axis represents frequency of CD11c-YFP+ DC and blood vessel, while the right axis 
represents frequency of MCA tumor (n =4). 
 
 
 
Figure 22 
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Figure 23: Brain tumor infiltrating T cells are organized in clusters around 
CD11c-YFP cells.   
a. Representative still intravital images of CD11c-YFP and T cellular interactions from 0 
– 30 min in a day 10 GL261 brain tumor (blue). The green spots are superimposed on 
T cells and represent the positions of T cells in the tumor. The color-coded lines 
Figure 23 
a 
b c 
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represent the tracks of T cells during the duration of acquisition of time-lapse images. 
In the bottom right image panel, the T cell track lines are segregated according to 
nearness to CD11c-YFP cells. The green lines represent tracks of proximal ( defined as 
0-7μm from the CD11c-YFP cell margin) T cells while the blue/violet lines indicate 
tracks of distal (defined as 9μm to infinity from CD11c-YFP cell margin) T cells. Scale 
bar represents 50µm.  
b. Graph shows the average distance of all T cells to CD11c-YFP cells (blue line; left Y 
axis) and the average speed of T cells (red line; right Y axis) in relation to the length of 
T cell migration time acquired (Represents experiments conducted 5-6 different times). 
c. Graphs show the squared average displacement of all T cells in GL261 and MCA 
tumor over the length of T cell migration time acquired (represents experiments 
conducted separately for ~5-6 different times). 
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3.3b. In situ imaging and quantification of myeloid cells in a novel myeloid reporter 
mouse reveals distinct localization of myeloid cell subsets in brain tumor. 
A better understanding of the myeloid immune cell composition of brain tumors 
is complicated by the presence of the brain resident microglia and infiltrating 
macrophages and monocytes.There are no reporter mouse models to properly 
delineate these two populations appropriately. Therefore, to characterize the myeloid 
cells in the brain tumor microenvironment, I generated a novel triple myeloid reporter 
mouse in which I could visualize different myeloid cells under the CX3CR1-GFP, 
CD11c-YFP, and CCR2-RFP promoters210,212,463.  With this new model, five myeloid 
cell types including microglia, patrolling monocytes (PMs), classical monocytes (CMs), 
mature and immature dendritic cells (DCs) can be potentially identified according to 
different combinations of fluorophore expression (Table 2).  
To gain insight into the composition and localization of brain tumor-associated 
myeloid cells, I then injected MCA cancer cells via the ICA and subsequently imaged 
engrafted brain tumors in fixed ex vivo thick brain tissue sections by using confocal 
microscopy.  Imaging revealed distinct localizations of the different myeloid cells in the 
tumor microenvironment (Fig.24a).  
Next, I developed a novel method of quantifying the myeloid cell populations 
directly from their actual localizations in the tumor and termed this method in situ tumor 
immune cytometry (iTIC). This method is detailed in chapter 2 and represents an 
advancement in cellular quantification in the field of imaging as it is the first method 
employing Imaris imaging software Spot detection tool and the recently developed 
Vantage analysis and plotting tool for cytometry purposes. The closest competing 
method to iTIC utilizes the colocalization tool on the same Imaris imaging software, but 
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has certain technical drawbacks464. For example, the colocalization values calculated 
and exported do not efficiently reproduce true fluorophore colocalization from an 
arithmetic and computational standpoint. In addition, the exported values have to be 
transported to Flowjo software for further analysis and graphing into dot plots. In 
contrast, the iTIC method utilizes the mean fluorophore intensity in a cell to calculate 
the extent of expression of different fluorophores expressed by the same cell of 
interest. Further, the dot plots are generated within the same software by using the 
Vantage tool. This allows for back and forth validation of the data as each spot can be 
visualized and interrogated by any user. Overall this approach is superior to 
conventional flow cytometry because cells are analyzed within retained tissue 
architecture and multi-layered tissue and does not involve cell processing as in flow 
cytometry tissue preparation, which could result in cell loss. Using the iTIC method, I 
was able to identify five distinct myeloid cell populations in the tumor microenvironment 
(Table 2) and account for their spatial localization in the tumor (Fig. 24b).  
After tissue analysis with iTIC, I identified the same five populations of myeloid 
cells outside the tumor and in the tumor regions (Fig. 24c). Interestingly, CD11c-YFP 
DCs were highly enriched in the tumor and were composed mainly of CD11c+ 
CX3CR1- and CD11c+ CX3CR1+ cells. In contrast, CX3CR1+ CD11c- cells were 
predominating outside the tumor region (Fig. 25a & b). In an attempt to better 
understand the composition of the tumor-infiltrating myeloid cells, I stratified the cells 
according to localization in the tumor core or tumor margin. I then analyzed the 
populations residing within each of these compartments and found a preferential 
enrichment of CD11c-YFP DCs (CD11c+ CX3CR1+ and CD11c+ CX3CR1-) at the 
tumor margin, while the CCR2 monocytes (CCR2+ CD11c- and CCR2+ CD11c+) were 
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preferentially enriched within the tumor core (Fig. 25c & d). More specifically, both 
mature and immature DCs dominated the margin and core of the tumor relative to the 
region outside the tumor denoted as the Extratumoral region ((ET); Fig. 24c).  
Interestingly, CMs as defined in Table 2, were preferentially enriched in the tumor core 
relative to the tumor margin or the region outside the tumor. Patrolling monocytes were 
few and were mostly localized in the core of the tumor and outside the tumor region. In 
support of our earlier observation (Fig. 19b), microglia were mostly present outside the 
tumor region relative to the tumor core and margin; however, there was no change in 
the density of microglia in the tumor versus the ET region (Fig.24c), suggesting that the 
tumor is not enriched for microglia as opposed to DCs and CMs.   
 
3.4b. CD11c-YFP cells are competent antigen presenting cells and T cell proliferation 
occurs in proximity to CD11c-YFP cells 
To determine the competence of CD11c-YFP cells to perform professional APC 
functions, I stained tumor-bearing brain tissue sections with MHC-II and by confocal 
imaging; I found preferential expression of MHC-II in tumor-associated CD11c-YFP 
cells compared to the surrounding CX3CR1+ CD11c- microglia (Fig. 26a). In addition, 
there were several examples of T cells undergoing proliferation in the brain tumor 
microenvironment. In most cases these events occurred in proximity to CD11c-YFP 
cells (Fig. 26b & movie 7). These data support the idea that CD11c-YFP cells are a 
key professional APC population in the brain tumor microenvironment. 
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Figure 24 
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Figure 24. In situ imaging and quantification of myeloid cells in a novel myeloid 
reporter mouse reveals distinct localization of myeloid cell subsets in brain 
tumor. 
a. Representative confocal maximum intensity projection of a 3-dimensional image of 
MCA brain tumor (blue) induced by ICA injection, CX3CR1-GFP (green), CD11c-YFP 
(white), and CCR2-RFP (red) cells.  
b. Arithmetic summation of individual myeloid subsets including CX3CR1-GFP, CD11c-
YFP, and CCR2-RFP cells on Imaris imaging software into a group defined as “parental 
group” (white). The parental group cells is split into two compartments, represented by 
spots (yellow), relative to the tumor; “in tumor” and “outside tumor”. The cells (spots) in 
tumor are further split with respect to the edge or core of the tumor as tumor margin 
and tumor core, respectively. CM = classical monocytes, PM = patrolling monocytes, 
and DC = dendritic cells. 
c. Graphs to the left and right show percentage and density, respectively, of myeloid 
cell subsets residing “outside tumor” or extratumoral (ET), “tumor core”, and “tumor 
margin.” (n = 4 mice from 2 different experiments). 
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Table 4.  
 
 
 
 
 
 
 
 
 
 
Table 2. Phenotypic myeloid cell markers used in this study. To define myeloid cell 
subsets based on these phenotypic markers, novel triple myeloid reporter mice were 
created to then define what populations may be operational within our brain tumor 
models. 
Different combinations of fluorophore marker expression were used to identify distinct 
myeloid cell subtypes including microglia, patrolling monocytes (PM), classical 
monocytes (CMs), and mature and immature DCs. 
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Figure 25 
Tumor myeloid cells 
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Figure 25. Various myeloid-derived immune populations have differential 
distribution in brain tumors.  
Vantage mode dot plots were generated using Imaris imaging software. Distinct 
myeloid cell subsets were identified based on genetically-tagged fluorophore 
expression in a triple myeloid reporter mouse strain based on relative in situ tissue 
location to brain tumor. Colors used in the dot plots are pseudo-colors and only indicate 
populations identified by the markers on the x and y axis. Representative dot plot to the 
left shows the percentage of the various tumor-infiltrating myeloid cells in situ, in (a) 
tumor, (b) extratumoral, (c) margin, and (d) core regions of MCA brain tumor. The 4 dot 
plots to the right show the percentage expression of CCR2-RFP by individual groups of 
myeloid cells in the leftmost panel. 
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 Figure 26. Confocal image and intravital microscopy reveal the presence of 
competent CD11c-YFP APC and T cell proliferation in brain tumor 
a. Representative left merged confocal image of MCA brain tumor-associated CD11c-
YFP cells and CX3CR1-GFP cells, reveals coexpression of CD11c-YFP and MHC-II. 
Single panels to the right show MCA tumor, CX3CR1-GFP, CD11c-YFP, and MHC-II 
expresson. 
b. Representative still images showing intravital time-lapse imaging capture of a T cell 
(hCD2-DsRed) undergoing proliferation in association with CD11c-DCs. Yellow sphere 
Figure 26 
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marks the boundary of a T cell undergoing cell division (Observed in >5 different 
experiments). 
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3.5b. Localization of BM-derived CD11c-YFP cells and T cells in brain tumor correlate 
after adoptive co-transfer 
Non-microglial myeloid cells such as monocytes are robustly mobilized from the 
BM during tissue inflammation including brain cancer248,419. Therefore, I wanted to test 
the idea that BM-derived CD11c-YFP cells localize in brain tumors and serve as 
precursors for tumor-associated DCs.  In addition, I wanted to determine whether 
tumor-infiltrating T cells localize in BM-derived CD11c-YFP cell niches in the brain 
tumor microenvironment. To accomplish this, I isolated whole bone marrow (BM) cells 
from wild type double reporter mice in which I could visualize CD11c-YFP cells and T 
cells, and transferred fresh BM isolates into CX3CR1-Knockout tumor-bearing mice. 
BM cells were transferred into animals in two different groups; the first group received 
BM cells one day before MCA cancer cells were injected to the brain via the ICA, and 
the second group received BM cells fourteen days after cancer cell injection. Upon 
imaging of late stage tumor-bearing tissue sections at day twenty after cancer cell 
injection, I found that BM-derived CD11c-YFP cells localized in brain tumor and 
surprisingly, T cells also localized in tumor-associated CD11c-YFP cell niches within  
brain tumor microenvironment in both groups of mice receiving BM cells at an early and 
late time point (Fig. 27a). The CD11c-YFP cells also bore striking morphological 
resemblance to endogenous brain tumor associated-DCs previously observed. 
Quantitatively, the CD11c-YFP cells were specifically localized in tumor in comparison 
with non-tumor regions (Fig. 27b). In addition, T cells correlated strongly with CD11c-
YFP cells in brain tumors from mice that received CD11c-YFP cells and T cells a day 
before or 14 days after cancer injection (Fig. 27c). This indicates that BM-derived 
CD11c-YFP monocytes populate brain tumors and presumably differentiate into 
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competent antigen presenting DCs at different stages of brain tumor growth. In 
addition, it supported the idea that CD11c-DCs play a role in the localization of T cells 
in brain tumor. 
3.6b. CD11c-YFP cells are important for the retention and motility of T cell subsets in 
brain tumor 
I reasoned that since T cells localize and tend to form clusters around CD11c-YFP cells 
in the local tumor milieu that CD11c-YFP cells might be important in regulating T cell 
dynamics. To test this idea, I evaluated double reporter mice in which I could both 
visualize CD11c-YFP cells and T cells and also manipulate CD11c-YFP cells; this was 
possible because the double reporter mouse strain also expressed diphtheria toxin 
receptor (DTR) under the CD11c promoter. In CD11c-DTR expressing mice, CD11c 
cells can be specifically depleted by consecutive injections of small concentrations 
(100ng/day) of diphtheria toxin (DT). I then implanted GL261 cancer cells intra-cranially 
into DTR-expressing or DTR-non-expressing control mouse brain, and imaged the 
tumor longitudinally. I chose an intermediate tumor growth time point of day 10 to begin 
imaging as this time point showed robust CD11c-YFP and T cell recruitment in the 
tumor in most mice. I then obtained baseline time-lapse movies of CD11c-YFP cells 
and T cells in the tumor at day 10 and this was followed by injecting mice with DT 
intraperitoneally (100ng/day) at days 11 and 12, before eventually obtaining post-DT 
treatment time-lapse movies at day 13 and day 16. I used 100ng/day of DT because it 
produced the most optimal and consistent depletion of CD11c-YFP cells over a short 
duration of only two days in my experience. Following treatment with DT, as expected, 
CD11c-YFP cells were almost completely eliminated in the tumor (Fig. 28a & movie 8). 
The numbers of T cells also decreased sharply (Fig. 28a & b); this was unexpected 
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because I had hypothesized that in the GL261 progressive tumor, T cells were “held” 
by DCs in presumably unproductive interactions and I anticipated that after elimination 
of the DCs, T cells would be released from interacting with CD11c-YFP cells, 
redistribute in the tumor and potentially show cytotoxic behavior.  I then analyzed the 
motility of T cells and found a significant reduction in the mean velocity of T cells post-
DT treatment when compared to the pre-DT baseline.  Correspondingly, T cells showed 
more arrest after DT treatment in comparison with the baseline (Fig. 29a-c and movie 
9). In contrast, there was no significant change in the motility of T cells in the DTR-non-
expressing control mice between pre-DT and post-DT scenarios.  (Fig. 29b-c & movie 
9). This indicates that CD11c-YFP cells are important for the retention of T cells in the 
tumor microenvironment and in controlling their motility. When I analyzed for FoxP3 
Tregs, which are much fewer than non-FoxP3 expressing T cells in brain tumor, I found 
that Treg motility was significantly decreased but less affected than T cells (Fig. 30 and 
movie 10). Overall, the experiments conducted here showed a critical role for CD11c-
DCs in retaining T cells and Tregs in GL261 brain tumor and in regulating their motility 
behavior.  
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Figure 27. Transfer of bone marrow cells into brain tumor-bearing mice reveals 
correlation of CD11c-YFP and T cell localization in tumor. 
a. Representative images showing the localization of CD11c-YFP cells (white) and T 
cells (hCD2-DsRed) in a 21-day MCA brain tumor after BM transfer. The left panel 
Figure 27 
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represents cell localization in tumor after BM cells were transferred a day before cancer 
cell injection via ICA. The right panel represents cell localization in tumor after BM 
transfer 14 days after cancer cell injection via ICA. 
b. Frequency of CD11c-YFP cells in MCA brain tumor (T) in comparison with non-
tumor (NT) regions of the brain. A group of colored dots in the graph represent all 
metastatic tumor nodules randomly imaged and analyzed from a single mouse. Each 
dot represents the number of CD11c-YFP cells localized within a single metastatic 
tumor nodule or field of view (n = 3 mice/group; ****P <0.0001; frequency of CD11c-
YFP cell analysis was done by non-linear mixed effects regression model).  
c. Correlation of total T cells per tumor nodule or field of view and CD11c-YFP cells in 
the same field of view. Left graph represents cell correlation in tumor in experiments in 
which BM was transferred to tumor-bearing mice 1 day before cancer cell injection and 
right graph represents cell correlation in tumor from experiment in which BM was 
transferred to tumor-bearing mice 14 days after cancer cell injection (n = 3 mice/group). 
Different colors represent tumor nodules from different mice. A group of dots of the 
same color in the graph represent all metastatic tumor nodules randomly imaged and 
analyzed from a single mouse. Each dot represents the correlation of the area of 
distribution of CD11c-YFP DC and T cell in a tumor nodule or field of view. 
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Figure 28. Longitudinal intravital imaging reveals CD11c-YFP cells are important 
for the retention and motility of T cell subsets in brain tumor.   
a. Representative still images of longitudinal imaging sessions of endogenous CD11c-
YFP cells (white), total T cells (red) and Gl261 brain tumor (blue) in CD11c-DTR 
transgenic mice at days 10, 13 and 16. Mice were treated with intraperitoneal injections 
Figure 28 
b. CD11c-YFP 
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of DT at days 11 and 12 (n = 5 mice in 5 different longitudinal experiments). Scale bar 
represents 50µm.  
b. Percentage of CD11c-YFP cells and T cells in the imaging field of view on days 10 
and 13 before and after depletion of CD11c-YFP cells, respectively. Each colored line 
represents longitudinal depletion of CD11c-YFP DCs and associated change in T cell 
numbers per field of view in a GL261 brain tumor-bearing mouse.  
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Figure 29. Longitudinal intravital imaging reveals CD11c-YFP cells are important 
for the retention and motility of T cell subsets in brain tumor.   
Figure 29 
c 
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a & b. Representative still images of longitudinal imaging sessions of endogenous 
CD11c-YFP cells, total T cells and Gl261-mCerulean glioma tumor in CD11c-DTR 
transgenic mice (upper image panels) and wild type mice (lower image panels) at days 
10 and 13. Mice were treated with intraperitoneal injections of DT at only days 11 and 
12.  
c. Graphs show mean velocity and arrest coefficient of T cells at days 10 and 13 before 
and after treatment of CD11c-DTR transgenic mice (n = 4 mice accumulated from 4 
different longitudinal experiments; experiment was repeated ~8 times and only movies 
with trackable T cells were included for analysis; mean velocity and arrest coefficient 
analysis were done by non-linear mixed effects regression model and Nested Mann-
Whitney-Wilcoxon Test, respectively; ***P < 0.001,  ****P < 0.0001, ns = not significant) 
and wild type mice with DT, respectively (n = 2 accumulated from 2 different 
longitudinal experiments; experiment was repeated ~6 times). Different colors 
represent T cells from different mice.  
 
 
 
 
 
 
 
133 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 30:  Longitudinal intravital imaging reveals CD11c-YFP cells are important 
for the retention and motility of Tregs in brain tumor.   
Representative still images obtained from longitudinal 2-photon intravital imaging 
sessions of GL261-mCerulean tumor, and endogenous Tregs at day 10 and 13. 
CD11c-DTR mice were treated by intraperitoneal injection of DT at days 11 and 12. 
Graphs show the mean velocity and arrest coefficient of Tregs before and after 
depletion of CD11c-YFP cells (n = 2 mice accumulated from 2 different longitudinal 
experiments; ns = not significant; **P = 0.01; experiment was conducted ~5 times and 
only movies with trackable T cells were included for analysis). Scale bar represents 
50μm. (Mean velocity and arrest coefficient analysis were done by Non-linear mixed 
effects regression model and Nested Mann-Whitney-Wilcoxon Test) 
Figure 30 
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3.7b. Batf3 transcription is not important for CD11c-DC-mediated control of brain tumor.  
Effective control of tumors generated in peripheral organs has been associated 
with efficient cross-presentation of antigens by Batf3-dependent DCs to CD8 T cells in 
the tumor bed279. As introduced in chapter 1, Batf3 is a transcription factor that 
regulates the development and function of CD8ɑ+/CD103 DCs. In Batf3-KO mice, 
CD8ɑ+/CD103 DCs are absent, and antigen cross-presentation is deficient. Therefore, 
I sought to test the role of Batf3-dependent CD8ɑ+ DCs in the control of brain tumor 
growth. To test this, I injected MCA cancer cells into the brains of WT or Batf3-KO mice 
via the internal carotid artery. Following visualization of sections of tumor-bearing brain 
tissues and quantification, tumor growth in Batf3-KO mice appeared comparable to 
growth in WT mice (Fig. 31a & b), indicating that MCA brain tumor growth is not 
dependent on the Batf3 transcriptional network in DCs, at least in the model tested 
here. In addition, visualization of CD11c-YFP cells and T cells in Batf3-KO mice 
revealed qualitatively comparable infiltration of CD11c-YFP cells and T cells in the 
tumor.  
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Figure 31. Batf3 is not important for CD11c-DC-mediated control of brain tumor.  
A. Growth of MCA fibrosarcoma in the brains of wild-type and Batf3-KO mice at day 20 
following injection of 105 fluorescent-labeled MCA- cells via the internal carotid artery. 
Tumor is in glow-scale and indicated by the white arrows. Scale bar represents 1mm. 
B. Graph shows percentage of brain tissue covered by tumor and each dot represents 
a mouse (n = 3 mice/group; ns = not significant; unpaired t test).  
C. Representative confocal images obtained from brain tissue sections from wild type 
and Batf3-KO mice at day 20 showing CD11c-YFP and T cells in association with MCA 
tumor.  
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Discussion 
To our knowledge, this is the first documented evidence of real time T cell 
dynamics in brain tumors. By applying different methods including direct and indirect 
cancer cell injection and longitudinal intravital imaging, I have uncovered a 
spatiotemporal relationship between T cells and CD11c DCs in brain tumors. 
Interestingly, this was pervasive across different tumor types evaluated, except for the 
poorly immunogenic B16-F10 melanoma, which had very few T cells and CD11c DCs 
present in the tumor to begin with. Overall, T cells formed clusters around CD11c DCs 
but this was not terribly surprising as this finding is consistent with a previous study that 
documented the “entrapment” of T cells in CD11c DC network465; however, the fact that 
T cells continued to migrate around CD11c DCs in a random pattern in such confined 
area was unexpected. Although migration of T cells in clusters or confined spaces 
usually reflect decreased velocity and prolonged interactions between T cells and 
CD11c DCs in studies utilizing model tumor antigens, I detected few events of long-
lived contacts between T cells and CD11c DCs in a model presumably involving 
polyclonal T cells. This suggests that T cells could be transiently interacting with CD11c 
DCs to gather signals for reactivation in the tumor or T cells are only organized in such 
patterns by yet unidentified CD11c DC-associated molecules or chemokine gradient(s). 
In support of the former, tumor associated CD11c DCs showed preferential expression 
of MHC-II and correspondingly, I observed multiple instances of T cell proliferation in 
MCA and GL261 tumor ̶ a phenomenon that may be a more common than previously 
believed. On the other hand, given the above observations it is also possible that T 
cells engaging CD11c DCs in short-lived contacts in the progressive GL261 model may 
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be undergoing tolerization in similarity to a DC/T cell interaction pattern previously 
detailed in the lymph node379.  
A key finding of this study is the demonstration that myeloid cells including 
dendritic cells and classical monocytes, rather than microglia, are preferentially 
enriched in brain tumors and play a dominant role in T cell tumor surveillance. This is in 
contrast with previous studies that have highlighted the predominance of microglia-like 
cells in various brain tumor types and their immune suppressive 
properties216,232,446,460,461,466-468. This discovery was made possible by the iTIC method, 
which I used to delineate and identify major myeloid cell subsets and their spatial 
localization in the brain tumor microenvironment. The distinct localization of mature 
dendritic cells and classical monocytes to the margin and core of the tumor, 
respectively, was particularly striking. These two cell populations have been 
documented to play distinct roles in tumor, with mature DCs playing mostly an anti-
tumor role, while the classical monocytes are known to be tumor supportive, at least in 
other types of extracranial tumor models28,255,258,356,419. In addition, the revelation of 
distinct organization patterns of “mature” and “immature DC” populations at the margin 
and core of the tumor by iTIC quantification methodology suggests likely ongoing 
differentiation of “immature DCs” or monocytes to mature DCs in the tumor and may 
involve cytokine or antigen-dependent differentiation mechanisms. However, it is also 
possible that the localization of mature DCs at the tumor margin and CM in the tumor 
core represent opposing forces during brain tumor progression, as mature DCs and CM 
have been shown to be mostly anti-tumor and pro-tumor258,419, respectively.  
Another surprising discovery in this study is that CD11c DCs control T cell 
retention and their migratory pattern in brain tumors. Although we nurtured the idea that 
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we could eliminate CD11c DCs to “free-up” T cells from CD11c DC “entrapment465,” the 
numbers of T cells decreased dramatically, rather than redistribute in the tumor, and 
the T cells became relatively less motile when compared to controls. This suggests that 
CD11c DCs are necessary for effective T cell surveillance in the tumor. It also suggests 
a role for strategies that enhance infiltration of DCs into the tumor microenvironment or 
combine DC and T cell for tumor immunotherapy as opposed to conventional strategies 
employing either DCs or T cells exclusively. For example, adoptive transfer of TILs or 
engineered chimeric antigen receptor (CAR) T cells may profit from an additional 
strategy of enhancing DC infiltration into the tumor to potentially aid in the retention and 
anti-tumor function of TILs or CAR-T cells at the tumor. This finding also aligns well 
with the recent observation of a subset of rare tumor-associated CD103+ DCs 
mediating the anti-tumor effects of anti-CTLA4 checkpoint blockade in 
melanoma457,469,470. Although we could not implicate the Batf3-dependent CD8α+ DCs, 
which shares the same transcription factors as CD103+ DCs, several compensatory 
transcriptional pathways such as Irf4 and Irf8 have recently been elucidated that allow 
the development of CD8α+ DCs. Importantly, Batf3-dependent CD8α+ DCs are absent 
in Batf3-knockout mice on the 129 SvEV mouse background but not the C57Bl6 
background, suggesting that mouse background may impact encoding of the Batf3-
knockout transgene471. In this study, C57Bl6 mice were used and this could further 
account for the disparity between our results and published findings279,280,285,286,471. 
Future experiments utilizing mice with complete absence of CD8a+/CD103+ in C57Bl6 
mice or other Batf3-KO mouse strains will be important in determining the role of this 
DC population in the immune control of brain tumors.  
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One limitation of this study is the lack of specificity of CD11c expression as a 
marker to distinguish DCs from other macrophages. While the CD11c-YFP transgenic 
mouse model remains very useful in gaining unprecedented appreciation of the 
dynamics of “DCs” and T cells in intravital imaging experiments, better mouse models 
that specifically identify only DCs will be important in clarifying the specific functions of 
DCs relative to other macrophage subtypes. However, theoretically, it may be 
impossible to distinguish all DCs from macrophages, as both cell types arise from a 
common macrophage dendritic progenitor (MDP)  cell, and these cells utilize very 
similar signaling pathways and genetic programs during differentiation472-475. In 
addition, given present technology, it is almost impossible to predict MDP differentiation 
into specific lineages and may present a challenge for developing a transgenic reporter 
mouse that fatefully reveals a single lineage. Also, confounding issues with local tissue 
factors such as cytokines altering the plasticity of potentially differentiated cell types 
cannot be excluded. This may add to the complexity of achieving a goal of cellular 
specificity for DC fluorescent reporter mouse models. Regardless, distinct DC subsets 
such as conventional DCs regulated by Zbtb46 transcription factor have been recently 
engineered for studies on conventional DCs457,476.     
The discovery of distinct myeloid cell organization in different tumor regions by 
the iTIC method provides a framework to begin understanding brain tumor-associated 
myeloid cells. Although this finding needs to be validated in more tumor types, it calls 
into question the long-held notions about myeloid cell types believed to be dominant in 
controlling brain tumor immune surveillance. In the literature, methods that appear to 
have been confounded by the techniques used to initiate brain tumors (intracranial 
injection) and process/analyse brain tumor specimens (flow cytometry procedures) may 
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have introduced immune cell artifacts such as trauma-induced inflammation and cell 
loss due to tissue processing, respectively, and led to confusion about the composition 
of tumor-infiltrating myeloid cells in brain tumor444-446. Presumably due to these 
limitations, most studies have pooled different tumor-associated myeloid cells under a 
single arc usually coined as the “microglia/macrophages” entity216,477-489. Regardless, 
distinguishing myeloid cell populations is still a difficult task as techniques and distinct 
surface markers to separate different subsets of myeloid cells infiltrating brain tumor in 
their native tumor microenvironment in situ are still being developed.  With availability 
of more reporter mice tagged with cell lineage-specific fluorophores210,212 myeloid cell 
lineages may likely be better teased apart to better understand the composition of 
myeloid cell types and their spatial organization in tumor. In fact, when this approach is 
potentially combined with conventional gene profiling methods such as in situ 
hybridization, a lot of new knowledge may be obtained in terms of associating gene 
expression to cellular phenotype, tissue localization, and dynamic cellular behavior.   
Based on the findings presented here, the presence of CD11c+ DC in tumor or 
similar DCs identified by more robust markers in human tissues may positively impact 
the prognosis of brain tumor patients being treated with immunotherapy. In support of 
this idea, a recent study showed that high expression of CD11c cells469 or DCs was a 
good prognostic factor for patients with different cancer types490,491. However, further 
experiments are needed to determine whether CD11c+ DC population is necessary 
during immunotherapy in brain tumor models.  
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CHAPTER 4: IMMUNE RESPONSE TOWARD BRAIN METASTASIS DEPENDS ON 
THE FRACTALKINE- CX3CR1 RECEPTOR AXIS 
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Introduction 
Immune surveillance of tumor is highly dependent on dynamic cell migration and 
cell-cell contact372,379,400,492,493. For effective immune surveillance to occur, T cells must 
travel to the site of the tumor after being primed by antigen presenting cells in tumor-
draining lymph nodes372,375,379,398. In tumor, T cells show migratory patterns that must 
be regulated for effective tumor control372. However, little is known about the molecular 
mechanisms regulating the dynamics of T cell tumor surveillance in the brain. 
Chemokines are widely known to regulate immune cell migration in host homeostasis, 
defense, and tolerance294,494. Studies of inflammatory disorders in mouse models have 
revealed the importance of chemokines in mediating innate and adaptive immune 
responses in autoimmunity, infection, and anti-tumor immune surveillance407,414,495.  
There are numerous chemokines that mediate immune responses within 
different tissues and they are organized in an organ-specific manner413,496. The stromal-
derived factor 1 (SDF1) chemokine and its receptors CXCR4/CXCR7 are necessary for 
embryonic survival including neuronal migration and vasculogenesis, and has been the 
most studied chemokine pathway in brain tumors497. Importantly, SDF1 and CXCR7 are 
upregulated in tumor endothelium, microglia, and glioma cancer cells in glioma tissue 
while CXCR4 has been shown to be highly expressed in high grade GBM and in glioma 
stem-like cells498-500. The SDF1 pathway works by preventing apoptosis in glioma cells 
and inducing increased tumor angiogenesis/vasculogenesis501-503; however, inhibition 
of CXCR4 or CXCR7 has resulted in increased apoptosis and decreased proliferation 
of glioma cells504-506. The monocyte chemoattractant protein 1 (MCP-1/CCL2) is 
another chemokine that is produced by microglia in inflammatory conditions or in 
glioma tissue and known to attract Tregs, effector T cells, and inflammatory monocytes 
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via its receptor CCR2347,419,502,507,508. In addition, the CCL22/CCR4 pathway has been 
implicated in recruiting T cells to brain tumor508-510. Microglia express CCR5 and 
inhibition of CCR5 prevented transition to an “M2” immune suppressive 
phenotype511,512. CXCL2-CXCR2 is up-regulated by brain resident perivascular myeloid 
cells and inhibition reduced tumor vessel density and glioma size513. Other chemokines 
expressed in glioma or implicated in glioma progression include CXCR3, CCL20/CCR6, 
CXCL16/CXCR6, CCL27/CCR10514-518.  
However, the aforementioned chemokines are inducible in glioma tissue and 
presumably operate equally in inflammatory conditions in other mammalian tissues as 
in glioma. In contrast, there may be chemokines that operate in an organ-specific 
manner even in the brain.   Fractalkine is one such chemokine that is highly expressed 
by neurons in the healthy brain, and to a lesser extent by epithelia in other tissues such 
as the kidney, lung, and uterus411,519. Fractalkine is known to control the migration of 
several myeloid cell types and some T cells via its only known receptor, CX3CR1419. 
Because of its high expression in the brain, Fractalkine could be a key regulator of anti-
tumor immunity in the brain; however, its involvement in brain tumor T cell immune 
surveillance is largely unexplored. Fractalkine is unique as it is the only member of the 
fourth class of CX3C- family of chemokines. It is constitutively membrane-bound on 
neurons and is produced as a long protein with cytoplasmic, transmembrane, mucin-
like stalk, and chemokine domains. In addition, it can assume a soluble form following 
cleavage by metalloproteinases such as ADAM10 and 17520. This form accesses the 
circulation and is important for the recruitment of CX3CR1-expressing cells412,519,520. 
Fractalkine may be released into the tissue and circulation in the setting of CNS 
injury521,522. In this regard, brain tumors show striking similarity to CNS injury events as 
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they progressively invade the surrounding tissue architecture and potentially induces 
responses from the surrounding brain tissue including neurons. Therefore, the 
possibility that traumatized neurons surrounding brain tumors could upregulate 
expression or release soluble Fractalkine is likely.  The process of brain tumor growth 
is associated with increased expression of metalloproteinases27,523 . Therefore it is 
probable that this process may be utilized in upregulating relevant metalloproteinases 
such as ADAM10 and 17, which could then cleave fractalkine into the circulation. 
CX3CR1 is a G-protein coupled receptor that is expressed on the surface 
membrane of various immune cell types including microglia, macrophages, monocytes, 
DCs, and T cells210,413. CX3CR1 is known to be important in cell migration and 
adhesion524-526. Using genetically engineered mice, CX3CR1 has been shown to be 
important in the pathogenesis of Alzheimer’s disease, atherosclerosis, diabetes 
mellitus, atopy, HIV, and cancer414,415,419,527,528. In addition, single nucleotide 
polymorphisms of CX3CR1 have been implicated in several inflammatory disease 
conditions such as atherosclerosis, HIV/AIDs, and atopic dermatitis529-531. Although 
deficiency of CX3CR1 was recently shown to regulate infiltration of immune 
suppressive monocytes in glioma progression419, its role in the regulation of brain tumor 
immune surveillance is lacking especially with regards to T cell involvement, and in the 
regulation of antigen presenting myeloid and T cell dynamics in brain tumor. Therefore, 
based on the expression of Fractalkine in the brain, I hypothesized that the Fractalkine-
CX3CR1 axis counteracts brain tumor progression by regulating anti-tumor immune 
responses.  
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Results 
4.1. MCA brain tumor progression is controlled by T cells 
Different tumor lines were found to have a differential propensity to grow within 
the brain of mice. Specifically, B16 melanoma and Lewis Lung Carcinoma (LLC) 
demonstrated engraftment and rapid growth within 14-21 days after in vivo injection.  In 
contrast, the fibrosarcoma line, MCA, initially demonstrated engraftment in the brain but 
failed to grow. This was not an issue of tissue kinetics or cancer cell viability since MCA 
demonstrated robust growth in vivo in the lung (Fig 32), indicating that there was a 
unique property of the MCA line that allowed immunological recognition and clearance.  
To determine whether adaptive immune surveillance is critical for progression of 
MCA brain tumor, I injected MCA cancer cells via the ICA to the brain of Rag-KO mice, 
which are deficient in T and B cells. After mice were sacrificed at late time points of day 
18-20, brain sections visualized by confocal microscopy revealed significantly larger 
tumor in brain of Rag-KO mice in comparison to wild type (WT) mice (Fig 33a &b). This 
established the role of the adaptive immune system in the control of ICA-induced MCA 
brain tumor.  
To specifically test the role of T cells in MCA anti-tumor immunity, CD8 cytotoxic 
T cells known to play a major role in killing cancer cells were depleted one day before 
or 5 days after MCA cancer cells were injected into C57Bl/6 WT mice as described in 
chapter 2. After depletion of CD8 T cells one day before cancer cell injection, MCA 
brain tumors were found to be significantly larger relative to WT control mice, indicating 
that CD8 T cells control MCA brain tumor growth (Figure 33c). However, depletion of 
CD8 T cells 5 days after injection of cancer cells resulted only in a trend towards 
increased MCA brain tumor growth. Furthermore, intravital microscopy of MCA brain 
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tumor in WT reporter mice revealed fragmentation of MCA tumor (Figure 33d and 
movie 11). This coincided with persistence of T cells in association with CD11c-YFP 
cells in the fragmenting tumor nodule, reminiscent of observations documented in 
chapter 4. Although T cells in associating with the tumor exhibited stable engagement, 
other T cells within the vicinity of the tumor showed less stable engagement or no 
engagement.  
 
4.2. The Fractalkine/CX3CR1 axis is dysregulated in glioblastoma patient myeloid cells 
and control of MCA brain metastases in mice depends on the Fractalkine/CX3CR1 
pathway 
To identify molecular candidates that may regulate brain tumor immune surveillance by 
T cells, I mined several databases including BioGPS which I analyzed for mRNA 
expression of chemokines in different mammalian tissues. Fractalkine was identified as 
a lead candidate based on species conservation and relatively higher expression in the 
brain in comparison with other mammalian tissues in mice and humans. (Fig. 34 & 35). 
In a bid to explore the role of Fractalkine in regulating brain tumor immune surveillance, 
healthy and tumor-bearing mice brain tissue sections were stained with anti-Fractalkine 
antibody in order to visualize the expression of Fractalkine. By using confocal 
microscopy, I found high expression of Fractalkine at the margin of MCA and GL261 
tumor as opposed to its discrete cellular localization in healthy brain tissue, presumably 
within neurons as has been previously documented410,519 (Fig. 36a & b). 
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Figure 32: MCA brain metastases establish efficiently in lung but not brain.  
a. Growth of B16, LLC, and MCA tumors (blue) in the brains or lungs of wild-type mice 
after injection of 105 fluorescent-labeled cancer cells via the internal carotid artery or 
tail vein, respectively. Panels within the red line rectangle indicate inefficient growth of 
MCA in the brains of mice at later time points 
b. Percentage of brain parenchyma area in coronal plane infiltrated by tumor. Each dot 
represents one mouse [GL261 (n = 5), LLC (n = 7), B16-F10 (n = 2), and MCA (n = 29); 
mice were pooled from >2 experiments]. The numbers in parenthesis in the x-axis 
represent the range of time points when mice were sacrificed for analysis. 
Figure 32 
a. 
b. 
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Figure 33: Growth of MCA is controlled by CD8 T cells.  
a. Confocal images of coronal brain sections from WT and Rag-KO mice showing 
growth of MCA at day 20 following ICA cancer cell injection.  Scale bar represents 
1mm.  
Figure 33 
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b. Graph shows the percentage of brain parenchyma infiltrated by tumor in the coronal 
plane and each dot represents a mouse (**P < 0.001; n = 7-13 mice/group; pooled from 
2 different experiments; Mann-Whitney non-parametric test).  
c. Growth of MCA in the brains of control mice or mice injected with anti-CD8α 
depleting antibody (100mg/ml; intraperitoneally; Clone #53-6.72, BioXcell, San Diego, 
CA) at day 20 following injection of MCA cancer cells via the ICA. Graph shows the 
percentage of the brain parenchyma area in coronal plane infiltrated by tumor and each 
dot represents a mouse (n = 5-8 mice/group, pooled from 2 different experiments). 
Scale bar represents 1mm. D-1 and D5 represent two different groups of mice that 
were treated with CD8 depleting antibody beginning one day before they were injected 
with cancer cells via the ICA or five days after cancer cells were injected in mice.  *P < 
0.05, ns = not significant.  
d. Representative image panels to the left show MCA-mCerulean fibrosarcoma brain 
tumor (blue) undergoing fragmentation in association with CD11c+DCs (white) and T 
cells (hCD2-DsRed; time span of active fragmentation is shown in the top left corner of 
the upper panels). Representative time-projection image panel in the middle shows 
areas of T cell persistence (pink) at the tumor site during a 1-hour time-lapse image 
acquisition. In the right panel, time color-coded tracks indicate T cell migration tracks 
over 1 hour; T cell migration tracks proximal to tumor/CD11c-YFP DCs appear more 
clustered in comparison with distal tracks. Scale bar represents 10μm.   
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To test for the relevance of Fractalkine signaling pathway in human brain tumor 
patients, NanoString digital color-coded barcode technology was used to measure the 
mRNA expression of Fractalkine receptor, CX3CR1. This was done using CD14+ 
peripheral blood monocytes from healthy donors and GBM patients, and CD14+ 
myeloid cells from normal post-mortem/epilepsy brain tissue and tumor-infiltrating GBM 
myeloid cells. Interestingly, CX3CR1 mRNA levels were significantly reduced in CD14+ 
PBMCs and GBM tumor-myeloid cells in almost all GBM patient specimens tested in 
comparison with control samples (Fig. 36c & d). Therefore, to test for the importance of 
Fractalkine signaling via CX3CR1 in brain tumor progression, MCA cancer cells were 
injected via the ICA into CX3CR1-KO mice, and wild type (WT) and CX3CR1-
heterozygous mice were used as controls. This was based on the reasoning that 
knockout of CX3CR1 would disrupt Fractalkine signaling and the consequent immune 
surveillance, thereby enabling progression of the spontaneously regressing MCA brain 
tumor. After confocal imaging of MCA tumor-bearing brain tissue sections and analysis, 
significantly larger tumors were found in CX3CR1-KO mice in comparison with WT 
mice. Unexpectedly, MCA tumors in CX3CR1 heterozygous mice were also 
significantly larger than in WT mice (Fig. 37). This suggested that Fractalkine signaling 
via CX3CR1 is important at different levels of its expression in counteracting the 
progression of brain tumors, at least in the MCA tumor model.  
In line with a role for Fractalkine/CX3CR1 signaling in tumor progression, I 
reasoned that absence of fractalkine signaling could impact the dynamics of CD11c-
YFP cells and T cells. Interestingly, when the density of T cells and CD11c-YFP cells 
was quantified in MCA tumor, both populations were highly reduced in CX3CR1-
heterozygous and CX3CR1-KO mice in comparison with WT mice (Fig. 38a-c). In 
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addition, the surface of tumor covered by T cells was reduced in CX3CR1-
heterozygous and CX3CR1-KO mice relative to WT controls; however, the capacity of 
T cells to contact cancer cells was not significantly altered (Fig. 39). This suggested 
that the Fractalkine/CX3CR1 signaling pathway supports the recruitment of CD11c-
YFP cells and T cells to MCA brain tumor.  
4.3. CX3CR1 controls T cell motility patterns in the tumor 
Finally, I investigated the role of Fractalkine/CX3CR1 signaling in regulation of T 
cell motility in brain tumor. To test this, MCA cancer cells were injected via the ICA  WT 
and CX3CR1-KO mice. By acquiring time-lapse movies of T cells in tumor-bearing WT 
or CX3CR1-KO mice between 7-10 days after cancer cell injection and tracking the T 
cells (Fig. 40a and movie 12), radial tracking plots of T cells showed that T cells in 
CX3CR1-KO mice diverged more from their track origin whereas those in WT mice 
were in swarmed or clustered in the tumor region and remained closer to their track 
origins (Fig. 40b). No difference in T cell velocity and meandering was found between 
CX3CR1-KO and WT mice; however, T cells in CX3CR1-KO mice were more diffuse, 
and were less arrested at the tumor (Fig. 40c). These data supports the idea that the 
lack of Fractalkine signaling via CX3CR1 leads to altered and inefficient anti-tumor T 
cell motility patterns in brain tumor. 
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Figure 34: Histogram showing gene expression level of fractalkine in different tissues 
and organs in mice (http://biogps.org/#goto=genereport&id=20312). 
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Figure 35: Histogram showing gene expression level of fractalkine in different tissues 
and organs in human tissue specimens http://biogps.org/#goto=genereport&id=20312). 
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 Figure 36 
Extratumoral region 
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Figure 36. Fractalkine is highly expressed at the margin of brain tumors, and 
expression of its receptor CX3CR1, is reduced in GBM patients.  
a. Representative confocal images of ex vivo brain tumor tissue sections showing 
expression of Fractalkine in normal brain, and MCA and GL261 brain tumors. MCA 
tumor was generated by ICA injection while GL261 was directly implanted by ICr-
injection. Scale bar represents 50μm. 
b. Intensity profile of Fractalkine obtained from 10 different MCA tumor nodules (n = 3). 
The intensity line profile cuts across the margin of the tumor beginning from inside the 
tumor and extending to relatively normal brain tissue.   
c. Gene expression level of CX3CR1 on CD14+ monocytes obtained from peripheral 
blood of healthy donors and GBM patients (n = 11; unpaired t test).  
d. Gene expression level of CD14+ myeloid cells obtained from normal brain tissue 
(post mortem/epilepsy patients) and GBM patients. Each dot represents a patient (n = 
11; unpaired t test).  
*Sungho Lee, MD PhD was helpful in staining normal brain tissues for Fractalkine in 
figure a. 
*Konrad Gabrusiewicz, PhD and Amy Heimberger, MD, were helpful in conducting and 
discussing experiments in figures c and d, and kindly shared the results for this thesis. 
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Figure 37. CX3CR1 deficiency in mice is important for efficient establishment of 
brain tumor.  
a. Representative confocal images of MCA cancer cell growth in the brains of WT, 
CX3CR1-heterozygous, and CX3CR1-KO mice at day 20 after injection via the ICA. 
Images are shown in glow-scale; white represents the maximum fluorescence intensity, 
red represents the minimum, and black indicates the lack of fluorescent signal. Brain 
parenchyma is outlined with red dashed lines for clarity.  
b. Graph to the right of the image panel shows the percentage of the brain parenchyma 
area in coronal plane infiltrated by tumor and each dot represents a mouse (n = 7-10; 
pooled from 3 different experiments; unpaired t test). Scale bar represents 9 mm.   *P = 
0.04, **P = 0.003, ns = not significant. 
 
Figure 37 
a 
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Figure 38. Fractalkine/CX3CR1 signaling is important for recruitment of DCs and 
T cells to the tumor.  
a. Representative confocal images of endogenous CD11c-YFP cell and T cell 
localization in WT, CX3CR1-heterozygous, and CX3CR1-KO mice.  
b. Density of CD11c-YFP cells in tumors analyzed in WT, CX3CR1-heterozygous, and 
CX3CR1-KO mice (DC index is defined as the volume of CD11c-YFP cells divided by 
the volume of the tumor). Each dot represents a tumor nodule (n = 3 mice per group; 
Mann-Whitney non-parametric test). 
a 
b c
   
Figure 38 
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c. Density of total T cells recruited to tumor nodules in WT, CX3CR1-heterozygous, 
and CX3CR1-KO mice (n = 3 mice; Mann-Whitney non-parametric test). 
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Figure 39. CX3CR1 controls tumor coverage by T cells but not extent of T cell 
surface contact to tumor 
a. Extent of tumor surface covered by T cells, and b. Extent of T cell surface contacting 
tumor in wild type, CX3CR1-heterozygous, and CX3CR1-KO mice. Each dot 
represents the total surface of a single tumor nodule covered by or contacting T cells. 
(n = 2-3 mice/group; Mann-Whitney non-parametric test).  
Figure 39 
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Figure 40. CX3CR1 is important for T cell motility patterns in brain tumor. 
a. Representative still images from intravital time-lapse imaging sessions showing MCA 
tumor (blue), blood vessels (hMW TRITC-dextran; cyan), and T cells (CD2-DsRed). T 
cell tracks are indicated by lines that are time color-coded.  
b. Representative displacement tracks of T cells in MCA brain tumor-bearing WT or 
CX3CR1-KO mice. Displacement tracks are time color-coded. 
c. T cell motility parameters in MCA brain tumor in WT or CX3CR1-KO mice including 
the mean velocity, meandering index, diffusion coefficient, and arrest coefficient. Each 
dot represents a T cell (n = 2 mice/ group; mean velocity, meandering index, and 
diffusion coefficient were analyzed by non-linear mixed effects regression model and 
arrest coefficient was analyzed by nested Mann-Whitney-Wilcoxon test). 
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Discussion 
In this study, I found that T cell surveillance of brain tumor is controlled by the 
Fractalkine/CX3CR1 signaling axis and that this signaling pathway counteracts MCA 
brain tumor progression These findings are consistent with the results of a recent study 
in which CX3CR1 deficiency was shown to be important in increasing the survival of 
brain tumor-bearing mice in which orthotopic brain tumor was generated by using a 
GEMM brain tumor-derived cancer cell line419.  In addition, lack of CX3CR1 was 
associated with increased recruitment of peripheral immune suppressive 
monocytes/macrophages increased in brain tumor419. However, they failed to identify 
any differences in in situ progression of brain tumor in the brains of CX3CR1-deficient 
mice in comparison with WT mice. Fractalkine expression was detected to be low or 
not expressed by tumor tissue or cancer cells indicating that fractalkine signaling was 
not responsible for recruitment of brain monocytes/macrophages. It appears that their 
focus on the accumulation of monocytes/macrophages inside the tumor core and their 
inability to identify the localization of DCs or T cells in their tumor model may have 
prevented interrogation of fractalkine in the peritumoral compartment as a key player in 
brain tumor progression. Here, I show that Fractalkine expression is increased 
especially at the margin of the tumor in both the MCA and GL261 model. This would 
indicate possible stress or damage to neurons adjacent to brain tumors, as neurons are 
known to constitutively express Fractalkine, and presumably upregulate this chemokine 
during inflammation. It is important to note that myeloid/T cell tumor infiltration has 
been observed in some studies to occur at the margins of tumor types studied532-534, 
and consistently in chapter 4, characterization of tumor-infiltrating myeloid cells 
revealed that mature DCs expressing CX3CR1 are abundant at the tumor margin. 
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Whether this indicates a chemokine-based segregation of myeloid cells into different 
tumor compartments is an area of active investigation.  
A key issue that was puzzling was that although the brain resident microglia 
show high expression of CX3CR1 in both steady state and in brain pathologies, they 
did not form clusters or aggregate around brain tumors as has been heavily 
documented in the literature446,467,477,486,489,535,536. One explanation for the findings in 
this thesis, as opposed to previous observations, may be that Fractalkine does not 
diffuse extensively into the brain parenchyma but is only locally upregulated and 
secreted around the tumor, and that the engraftment and invasion of tumor, for 
example MCA, from within the vasculature into the brain tissue allows for preferential 
secretion of Fractalkine into the circulation. This may then lead to the cascade of 
preferential recruitment of myeloid cells such as BM-derived monocytes rather than 
microglia. In support of this idea, I have observed multiple times that tumor-associated 
DCs are usually proximal to the brain vasculature. Another possibility is that steady 
state constitutive expression of membrane-bound Fractalkine in neurons and high 
expression of CX3CR1 in microglia may exist to tether microglia to neurons in order to 
enable an efficient physiologic neuron-pruning function for microglia and to also prevent 
potentially “neurotoxic” microglia from roaming free in the brain tissue416,537,538. 
Therefore, if this idea holds true, it is possible that relatively distal microglia from the 
tumor margins are not recruited because constitutively membrane-bound Fractalkine in 
intact neurons retain the capacity to tether microglia and prevent microglia recruitment 
to the tumor. In extension, it may be possible that in much larger tumors that have 
invaded significant regions of the brain, more microglia are recruited into the tumor, and 
that in CX3CR1-KO mice, microglia are untethered and able to infiltrate the tumor and 
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contribute to tumor progression; however, more work is needed to test these ideas. 
Alternative possibilities may involve the contribution of other chemokines and/or 
differences in chemokine signaling pathways between microglia and other myeloid cells 
such as DCs.  
The decreased density of T cells and CD11c DCs in brain tumor in the absence 
of CX3CR1 implicates Fractalkine as a major regulator of DC and T cell surveillance in 
the tumor. In fact, analysis of T cell motility behavior in CX3CR1-KO mice showed 
altered patterns of T cell movement suggesting that Fractalkine signaling via CX3CR1 
is important for the local migration of T cells in the tumor. However, if this pathway were 
dominant in deciding the recruitment of DCs and T cells, then such recruitment should 
be observed in melanoma brain tumor such as B16-F10 mouse tumor model. As this 
was not the case according to my observations in chapter 4, it indicates that there are 
other mechanisms that may be necessary for immune cell recruitment. Another 
explanation for differences in immune cell infiltration in cancer is their immunogenicity, 
which is an area of intense interest. Another possibility is that different cancer cells may 
vary in the extent to which they can induce cleavage and secretion of Fractalkine into 
the circulation. Therefore, more work is needed to evaluate the role of MMPs such as 
ADAM10 and 17 in the different tumor models as a potential mechanism underlying the 
differences in immune cell recruitment.  
In human brain tumor patient specimens, CX3CR1 expression in CD14+ myeloid 
cells was reduced in both brain tumor tissues and in the peripheral blood, suggesting a 
similarity to our studies in mice in which CX3CR1-KO enhances brain tumor 
progression. However, a role for Fractalkine/CX3CR1 signaling in patient survival was 
unclear from preliminary analysis of TCGA datasets as the expression of CX3CR1 in 
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patient tissue was conducted in only very few patients and healthy tissues with 
insufficient statistical power.  Regardless, there are several possibilities that might 
cause a reduction in the expression of CX3CR1 in CD14+ monocytes in human patient 
brain tumor including de novo genetic mutations, chemotherapy-induced 
downregulation, or preferential migration and localization of CX3CR1 low-expressing 
CD14+ monocytes in brain tumors that could have been preferentially sampled. In 
addition, CX3CR1 expression may be downregulated as a mechanism of tumor 
immune evasion or it may indicate disruption of fractalkine/CX3CR1 feedback loop. 
These possibilities will be dissected in future studies to gain better insight into the 
significance of reduced CX3CR1 expression on CD14+ monocytes in brain tumors of 
patients with GBM. Although more work needs to be done to elucidate the effect of 
reduced CX3CR1 mRNA expression in patients with GBM in functional human studies, 
the corresponding decrease in both brain myeloid cells and peripheral blood monocytes 
makes CX3CR1 expression an attractive tool for patient stratification for the purposes 
of prognostication, treatment, and follow-up.  
Given these findings, the fractalkine/CX3CR1 chemokine pathway represents an 
attractive immunotherapeutic modulation pathway for guiding endogenous or adoptive 
transfer of T cells to brain tumor sites. Development of strategies modulating this 
pathway may be crucial in providing new immunotherapeutic strategies aimed at 
treating brain tumors.  
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CHAPTER 5: SUMMARY, GLOBAL DISCUSSION, AND FUTURE DIRECTIONS 
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5.1. Summary 
Immune cells residing in tumor microenvironment play a critical role in tumor 
progression. In this thesis, I have documented important technical advances in intravital 
imaging of brain tumors that enable the visualization of immune cells in a near-
physiological state. I have applied several innovative approaches and tumor models in 
elucidating the spatiotemporal dynamics of tumor-infiltrating T cells in relation to CD11c 
DCs. The method of in situ immune cell characterization in a novel myeloid cell mouse 
model reported here has revealed an unappreciated organization of myeloid cells in 
brain tumors. In addition, I have determined a mechanism of cellular control of T cell 
dynamics in the brain tumor microenvironment as well as a molecular chemokine cue 
that controls brain tumor progression, immune cell recruitment and migratory behavior. 
In sum, the data presented here provides a platform from which future studies could 
take off and in which multiple areas of cellular and molecular regulation could be better 
clarified and applied in the development of novel immunotherapy strategies.  
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 Figure 41. Model illustrating brain tumor immune surveillance. 
The figure depicts a model in which growth of brain tumor causes damage of neurons 
and subsequent release of Fractalkine. DCs and T cells are recruited to the tumor, in 
part, by Fractalkine. DCs organize around the tumor margin and T cells form clusters 
around DCs. Other T cells migrate within the tumor. 
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5.2. Future implications of applying a near-physiological brain tumor imaging system 
An elusive aspect of brain tumor immunology has been the lack of 
understanding of the reactivity of brain resident microglia to brain tumors beginning 
from a single cancer cell stage and the differential participation and contribution of 
resident and/or infiltrating myeloid immune cells in tumor progression. By using a new 
approach, I have clarified that microglia are generally non-reactive to cancer cell growth 
in the brain at early time points. Microglia were not recruited to the cancer cells, nor did 
they transform their morphology into an “activated” phenotype. In support of this, 
microglia somas were observed to remain relatively sessile despite appreciable tumor 
growth in brain tissue. Irrespective of the presence of cancer the microglia maintained 
probing activity, continuously extending and retracting dendritic processes toward 
vasculature and presumably other brain structures including neurons and astrocytes. 
Whether the scanning activity of microglia dendrites changes significantly in the 
presence of cancer cells in the brain was not apparent in the studies conducted here, 
but remains to be investigated. Even at later stages of advanced tumor growth, 
appreciable infiltration of microglia into the tumor was not observed.  However, it is 
possible that a certain range of tumor size or brain tissue compression and/or damage 
unidentified here could trigger microglia to infiltrate into the tumor. Therefore, I am not 
able to absolutely exclude that microglia are active participants in brain tumor. This 
ambivalence is complicated by the fact that there is no appropriate technique available 
for the specific depletion of microglia to ascertain its real contribution to tumor 
progression. Some techniques that have been tested for depletion of microglia in mice 
brain include brain irradiation, Clodronate-liposome, Mac-1-Saporin, Colony Stimulating 
Factor 1 Receptor inhibitor (CSF1R; PLX5622), use of ganciclovir-mediated ablation on 
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tga20/CD11b Thymidine Kinase of Herpes Simplex Virus (HSVTK) transgenic mice, 
CX3CR1-DTR transgenic mice, and IL-34-KO mice225,236,539-543. Some of these systems 
have found use in the study of neurodegenerative diseases such as Alzheimer’s or 
prion diseases where microglia but not extracranial myeloid cells are believed to play a 
major role in disease progression; however, none of these systems eliminate microglia 
specifically and most are sub-optimal in depletion efficacy. Also, microglia do not 
respond to irradiation strategies as they are radio-resistant221,544. At most, if an 
appreciable percentage of microglia is eliminated by any of the listed strategies, the 
depletion effect on extracranial myeloid cells in the periphery is disregarded. If the role 
of microglia is to be definitively distinguished from incoming myeloid cells in brain tumor 
studies, a system that targets only microglia for depletion will need to be established. 
Nevertheless, since myeloid cells such as monocytes but not microglia can be depleted 
by irradiation, combining this approach with chimeric reporter mouse bone marrow 
adoptive transfer experimental systems, in addition to the novel intravital near-
physiological imaging system developed here, may help to partially answer this 
question. It is also possible that microglia may regulate brain tumor progression 
indirectly by interacting with other tumor immune infiltrates and this is an area of future 
study.  
5.3. Outstanding questions on DC-T cell interactions   
Anti-tumor immunity is known to depend on productive interactions between 
DCs and T cells in the lymph node379,457. Recently, however, there has been a 
paradigm shift from studying the in vivo dynamic interactions between DCs and T cells 
in the lymph node as a standard for understanding anti-tumor immune response to a 
new model involving real time visualization and mechanistic probing of DC-T cell 
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interactions in the tumor microenvironment 375,402,465,469,476. This thesis has for the first 
time extended previous breakthroughs in imaging tumor DC-T cell interactions in 
tissues and organs such as the mammary tissue and skin to the brain.  I have shown 
that there is robust infiltration of endogenous DCs and T cells to brain tumors and that 
their dynamics are correlated in space and time. Interestingly, T cells cluster around 
foci of DCs, maintain high migratory velocities even when proximal to DCs, and appear 
to make transient contacts with DCs. This is in contrast to previous studies that have 
employed model antigens such as ovalbumin to model tumor antigens and showed 
persistent interactions between DCs and T cells with long-lived contacts, that would 
suggest that prolonged DC/T cell interactions in an endogenous setting are infrequent 
375,465.  Also, further cell tracking analysis revealed that T cells within clusters around 
DCs exhibit random motility when observed for short periods of imaging; however, they 
become highly confined around DCs in more prolonged observations especially in 
tumors undergoing rejection, which is not a known occurrence in human brain tumors. 
Apart from differences in cancer cell immunogenicity that may explain differences in 
interaction patterns of T cells with DCs, it will be important to determine whether 
migration of T cells around DCs is regulated by adhesion molecules like integrins or 
more diffusive molecules such as chemokines. Whether T cells receive differential 
levels of stimulation by the DCs or produce varying levels of cytotoxic molecules during 
tumor rejection versus progression was not investigated here, but should be examined 
in a future study.  
Functional studies employing mouse models such as NFAT-GFP, Nurr77-GFP, 
or interferon-gamma (IFN-y)-GFP reporter transgenic mice in which the activation 
status of T cells can be observed in real time during cellular interactions will be useful 
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in determining the effect of DC-T cell interactions in either scenario.  In addition, future 
application of technologies that  visualize intracellular calcium flux in T cells will enable 
better understanding of potential DC-T cell immune synapses in tumor393-395,545-548. 
Reactivation of T cells in the tumor is a desired outcome in tumor 
immunotherapy375. Chronic unproductive activation or exhaustion of T cells in tumor 
has been well documented and targeted by checkpoint blockade immunotherapy26,57. 
However, little is known about the spatial interactions needed by T cells to integrate full 
activation signals for effective functioning in vivo. Even less is known about the 
molecular signals required for such interactions. An important question that remains 
unanswered is “how do T cells “find” DCs such as CD11c+ DCs to interact with within 
the multitude of different potential APCs in the tumor microenvironment and what 
factors lead to the formation of T cell clusters around DCs?” This is crucial to 
understand because it could guide therapeutic strategies that aim to enhance the 
recruitment of endogenous and exogenous transferred T cells to the tumor 
microenvironment.  
Bear in mind that the novel triple myeloid reporter mouse established and 
evaluated here is an attempt to better understand the diverse myeloid cells in situ in 
tumor microenvironment; however, it likely does not reveal all myeloid cells that could 
potentially infiltrate brain tumor. In addition, although CD11c is highly expressed by 
DCs, some monocytes and macrophages express this marker. Therefore, to partly 
answer the question stated above, models that are engineered for visualization of 
spectrally distinct DC subsets such as conventional DCs in addition to macrophages, 
monocytes, and T cells will have to be established in order to delineate the interaction 
patterns of T cells within a diverse pool of myeloid cells.  
174 
 
Another equally pertinent question is how T cells migrate between DCs and the 
adjacent tumor and determine which cancer cell(s) to attack or kill; Do T cells kill better 
in prolonged interactions with tumor or in repeated on-off brief contacts? Do T cells that 
have previously killed continue in a killing “spree” (serial killing) or do they migrate back 
to DCs to be re-activated? Are lone T cells enough to effectively kill single cancer cells 
or does the killing efficacy increase in a T cell number-dependent manner in which 
more than one T cell makes contact with a cancer cell? Are cancer cells being killed 
when T cells are simultaneously contacting both DCs and cancer cells or can T cells kill 
cancer cells indirectly via DCs while maintaining DC-T cell contact?  These are 
important questions that must be answered in vivo to better understand ways of 
improving T cell killing efficiency.  
In observations documented here, active fragmentation of tumor and cancer 
cells was observed in association with T cells stably contacting DCs and/or tumor. An 
interesting speculation that arises from this is whether a mechanism of tumor killing by 
T cells involves initial disruption of adhesion molecules between cancer cells in the 
tumor before T cell-derived cytotoxic molecules are released or whether tumor 
fragmentation is only sequelae of a killing event. This seems plausible because the 
compact architecture of solid tumors may prevent effective T cell infiltration and killing. 
Therefore, if T cells are to engage cancer cells effectively, individual cancer cell surface 
area may have to be increased by mechanisms that cause disruption of cell-cell 
adhesion molecules in a tumor bulk. Whether T cells begin killing by first identifying and 
targeting weak links within the tumor is an interesting idea open for exploration. 
Another important finding in this study is the dominant control exhibited by 
CD11c DCs on T cell retention and motility in brain tumor. This is in contrast with 
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previous studies in other tissues suggesting that T cells may be prevented from 
performing surveillance function in the tumor by being held in unproductive interactions 
with DCs465. In fact, when we adoptively transferred small numbers of T cells and DCs 
into brain tumor-bearing mice, T cells surprisingly localized in DC niches in the tumor, 
indicating that T cell homing and localization may actually be dependent on DCs. It also 
raises questions as to the functions played by specific myeloid cell populations in the 
tumor. Do some myeloid cell subsets synergize with DCs in retaining T cells? Do T 
cells exist in a Yin Yang situation in which their myeloid interaction partner is 
determined by the tumor cytokine milieu? Does the tumor host organ determine what 
interaction partners T cells will preferentially engage with?  Even within the T cell 
population, the difference in the patterns of interaction between individual T cell 
subsets with tumor-associated myeloid cells is yet to be determined. It will be critical to 
evaluate the interaction patterns of Tregs and its potential myeloid cell partners in the 
tumor as this is an attractive T cell target for enhancing the efficacy of immunotherapy. 
Future studies should also determine the cellular and molecular regulators of Treg 
retention and motility as this may provide insight into potential targets applicable in both 
tumor immunology as well as autoimmune studies.  
The neuronal chemokine Fractalkine has been implicated in cancer progression 
as well as in the regulation of immune cells419. The contextual elucidation of Fractalkine 
expression in brain tumor in relation to how tumor-associated myeloid cells are 
organized was achieved in this study. In observing robust Fractalkine expression at the 
margin of the tumor, it is tempting to speculate that the tumor directed tissue injury; in 
particular stress or damage impacted on adjacent neurons that may guide tumor 
immune surveillance. The idea that the innate immune system is capable of detecting 
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and responding to DAMPs via PRRs in host sterile tissue or noninfectious states lends 
support to this speculation112,113,549-552.  
There are several types of DAMPs including chromatin-associated high-mobility 
group box 1 (HMGB1), heat shock proteins (HSPs), deoxyribonucleotide adenine 
triphosphate (DNA), ribonucleotide adenine triphosphate (RNA), S100 molecules, 
purine metabolites such as adenosine triphosphate (ATP), and hyaluronan 
fragments549,553-555. Examples of PRRs utilized in the detection of DAMPs include Toll-
like, RIG-I-like, and NOD-like receptor families. Interestingly, DAMP molecules such as 
S100 are expressed by neurons and glial cells and are utilized clinically to assess for 
brain injury553-555. In addition, pathways including ATP/purinergic receptors and HSPs 
are involved in neuronal and glial physiologic functions such as neurotransmission. 
Whether the signaling of these molecules engage innate myeloid cell PRRs at the 
margin of brain tumor, initiate innate immune responses and synergize with neuron-
derived fractalkine to regulate T cell surveillance will be an interesting area to explore. 
In partial support of this idea, the data here shows that CX3CR1-GFP+ CD11c DCs 
and T cells organize around the margin of brain tumor, and in the absence of 
Fractalkine/CX3CR1 signaling, DCs and T cell numbers were decreased, and the 
motility of the few tumor-infiltrating T cells was more diffuse. Although it has long been 
established that the premise of immune surveillance is based on T cell recognition of 
tumor-associated antigens, it will be interesting to explore whether reaction to tissue 
injury in and of itself is enough to set off a parallel T cell surveillance mechanism in 
tumor. In fact, the immune infiltrates during wound healing bear strong similarity to 
those in tumors, and cancer has been suitably termed “a wound that never heals35.” In 
this regard, groups of antigen non-specific T cells identified in tumor and named 
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“bystander T cells” have unveiled an interesting area in tumor immunology. Whether 
“bystander T cells” are recruited due to the tumor or tissue damage remains a matter of 
speculation. In support of the latter, a study showed that bystander T cells can be 
redirected to kill the stromal component (also a component of wounds) thereby causing 
tumor regression556.  Nevertheless, one of the goals of future studies should be 
focused on elucidating the signals governing the recruitment of “bystander” T cells to 
the tumor, determine their interaction partners in the tumor and how they differ from 
antigen-experienced T cells, delineate the factors that regulate them, and potentially 
manipulate them for therapy.  
5.4. Improvement in intravital imaging of immune cell dynamics in tumor  
Generally, the extent of visualization during intravital imaging is limited by both 
the diffraction index of the tissue being imaged and the numerical aperture of the 
imaging objective441,557,558. In particular, intravital imaging in the brain is complicated by 
the layers of protective tissue and the high lipid content of brain cells, which increase 
light scattering and reduces the depth of tissue that can be sampled441. Although micro-
endoscopes have been used for deep tissue imaging of tumor in mice brain, the 
traumatic nature of this approach may confound real immune cell behavior and 
function559. In addition, recent development of tissue “clearing”, which is a systematic 
process that has been applied to eliminate lipid from the brain and preserves only 
cellular architecture, has enabled high-resolution visualization of deep brain regions 
that were otherwise unreachable by previous techniques; however, such techniques 
can only be applied to non-living fixed brain tissues560,561. Another limitation in imaging 
is the numerical aperture of the imaging objective lens561. This limits sampling of 
immune cell interactions in large tumors located in a three-dimensional space and the 
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extent to which analysis can be done to understand the behavior of T cells in the tumor. 
In general, despite the advantage of two-photon microscopes over confocal imaging in 
terms of depth and other qualities, imaging large and deep areas of the intact brain still 
remains a challenge.  
5.5. Significance of this study and implications for cancer immunotherapy 
I have developed and applied a novel experimental system in illuminating the 
early immune cell events in brain tumor beginning at a single cell level. In combination 
with this, I have applied broadly conventional imaging approaches in studying immune 
cell dynamics in different brain tumors and elucidated DC-T cell interactions. Given the 
differences in immune cell recruitment and tumor progression in the tumor models 
used, it will be important to profile tumor cell genes from each tumor type as well as 
sequence the antigens presumably recognized by T cells to create a clearer picture of 
the differences between experimental tumor types and enhance studies that may be 
relevant in better understanding human tumors. GEMM tumor models are the gold 
standard for understanding biological phenomena and especially for translating 
research findings to the clinic. Therefore, it will be crucial to evaluate DC-T cell 
interactions in appropriate GEMM models that harbor genetic mutations that are known 
to drive progression of human tumors and possibly contribute to tumor immunogenicity.   
I show here that myeloid cells are organized in distinct compartments within 
brain tumor microenvironment. Importantly, CD11c+ DCs reside mostly at the tumor 
margin. However, present analysis of tumor immune cell infiltration in patients with 
brain tumor is done using tumor biopsy specimen obtained from within the core of the 
tumor that may not truly reflect the immune infiltrates in the tumor microenvironment. 
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Therefore, the findings here should be translated to the clinic to guide neurosurgical 
biopsy procedures for immunological evaluation especially when immunotherapy 
strategies are being considered. I also show that CD11c+ DCs and T cells are 
correlated in space and that CD11c+ DCs control the retention and motility of effector T 
cells in brain tumors. Consistently, tissue-resident memory T cells have also been 
shown to be preferentially organized around DCs for prolonged periods after clearance 
of model viral infections in mice brain371. This has implications for brain tumor 
immunotherapy as interactions between T cells and DCs in brain tumors has been 
unappreciated as opposed to microglia and macrophages. Identifying and 
understanding potential molecular signals that control recruitment, retention, and 
survival of DCs in the tumor could present targets for modulating anti-tumor immune 
response, for example by specifically eliminating tumor-infiltrating DCs and associated 
T cells molecularly, and replacing the tumor microenvironment with “new” immune cells 
in addition to therapies that prevent tumor-mediated immune suppression. This strategy 
may find relevance in cellular transplantation in which whole body radiation, which 
could be injurious to normal tissue, is used to eliminate immune cells such as T cells 
before adoptive transfer of exogenous cells. Further, since DCs and T cells appear to 
work together during anti-tumor immune response, another strategy for tumor 
immunotherapy could entail adoptive transfer of competent antigen-presenting DCs 
and cytotoxic T cells serially or simultaneously into patients rather than conventional 
approaches employing either DCs of T cells exclusively. This strategy may aid in the 
persistence of adoptively transferred T cells in the tumor. Also, in addition to adoptive 
transfer of DCs, adjuvants such as Flt3-ligand vaccine (FVAX) may be used to 
stimulate increase in endogenous DC numbers in situations where exogenous DC cell 
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culture may produce low yield or alterations in DC functions470.  Another avenue for 
application is in checkpoint blockade immunotherapy. The present goal for this type of 
therapy is to increase the percentage of patients that respond to this treatment 
strategy. Therefore, based on the data here, there is compelling reason to examine the 
composition of DCs in brain tumor or other tumor types in patients before initiating 
treatment or in patients who show partial or no response to treatment to determine 
whether lack of DCs may play a role in this regard. This could serve as a method of 
predicting treatment response. There is also support for combining DC treatment 
methods such as adoptive cell transfer or FVAX with T cell checkpoint blockade. 
However, more work needs to be done to better understand how DCs may regulate T 
cells in tumor during checkpoint blockade immunotherapy in preclinical models.  
In addition, I have also demonstrated a role for Fractalkine signaling in brain 
tumor progression and in the control of tumor-infiltrating T cell recruitment and 
migration. Although I have not directly elaborated on the function of Fractalkine ligand 
in tumor progression or immune cell dynamics, this molecular pathway is an attractive 
target for modulating immune cells and potentially enhancing cancer immunotherapy. A 
major goal in adoptive T cell therapy in which infusion of exogenous T cell infiltrating 
lymphocytes or CAR T cells is done in patients with tumor, is to successfully direct the 
infused T cells to the tissue of interest. Thus, engineering CAR T cells with chemokine 
receptors such as CX3CR1 may help enhance cellular migration to the tumor.  
However, further studies are required to understand whether there is a functional 
significance to the changes in Fractalkine receptor CX3CR1, in GBM patients, and 
whether mouse observations are applicable in human brain tumor. Another aspect of 
this pathway that could be potentially modulated is the expression of ADAM10 and 17. 
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These MMPs are needed for Fractalkine cleavage and secretion into the circulation. 
Therefore, strategies that increase their expression may help maintain the secretion 
and levels of soluble Fractalkine in the circulation. This may assist in preventing 
downregulation of CX3CR1 expression in anti-tumor myeloid cells562. However, more 
work is required to better understand the regulating mechanisms involved in this 
process. 
In sum, I have elucidated the dynamic behavior of immune cells in brain tumor 
and the studies conducted in this thesis have revealed novel cellular and molecular 
regulatory mechanisms in immune cell recruitment and interaction. This work paves 
way for exploration of other mechanisms involved in the regulation of brain tumor 
immune surveillance and potentially other cancer types.  
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